#FORMAT=WebAnno TSV 3.2


#Text=[0689] A novel genes URLC1 were found.
1-1	0-1	[	
1-2	1-5	0689	
1-3	5-6	]	
1-4	7-8	A	
1-5	9-14	novel	
1-6	15-20	genes	
1-7	21-26	URLC1	
1-8	27-31	were	
1-9	32-37	found	
1-10	37-38	.	

#Text=It's nucleotide sequence and the amino acid sequence encoded thereby are shown with following SEQ ID NOs in the sequence listing: TABLE-US-00013 Nucleic sequence Amino acid sequence URLC1 SEQ ID NO: 1 SEQ ID NO: 2
#Text=[0690] The results obtained above are summarized below for each of the genes of the present invention: [0691] NSC 807: KOC1; this gene encodes an hnRNA K-homology (KH) domain and an RNA recognition motif (RRM) domain.
2-1	39-43	It's	
2-2	44-54	nucleotide	
2-3	55-63	sequence	
2-4	64-67	and	
2-5	68-71	the	
2-6	72-77	amino	
2-7	78-82	acid	
2-8	83-91	sequence	
2-9	92-99	encoded	
2-10	100-107	thereby	
2-11	108-111	are	
2-12	112-117	shown	
2-13	118-122	with	
2-14	123-132	following	
2-15	133-136	SEQ	
2-16	137-139	ID	
2-17	140-143	NOs	
2-18	144-146	in	
2-19	147-150	the	
2-20	151-159	sequence	
2-21	160-167	listing	
2-22	167-168	:	
2-23	169-177	TABLE-US	
2-24	177-178	-	
2-25	178-183	00013	
2-26	184-191	Nucleic	
2-27	192-200	sequence	
2-28	201-206	Amino	
2-29	207-211	acid	
2-30	212-220	sequence	
2-31	221-226	URLC1	
2-32	227-230	SEQ	
2-33	231-233	ID	
2-34	234-236	NO	
2-35	236-237	:	
2-36	238-239	1	
2-37	240-243	SEQ	
2-38	244-246	ID	
2-39	247-249	NO	
2-40	249-250	:	
2-41	251-252	2	
2-42	253-254	[	
2-43	254-258	0690	
2-44	258-259	]	
2-45	260-263	The	
2-46	264-271	results	
2-47	272-280	obtained	
2-48	281-286	above	
2-49	287-290	are	
2-50	291-301	summarized	
2-51	302-307	below	
2-52	308-311	for	
2-53	312-316	each	
2-54	317-319	of	
2-55	320-323	the	
2-56	324-329	genes	
2-57	330-332	of	
2-58	333-336	the	
2-59	337-344	present	
2-60	345-354	invention	
2-61	354-355	:	
2-62	356-357	[	
2-63	357-361	0691	
2-64	361-362	]	
2-65	363-366	NSC	
2-66	367-370	807	
2-67	370-371	:	
2-68	372-376	KOC1	
2-69	376-377	;	
2-70	378-382	this	
2-71	383-387	gene	
2-72	388-395	encodes	
2-73	396-398	an	
2-74	399-404	hnRNA	
2-75	405-415	K-homology	
2-76	416-417	(	
2-77	417-419	KH	
2-78	419-420	)	
2-79	421-427	domain	
2-80	428-431	and	
2-81	432-434	an	
2-82	435-438	RNA	
2-83	439-450	recognition	
2-84	451-456	motif	
2-85	457-458	(	
2-86	458-461	RRM	
2-87	461-462	)	
2-88	463-469	domain	
2-89	469-470	.	

#Text=The function of the KH domain to bind to the 5'UTR of the IGF-II (IGF2) leader 3' mRNA, may repress the translation of IGF-II during late development.
3-1	471-474	The	
3-2	475-483	function	
3-3	484-486	of	
3-4	487-490	the	
3-5	491-493	KH	
3-6	494-500	domain	
3-7	501-503	to	
3-8	504-508	bind	
3-9	509-511	to	
3-10	512-515	the	
3-11	516-517	5	
3-12	517-518	'	
3-13	518-521	UTR	
3-14	522-524	of	
3-15	525-528	the	
3-16	529-535	IGF-II	
3-17	536-537	(	
3-18	537-541	IGF2	
3-19	541-542	)	
3-20	543-549	leader	
3-21	550-551	3	
3-22	551-552	'	
3-23	553-557	mRNA	
3-24	557-558	,	
3-25	559-562	may	
3-26	563-570	repress	
3-27	571-574	the	
3-28	575-586	translation	
3-29	587-589	of	
3-30	590-596	IGF-II	
3-31	597-603	during	
3-32	604-608	late	
3-33	609-620	development	
3-34	620-621	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest usefulness of this gene as a novel diagnostic marker and target for new drugs and immunotherapy. [0692] NSC 810: TTK; this gene encodes an S TKc domain.
4-1	622-625	The	
4-2	626-631	lower	
4-3	632-642	expression	
4-4	643-645	of	
4-5	646-650	this	
4-6	651-655	gene	
4-7	656-658	in	
4-8	659-665	normal	
4-9	666-673	tissues	
4-10	673-674	,	
4-11	675-679	high	
4-12	680-690	expression	
4-13	691-693	in	
4-14	694-700	NSCLCs	
4-15	700-701	,	
4-16	702-705	and	
4-17	706-713	reduced	
4-18	714-720	growth	
4-19	720-721	,	
4-20	722-735	proliferation	
4-21	736-739	and	
4-22	739-740	/	
4-23	740-742	or	
4-24	743-751	survival	
4-25	752-754	of	
4-26	755-758	the	
4-27	759-770	transfected	
4-28	771-776	cells	
4-29	777-779	by	
4-30	780-783	the	
4-31	784-795	suppression	
4-32	796-798	of	
4-33	799-803	this	
4-34	804-808	gene	
4-35	809-816	suggest	
4-36	817-827	usefulness	
4-37	828-830	of	
4-38	831-835	this	
4-39	836-840	gene	
4-40	841-843	as	
4-41	844-845	a	
4-42	846-851	novel	
4-43	852-862	diagnostic	
4-44	863-869	marker	
4-45	870-873	and	
4-46	874-880	target	
4-47	881-884	for	
4-48	885-888	new	
4-49	889-894	drugs	
4-50	895-898	and	
4-51	899-912	immunotherapy	
4-52	912-913	.	
4-53	914-915	[	
4-54	915-919	0692	
4-55	919-920	]	
4-56	921-924	NSC	
4-57	925-928	810	
4-58	928-929	:	
4-59	930-933	TTK	
4-60	933-934	;	
4-61	935-939	this	
4-62	940-944	gene	
4-63	945-952	encodes	
4-64	953-955	an	
4-65	956-957	S	
4-66	958-961	TKc	
4-67	962-968	domain	
4-68	968-969	.	

#Text=The protein encoded by the gene phosphorylates proteins on serine, threonine and tyrosine, which phosphorylation probably is associated with cell proliferation.
5-1	970-973	The	
5-2	974-981	protein	
5-3	982-989	encoded	
5-4	990-992	by	
5-5	993-996	the	
5-6	997-1001	gene	
5-7	1002-1016	phosphorylates	
5-8	1017-1025	proteins	
5-9	1026-1028	on	
5-10	1029-1035	serine	
5-11	1035-1036	,	
5-12	1037-1046	threonine	
5-13	1047-1050	and	
5-14	1051-1059	tyrosine	
5-15	1059-1060	,	
5-16	1061-1066	which	
5-17	1067-1082	phosphorylation	
5-18	1083-1091	probably	
5-19	1092-1094	is	
5-20	1095-1105	associated	
5-21	1106-1110	with	
5-22	1111-1115	cell	
5-23	1116-1129	proliferation	
5-24	1129-1130	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy.
6-1	1131-1134	The	
6-2	1135-1140	lower	
6-3	1141-1151	expression	
6-4	1152-1154	of	
6-5	1155-1159	this	
6-6	1160-1164	gene	
6-7	1165-1167	in	
6-8	1168-1174	normal	
6-9	1175-1182	tissues	
6-10	1182-1183	,	
6-11	1184-1188	high	
6-12	1189-1199	expression	
6-13	1200-1202	in	
6-14	1203-1209	NSCLCs	
6-15	1209-1210	,	
6-16	1211-1214	and	
6-17	1215-1222	reduced	
6-18	1223-1229	growth	
6-19	1229-1230	,	
6-20	1231-1244	proliferation	
6-21	1245-1248	and	
6-22	1248-1249	/	
6-23	1249-1251	or	
6-24	1252-1260	survival	
6-25	1261-1263	of	
6-26	1264-1267	the	
6-27	1268-1279	transfected	
6-28	1280-1285	cells	
6-29	1286-1288	by	
6-30	1289-1292	the	
6-31	1293-1304	suppression	
6-32	1305-1307	of	
6-33	1308-1312	this	
6-34	1313-1317	gene	
6-35	1318-1325	suggest	
6-36	1326-1330	that	
6-37	1331-1335	this	
6-38	1336-1340	gene	
6-39	1341-1346	might	
6-40	1347-1349	be	
6-41	1350-1356	useful	
6-42	1357-1359	as	
6-43	1360-1361	a	
6-44	1362-1367	novel	
6-45	1368-1378	diagnostic	
6-46	1379-1385	marker	
6-47	1386-1389	and	
6-48	1390-1396	target	
6-49	1397-1400	for	
6-50	1401-1404	new	
6-51	1405-1410	drugs	
6-52	1411-1414	and	
6-53	1415-1428	immunotherapy	
6-54	1428-1429	.	

#Text=According to the present invention, the TTK protein expressed in stable transfectant promoted the growth of COS-7 cells in a dose dependent manner.
7-1	1430-1439	According	
7-2	1440-1442	to	
7-3	1443-1446	the	
7-4	1447-1454	present	
7-5	1455-1464	invention	
7-6	1464-1465	,	
7-7	1466-1469	the	
7-8	1470-1473	TTK	
7-9	1474-1481	protein	
7-10	1482-1491	expressed	
7-11	1492-1494	in	
7-12	1495-1501	stable	
7-13	1502-1514	transfectant	
7-14	1515-1523	promoted	
7-15	1524-1527	the	
7-16	1528-1534	growth	
7-17	1535-1537	of	
7-18	1538-1541	COS	
7-19	1541-1542	-	
7-20	1542-1543	7	
7-21	1544-1549	cells	
7-22	1550-1552	in	
7-23	1553-1554	a	
7-24	1555-1559	dose	
7-25	1560-1569	dependent	
7-26	1570-1576	manner	
7-27	1576-1577	.	

#Text=This result suggested that over-expression of TTK exerts a transforming effect on mammalian cells.
8-1	1578-1582	This	
8-2	1583-1589	result	
8-3	1590-1599	suggested	
8-4	1600-1604	that	
8-5	1605-1620	over-expression	
8-6	1621-1623	of	
8-7	1624-1627	TTK	
8-8	1628-1634	exerts	
8-9	1635-1636	a	
8-10	1637-1649	transforming	
8-11	1650-1656	effect	
8-12	1657-1659	on	
8-13	1660-1669	mammalian	
8-14	1670-1675	cells	
8-15	1675-1676	.	

#Text=These data reveal that TTK might be a novel oncogene for NSCLC and suggest that a promising therapeutic strategy for treating lung cancers may be established by targeting TTK. [0693] NSC 811: SDC1; this gene encodes a putative band 4.1 homologues' binding motif (4.1 m) domain.
9-1	1677-1682	These	
9-2	1683-1687	data	
9-3	1688-1694	reveal	
9-4	1695-1699	that	
9-5	1700-1703	TTK	
9-6	1704-1709	might	
9-7	1710-1712	be	
9-8	1713-1714	a	
9-9	1715-1720	novel	
9-10	1721-1729	oncogene	
9-11	1730-1733	for	
9-12	1734-1739	NSCLC	
9-13	1740-1743	and	
9-14	1744-1751	suggest	
9-15	1752-1756	that	
9-16	1757-1758	a	
9-17	1759-1768	promising	
9-18	1769-1780	therapeutic	
9-19	1781-1789	strategy	
9-20	1790-1793	for	
9-21	1794-1802	treating	
9-22	1803-1807	lung	
9-23	1808-1815	cancers	
9-24	1816-1819	may	
9-25	1820-1822	be	
9-26	1823-1834	established	
9-27	1835-1837	by	
9-28	1838-1847	targeting	
9-29	1848-1851	TTK	
9-30	1851-1852	.	
9-31	1853-1854	[	
9-32	1854-1858	0693	
9-33	1858-1859	]	
9-34	1860-1863	NSC	
9-35	1864-1867	811	
9-36	1867-1868	:	
9-37	1869-1873	SDC1	
9-38	1873-1874	;	
9-39	1875-1879	this	
9-40	1880-1884	gene	
9-41	1885-1892	encodes	
9-42	1893-1894	a	
9-43	1895-1903	putative	
9-44	1904-1908	band	
9-45	1909-1912	4.1	
9-46	1913-1923	homologues	
9-47	1923-1924	'	
9-48	1925-1932	binding	
9-49	1933-1938	motif	
9-50	1939-1940	(	
9-51	1940-1943	4.1	
9-52	1944-1945	m	
9-53	1945-1946	)	
9-54	1947-1953	domain	
9-55	1953-1954	.	

#Text=The protein encoded by the gene is a cell surface proteoglycan, syndecan, which is an integral membrane protein acting as a receptor for extracellular matrix.
10-1	1955-1958	The	
10-2	1959-1966	protein	
10-3	1967-1974	encoded	
10-4	1975-1977	by	
10-5	1978-1981	the	
10-6	1982-1986	gene	
10-7	1987-1989	is	
10-8	1990-1991	a	
10-9	1992-1996	cell	
10-10	1997-2004	surface	
10-11	2005-2017	proteoglycan	
10-12	2017-2018	,	
10-13	2019-2027	syndecan	
10-14	2027-2028	,	
10-15	2029-2034	which	
10-16	2035-2037	is	
10-17	2038-2040	an	
10-18	2041-2049	integral	
10-19	2050-2058	membrane	
10-20	2059-2066	protein	
10-21	2067-2073	acting	
10-22	2074-2076	as	
10-23	2077-2078	a	
10-24	2079-2087	receptor	
10-25	2088-2091	for	
10-26	2092-2105	extracellular	
10-27	2106-2112	matrix	
10-28	2112-2113	.	

#Text=It belongs to the group of transmembrane heparin sulfate proteoglycans.
11-1	2114-2116	It	
11-2	2117-2124	belongs	
11-3	2125-2127	to	
11-4	2128-2131	the	
11-5	2132-2137	group	
11-6	2138-2140	of	
11-7	2141-2154	transmembrane	
11-8	2155-2162	heparin	
11-9	2163-2170	sulfate	
11-10	2171-2184	proteoglycans	
11-11	2184-2185	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0694] NSC 812:NMB; this gene encodes a signal peptide and a transmembrane domain.
12-1	2186-2189	The	
12-2	2190-2195	lower	
12-3	2196-2206	expression	
12-4	2207-2209	of	
12-5	2210-2214	this	
12-6	2215-2219	gene	
12-7	2220-2222	in	
12-8	2223-2229	normal	
12-9	2230-2237	tissues	
12-10	2237-2238	,	
12-11	2239-2243	high	
12-12	2244-2254	expression	
12-13	2255-2257	in	
12-14	2258-2264	NSCLCs	
12-15	2264-2265	,	
12-16	2266-2269	and	
12-17	2270-2277	reduced	
12-18	2278-2284	growth	
12-19	2284-2285	,	
12-20	2286-2299	proliferation	
12-21	2300-2303	and	
12-22	2303-2304	/	
12-23	2304-2306	or	
12-24	2307-2315	survival	
12-25	2316-2318	of	
12-26	2319-2322	the	
12-27	2323-2334	transfected	
12-28	2335-2340	cells	
12-29	2341-2343	by	
12-30	2344-2347	the	
12-31	2348-2359	suppression	
12-32	2360-2362	of	
12-33	2363-2367	this	
12-34	2368-2372	gene	
12-35	2373-2380	suggest	
12-36	2381-2385	that	
12-37	2386-2390	this	
12-38	2391-2395	gene	
12-39	2396-2401	might	
12-40	2402-2404	be	
12-41	2405-2411	useful	
12-42	2412-2414	as	
12-43	2415-2416	a	
12-44	2417-2422	novel	
12-45	2423-2433	diagnostic	
12-46	2434-2440	marker	
12-47	2441-2444	and	
12-48	2445-2451	target	
12-49	2452-2455	for	
12-50	2456-2459	new	
12-51	2460-2465	drugs	
12-52	2466-2469	and	
12-53	2470-2483	immunotherapy	
12-54	2483-2484	.	
12-55	2485-2486	[	
12-56	2486-2490	0694	
12-57	2490-2491	]	
12-58	2492-2495	NSC	
12-59	2496-2499	812	
12-60	2499-2500	:	
12-61	2500-2503	NMB	
12-62	2503-2504	;	
12-63	2505-2509	this	
12-64	2510-2514	gene	
12-65	2515-2522	encodes	
12-66	2523-2524	a	
12-67	2525-2531	signal	
12-68	2532-2539	peptide	
12-69	2540-2543	and	
12-70	2544-2545	a	
12-71	2546-2559	transmembrane	
12-72	2560-2566	domain	
12-73	2566-2567	.	

#Text=The protein encoded by the gene functions as a neuromedin B, a member of the bombesin family, which is an autocrine growth factors for lung carcinomas.
13-1	2568-2571	The	
13-2	2572-2579	protein	
13-3	2580-2587	encoded	
13-4	2588-2590	by	
13-5	2591-2594	the	
13-6	2595-2599	gene	
13-7	2600-2609	functions	
13-8	2610-2612	as	
13-9	2613-2614	a	
13-10	2615-2625	neuromedin	
13-11	2626-2627	B	
13-12	2627-2628	,	
13-13	2629-2630	a	
13-14	2631-2637	member	
13-15	2638-2640	of	
13-16	2641-2644	the	
13-17	2645-2653	bombesin	
13-18	2654-2660	family	
13-19	2660-2661	,	
13-20	2662-2667	which	
13-21	2668-2670	is	
13-22	2671-2673	an	
13-23	2674-2683	autocrine	
13-24	2684-2690	growth	
13-25	2691-2698	factors	
13-26	2699-2702	for	
13-27	2703-2707	lung	
13-28	2708-2718	carcinomas	
13-29	2718-2719	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0695] NSC 816: PIR51; the protein encoded by the gene is localized in the nucleus and no domain was found in the protein.
14-1	2720-2723	The	
14-2	2724-2729	lower	
14-3	2730-2740	expression	
14-4	2741-2743	of	
14-5	2744-2748	this	
14-6	2749-2753	gene	
14-7	2754-2756	in	
14-8	2757-2763	normal	
14-9	2764-2771	tissues	
14-10	2771-2772	,	
14-11	2773-2777	high	
14-12	2778-2788	expression	
14-13	2789-2791	in	
14-14	2792-2798	NSCLCs	
14-15	2798-2799	,	
14-16	2800-2803	and	
14-17	2804-2811	reduced	
14-18	2812-2818	growth	
14-19	2818-2819	,	
14-20	2820-2833	proliferation	
14-21	2834-2837	and	
14-22	2837-2838	/	
14-23	2838-2840	or	
14-24	2841-2849	survival	
14-25	2850-2852	of	
14-26	2853-2856	the	
14-27	2857-2868	transfected	
14-28	2869-2874	cells	
14-29	2875-2877	by	
14-30	2878-2881	the	
14-31	2882-2893	suppression	
14-32	2894-2896	of	
14-33	2897-2901	this	
14-34	2902-2906	gene	
14-35	2907-2914	suggest	
14-36	2915-2919	that	
14-37	2920-2924	this	
14-38	2925-2929	gene	
14-39	2930-2935	might	
14-40	2936-2938	be	
14-41	2939-2945	useful	
14-42	2946-2948	as	
14-43	2949-2950	a	
14-44	2951-2956	novel	
14-45	2957-2967	diagnostic	
14-46	2968-2974	marker	
14-47	2975-2978	and	
14-48	2979-2985	target	
14-49	2986-2989	for	
14-50	2990-2993	new	
14-51	2994-2999	drugs	
14-52	3000-3003	and	
14-53	3004-3017	immunotherapy	
14-54	3017-3018	.	
14-55	3019-3020	[	
14-56	3020-3024	0695	
14-57	3024-3025	]	
14-58	3026-3029	NSC	
14-59	3030-3033	816	
14-60	3033-3034	:	
14-61	3035-3040	PIR51	
14-62	3040-3041	;	
14-63	3042-3045	the	
14-64	3046-3053	protein	
14-65	3054-3061	encoded	
14-66	3062-3064	by	
14-67	3065-3068	the	
14-68	3069-3073	gene	
14-69	3074-3076	is	
14-70	3077-3086	localized	
14-71	3087-3089	in	
14-72	3090-3093	the	
14-73	3094-3101	nucleus	
14-74	3102-3105	and	
14-75	3106-3108	no	
14-76	3109-3115	domain	
14-77	3116-3119	was	
14-78	3120-3125	found	
14-79	3126-3128	in	
14-80	3129-3132	the	
14-81	3133-3140	protein	
14-82	3140-3141	.	

#Text=The protein functions as a DNA- and RNA-binding protein; interacts with the RAD51 recombinase protein involved in DNA recombination and repair.
15-1	3142-3145	The	
15-2	3146-3153	protein	
15-3	3154-3163	functions	
15-4	3164-3166	as	
15-5	3167-3168	a	
15-6	3169-3172	DNA	
15-7	3172-3173	-	
15-8	3174-3177	and	
15-9	3178-3189	RNA-binding	
15-10	3190-3197	protein	
15-11	3197-3198	;	
15-12	3199-3208	interacts	
15-13	3209-3213	with	
15-14	3214-3217	the	
15-15	3218-3223	RAD51	
15-16	3224-3235	recombinase	
15-17	3236-3243	protein	
15-18	3244-3252	involved	
15-19	3253-3255	in	
15-20	3256-3259	DNA	
15-21	3260-3273	recombination	
15-22	3274-3277	and	
15-23	3278-3284	repair	
15-24	3284-3285	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as novel diagnostic marker and target for new drugs and immunotherapy. [0696] NSC 825: ANLN; this gene encodes a PH domain, several putative functions of which have been suggested: (1) binding to the beta/gamma subunit of heterotrimeric G proteins; (2) binding to lipids, e.g., phosphatidylinositol-4,5-bisphosphate; (3) binding to phosphorylated Ser/Thr residues; and (4) attachment to membranes by an unknown mechanism.
16-1	3286-3289	The	
16-2	3290-3295	lower	
16-3	3296-3306	expression	
16-4	3307-3309	of	
16-5	3310-3314	this	
16-6	3315-3319	gene	
16-7	3320-3322	in	
16-8	3323-3329	normal	
16-9	3330-3337	tissues	
16-10	3337-3338	,	
16-11	3339-3343	high	
16-12	3344-3354	expression	
16-13	3355-3357	in	
16-14	3358-3364	NSCLCs	
16-15	3364-3365	,	
16-16	3366-3369	and	
16-17	3370-3377	reduced	
16-18	3378-3384	growth	
16-19	3384-3385	,	
16-20	3386-3399	proliferation	
16-21	3400-3403	and	
16-22	3403-3404	/	
16-23	3404-3406	or	
16-24	3407-3415	survival	
16-25	3416-3418	of	
16-26	3419-3422	the	
16-27	3423-3434	transfected	
16-28	3435-3440	cells	
16-29	3441-3443	by	
16-30	3444-3447	the	
16-31	3448-3459	suppression	
16-32	3460-3462	of	
16-33	3463-3467	this	
16-34	3468-3472	gene	
16-35	3473-3480	suggest	
16-36	3481-3485	that	
16-37	3486-3490	this	
16-38	3491-3495	gene	
16-39	3496-3501	might	
16-40	3502-3504	be	
16-41	3505-3511	useful	
16-42	3512-3514	as	
16-43	3515-3520	novel	
16-44	3521-3531	diagnostic	
16-45	3532-3538	marker	
16-46	3539-3542	and	
16-47	3543-3549	target	
16-48	3550-3553	for	
16-49	3554-3557	new	
16-50	3558-3563	drugs	
16-51	3564-3567	and	
16-52	3568-3581	immunotherapy	
16-53	3581-3582	.	
16-54	3583-3584	[	
16-55	3584-3588	0696	
16-56	3588-3589	]	
16-57	3590-3593	NSC	
16-58	3594-3597	825	
16-59	3597-3598	:	
16-60	3599-3603	ANLN	
16-61	3603-3604	;	
16-62	3605-3609	this	
16-63	3610-3614	gene	
16-64	3615-3622	encodes	
16-65	3623-3624	a	
16-66	3625-3627	PH	
16-67	3628-3634	domain	
16-68	3634-3635	,	
16-69	3636-3643	several	
16-70	3644-3652	putative	
16-71	3653-3662	functions	
16-72	3663-3665	of	
16-73	3666-3671	which	
16-74	3672-3676	have	
16-75	3677-3681	been	
16-76	3682-3691	suggested	
16-77	3691-3692	:	
16-78	3693-3694	(	
16-79	3694-3695	1	
16-80	3695-3696	)	
16-81	3697-3704	binding	
16-82	3705-3707	to	
16-83	3708-3711	the	
16-84	3712-3716	beta	
16-85	3716-3717	/	
16-86	3717-3722	gamma	
16-87	3723-3730	subunit	
16-88	3731-3733	of	
16-89	3734-3748	heterotrimeric	
16-90	3749-3750	G	
16-91	3751-3759	proteins	
16-92	3759-3760	;	
16-93	3761-3762	(	
16-94	3762-3763	2	
16-95	3763-3764	)	
16-96	3765-3772	binding	
16-97	3773-3775	to	
16-98	3776-3782	lipids	
16-99	3782-3783	,	
16-100	3784-3787	e.g	
16-101	3787-3788	.	
16-102	3788-3789	,	
16-103	3790-3810	phosphatidylinositol	
16-104	3810-3811	-	
16-105	3811-3814	4,5	
16-106	3814-3815	-	
16-107	3815-3827	bisphosphate	
16-108	3827-3828	;	
16-109	3829-3830	(	
16-110	3830-3831	3	
16-111	3831-3832	)	
16-112	3833-3840	binding	
16-113	3841-3843	to	
16-114	3844-3858	phosphorylated	
16-115	3859-3862	Ser	
16-116	3862-3863	/	
16-117	3863-3866	Thr	
16-118	3867-3875	residues	
16-119	3875-3876	;	
16-120	3877-3880	and	
16-121	3881-3882	(	
16-122	3882-3883	4	
16-123	3883-3884	)	
16-124	3885-3895	attachment	
16-125	3896-3898	to	
16-126	3899-3908	membranes	
16-127	3909-3911	by	
16-128	3912-3914	an	
16-129	3915-3922	unknown	
16-130	3923-3932	mechanism	
16-131	3932-3933	.	

#Text=The gene encodes an actin binding protein that interacts with cleavage furrow proteins, such as septins, and may play a role in cytokinesis.
17-1	3934-3937	The	
17-2	3938-3942	gene	
17-3	3943-3950	encodes	
17-4	3951-3953	an	
17-5	3954-3959	actin	
17-6	3960-3967	binding	
17-7	3968-3975	protein	
17-8	3976-3980	that	
17-9	3981-3990	interacts	
17-10	3991-3995	with	
17-11	3996-4004	cleavage	
17-12	4005-4011	furrow	
17-13	4012-4020	proteins	
17-14	4020-4021	,	
17-15	4022-4026	such	
17-16	4027-4029	as	
17-17	4030-4037	septins	
17-18	4037-4038	,	
17-19	4039-4042	and	
17-20	4043-4046	may	
17-21	4047-4051	play	
17-22	4052-4053	a	
17-23	4054-4058	role	
17-24	4059-4061	in	
17-25	4062-4073	cytokinesis	
17-26	4073-4074	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0697] NSC 841: URLC2; this gene encodes a Jmjc domain (a domain family that is a part of the cupin metalloenzyme).
18-1	4075-4078	The	
18-2	4079-4084	lower	
18-3	4085-4095	expression	
18-4	4096-4098	of	
18-5	4099-4103	this	
18-6	4104-4108	gene	
18-7	4109-4111	in	
18-8	4112-4118	normal	
18-9	4119-4126	tissues	
18-10	4126-4127	,	
18-11	4128-4132	high	
18-12	4133-4143	expression	
18-13	4144-4146	in	
18-14	4147-4153	NSCLCs	
18-15	4153-4154	,	
18-16	4155-4158	and	
18-17	4159-4166	reduced	
18-18	4167-4173	growth	
18-19	4173-4174	,	
18-20	4175-4188	proliferation	
18-21	4189-4192	and	
18-22	4192-4193	/	
18-23	4193-4195	or	
18-24	4196-4204	survival	
18-25	4205-4207	of	
18-26	4208-4211	the	
18-27	4212-4223	transfected	
18-28	4224-4229	cells	
18-29	4230-4232	by	
18-30	4233-4236	the	
18-31	4237-4248	suppression	
18-32	4249-4251	of	
18-33	4252-4256	this	
18-34	4257-4261	gene	
18-35	4262-4269	suggest	
18-36	4270-4274	that	
18-37	4275-4279	this	
18-38	4280-4284	gene	
18-39	4285-4290	might	
18-40	4291-4293	be	
18-41	4294-4300	useful	
18-42	4301-4303	as	
18-43	4304-4305	a	
18-44	4306-4311	novel	
18-45	4312-4322	diagnostic	
18-46	4323-4329	marker	
18-47	4330-4333	and	
18-48	4334-4340	target	
18-49	4341-4344	for	
18-50	4345-4348	new	
18-51	4349-4354	drugs	
18-52	4355-4358	and	
18-53	4359-4372	immunotherapy	
18-54	4372-4373	.	
18-55	4374-4375	[	
18-56	4375-4379	0697	
18-57	4379-4380	]	
18-58	4381-4384	NSC	
18-59	4385-4388	841	
18-60	4388-4389	:	
18-61	4390-4395	URLC2	
18-62	4395-4396	;	
18-63	4397-4401	this	
18-64	4402-4406	gene	
18-65	4407-4414	encodes	
18-66	4415-4416	a	
18-67	4417-4421	Jmjc	
18-68	4422-4428	domain	
18-69	4429-4430	(	
18-70	4430-4431	a	
18-71	4432-4438	domain	
18-72	4439-4445	family	
18-73	4446-4450	that	
18-74	4451-4453	is	
18-75	4454-4455	a	
18-76	4456-4460	part	
18-77	4461-4463	of	
18-78	4464-4467	the	
18-79	4468-4473	cupin	
18-80	4474-4487	metalloenzyme	
18-81	4487-4488	)	
18-82	4488-4489	.	

#Text=The protein encoded by the gene probably is an enzyme with unknown functions that regulates the chromatin reorganization processes.
19-1	4490-4493	The	
19-2	4494-4501	protein	
19-3	4502-4509	encoded	
19-4	4510-4512	by	
19-5	4513-4516	the	
19-6	4517-4521	gene	
19-7	4522-4530	probably	
19-8	4531-4533	is	
19-9	4534-4536	an	
19-10	4537-4543	enzyme	
19-11	4544-4548	with	
19-12	4549-4556	unknown	
19-13	4557-4566	functions	
19-14	4567-4571	that	
19-15	4572-4581	regulates	
19-16	4582-4585	the	
19-17	4586-4595	chromatin	
19-18	4596-4610	reorganization	
19-19	4611-4620	processes	
19-20	4620-4621	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as novel diagnostic marker and target for new drugs and immunotherapy.
20-1	4622-4625	The	
20-2	4626-4631	lower	
20-3	4632-4642	expression	
20-4	4643-4645	of	
20-5	4646-4650	this	
20-6	4651-4655	gene	
20-7	4656-4658	in	
20-8	4659-4665	normal	
20-9	4666-4673	tissues	
20-10	4673-4674	,	
20-11	4675-4679	high	
20-12	4680-4690	expression	
20-13	4691-4693	in	
20-14	4694-4700	NSCLCs	
20-15	4700-4701	,	
20-16	4702-4705	and	
20-17	4706-4713	reduced	
20-18	4714-4720	growth	
20-19	4720-4721	,	
20-20	4722-4735	proliferation	
20-21	4736-4739	and	
20-22	4739-4740	/	
20-23	4740-4742	or	
20-24	4743-4751	survival	
20-25	4752-4754	of	
20-26	4755-4758	the	
20-27	4759-4770	transfected	
20-28	4771-4776	cells	
20-29	4777-4779	by	
20-30	4780-4783	the	
20-31	4784-4795	suppression	
20-32	4796-4798	of	
20-33	4799-4803	this	
20-34	4804-4808	gene	
20-35	4809-4816	suggest	
20-36	4817-4821	that	
20-37	4822-4826	this	
20-38	4827-4831	gene	
20-39	4832-4837	might	
20-40	4838-4840	be	
20-41	4841-4847	useful	
20-42	4848-4850	as	
20-43	4851-4856	novel	
20-44	4857-4867	diagnostic	
20-45	4868-4874	marker	
20-46	4875-4878	and	
20-47	4879-4885	target	
20-48	4886-4889	for	
20-49	4890-4893	new	
20-50	4894-4899	drugs	
20-51	4900-4903	and	
20-52	4904-4917	immunotherapy	
20-53	4917-4918	.	

#Text=According to the present study, the suppression of URLC2 induced apoptosis of LC319 cells.
21-1	4919-4928	According	
21-2	4929-4931	to	
21-3	4932-4935	the	
21-4	4936-4943	present	
21-5	4944-4949	study	
21-6	4949-4950	,	
21-7	4951-4954	the	
21-8	4955-4966	suppression	
21-9	4967-4969	of	
21-10	4970-4975	URLC2	
21-11	4976-4983	induced	
21-12	4984-4993	apoptosis	
21-13	4994-4996	of	
21-14	4997-5002	LC319	
21-15	5003-5008	cells	
21-16	5008-5009	.	

#Text=Moreover, URLC2 protein expressed in stable transfectant promoted the growth of NIH3T3 cells in a dose dependent manner.
22-1	5010-5018	Moreover	
22-2	5018-5019	,	
22-3	5020-5025	URLC2	
22-4	5026-5033	protein	
22-5	5034-5043	expressed	
22-6	5044-5046	in	
22-7	5047-5053	stable	
22-8	5054-5066	transfectant	
22-9	5067-5075	promoted	
22-10	5076-5079	the	
22-11	5080-5086	growth	
22-12	5087-5089	of	
22-13	5090-5096	NIH3T3	
22-14	5097-5102	cells	
22-15	5103-5105	in	
22-16	5106-5107	a	
22-17	5108-5112	dose	
22-18	5113-5122	dependent	
22-19	5123-5129	manner	
22-20	5129-5130	.	

#Text=This result suggests that over-expressed URLC2 have a transforming effect on mammalian cells.
23-1	5131-5135	This	
23-2	5136-5142	result	
23-3	5143-5151	suggests	
23-4	5152-5156	that	
23-5	5157-5171	over-expressed	
23-6	5172-5177	URLC2	
23-7	5178-5182	have	
23-8	5183-5184	a	
23-9	5185-5197	transforming	
23-10	5198-5204	effect	
23-11	5205-5207	on	
23-12	5208-5217	mammalian	
23-13	5218-5223	cells	
23-14	5223-5224	.	

#Text=These data reveal that URLC2 might be a novel oncogene for NSCLC and suggest that a promising therapeutic strategy for treating lung cancers can be established by focusing on the URLC2. [0698] NSC 849:GJB5; this gene encodes a gap junction protein, beta 5 (connexin 31.1).
24-1	5225-5230	These	
24-2	5231-5235	data	
24-3	5236-5242	reveal	
24-4	5243-5247	that	
24-5	5248-5253	URLC2	
24-6	5254-5259	might	
24-7	5260-5262	be	
24-8	5263-5264	a	
24-9	5265-5270	novel	
24-10	5271-5279	oncogene	
24-11	5280-5283	for	
24-12	5284-5289	NSCLC	
24-13	5290-5293	and	
24-14	5294-5301	suggest	
24-15	5302-5306	that	
24-16	5307-5308	a	
24-17	5309-5318	promising	
24-18	5319-5330	therapeutic	
24-19	5331-5339	strategy	
24-20	5340-5343	for	
24-21	5344-5352	treating	
24-22	5353-5357	lung	
24-23	5358-5365	cancers	
24-24	5366-5369	can	
24-25	5370-5372	be	
24-26	5373-5384	established	
24-27	5385-5387	by	
24-28	5388-5396	focusing	
24-29	5397-5399	on	
24-30	5400-5403	the	
24-31	5404-5409	URLC2	
24-32	5409-5410	.	
24-33	5411-5412	[	
24-34	5412-5416	0698	
24-35	5416-5417	]	
24-36	5418-5421	NSC	
24-37	5422-5425	849	
24-38	5425-5426	:	
24-39	5426-5430	GJB5	
24-40	5430-5431	;	
24-41	5432-5436	this	
24-42	5437-5441	gene	
24-43	5442-5449	encodes	
24-44	5450-5451	a	
24-45	5452-5455	gap	
24-46	5456-5464	junction	
24-47	5465-5472	protein	
24-48	5472-5473	,	
24-49	5474-5478	beta	
24-50	5479-5480	5	
24-51	5481-5482	(	
24-52	5482-5490	connexin	
24-53	5491-5495	31.1	
24-54	5495-5496	)	
24-55	5496-5497	.	

#Text=GJB5 is a member of the connexin family (beta-type (group i) subfamily).
25-1	5498-5502	GJB5	
25-2	5503-5505	is	
25-3	5506-5507	a	
25-4	5508-5514	member	
25-5	5515-5517	of	
25-6	5518-5521	the	
25-7	5522-5530	connexin	
25-8	5531-5537	family	
25-9	5538-5539	(	
25-10	5539-5548	beta-type	
25-11	5549-5550	(	
25-12	5550-5555	group	
25-13	5556-5557	i	
25-14	5557-5558	)	
25-15	5559-5568	subfamily	
25-16	5568-5569	)	
25-17	5569-5570	.	

#Text=It is reported that one gap junction consists of a cluster of closely packed pairs of transmembrane channels, connexons, through which materials of low molecular weight diffuse from one cell to a neighboring cell.
26-1	5571-5573	It	
26-2	5574-5576	is	
26-3	5577-5585	reported	
26-4	5586-5590	that	
26-5	5591-5594	one	
26-6	5595-5598	gap	
26-7	5599-5607	junction	
26-8	5608-5616	consists	
26-9	5617-5619	of	
26-10	5620-5621	a	
26-11	5622-5629	cluster	
26-12	5630-5632	of	
26-13	5633-5640	closely	
26-14	5641-5647	packed	
26-15	5648-5653	pairs	
26-16	5654-5656	of	
26-17	5657-5670	transmembrane	
26-18	5671-5679	channels	
26-19	5679-5680	,	
26-20	5681-5690	connexons	
26-21	5690-5691	,	
26-22	5692-5699	through	
26-23	5700-5705	which	
26-24	5706-5715	materials	
26-25	5716-5718	of	
26-26	5719-5722	low	
26-27	5723-5732	molecular	
26-28	5733-5739	weight	
26-29	5740-5747	diffuse	
26-30	5748-5752	from	
26-31	5753-5756	one	
26-32	5757-5761	cell	
26-33	5762-5764	to	
26-34	5765-5766	a	
26-35	5767-5778	neighboring	
26-36	5779-5783	cell	
26-37	5783-5784	.	

#Text=A connexon is composed of a hexamer of connexins.
27-1	5785-5786	A	
27-2	5787-5795	connexon	
27-3	5796-5798	is	
27-4	5799-5807	composed	
27-5	5808-5810	of	
27-6	5811-5812	a	
27-7	5813-5820	hexamer	
27-8	5821-5823	of	
27-9	5824-5833	connexins	
27-10	5833-5834	.	

#Text=The protein encoded by the gene was mainly detected in the cytoplasmic membrane by the immunocytochemical analysis.
28-1	5835-5838	The	
28-2	5839-5846	protein	
28-3	5847-5854	encoded	
28-4	5855-5857	by	
28-5	5858-5861	the	
28-6	5862-5866	gene	
28-7	5867-5870	was	
28-8	5871-5877	mainly	
28-9	5878-5886	detected	
28-10	5887-5889	in	
28-11	5890-5893	the	
28-12	5894-5905	cytoplasmic	
28-13	5906-5914	membrane	
28-14	5915-5917	by	
28-15	5918-5921	the	
28-16	5922-5940	immunocytochemical	
28-17	5941-5949	analysis	
28-18	5949-5950	.	

#Text=The lower expression of this gene in normal tissues and high expression in NSCLCs suggest that this gene might be useful as a diagnostic marker (i.e., in diagnosis using serum or sputum) and therapeutic target for NSCLCs. [0699] NSC 855: LNIR; this gene encodes a signal peptide, immunoglobulin, immunoglobulin C2 domain and one transmembrane domain.
29-1	5951-5954	The	
29-2	5955-5960	lower	
29-3	5961-5971	expression	
29-4	5972-5974	of	
29-5	5975-5979	this	
29-6	5980-5984	gene	
29-7	5985-5987	in	
29-8	5988-5994	normal	
29-9	5995-6002	tissues	
29-10	6003-6006	and	
29-11	6007-6011	high	
29-12	6012-6022	expression	
29-13	6023-6025	in	
29-14	6026-6032	NSCLCs	
29-15	6033-6040	suggest	
29-16	6041-6045	that	
29-17	6046-6050	this	
29-18	6051-6055	gene	
29-19	6056-6061	might	
29-20	6062-6064	be	
29-21	6065-6071	useful	
29-22	6072-6074	as	
29-23	6075-6076	a	
29-24	6077-6087	diagnostic	
29-25	6088-6094	marker	
29-26	6095-6096	(	
29-27	6096-6099	i.e	
29-28	6099-6100	.	
29-29	6100-6101	,	
29-30	6102-6104	in	
29-31	6105-6114	diagnosis	
29-32	6115-6120	using	
29-33	6121-6126	serum	
29-34	6127-6129	or	
29-35	6130-6136	sputum	
29-36	6136-6137	)	
29-37	6138-6141	and	
29-38	6142-6153	therapeutic	
29-39	6154-6160	target	
29-40	6161-6164	for	
29-41	6165-6171	NSCLCs	
29-42	6171-6172	.	
29-43	6173-6174	[	
29-44	6174-6178	0699	
29-45	6178-6179	]	
29-46	6180-6183	NSC	
29-47	6184-6187	855	
29-48	6187-6188	:	
29-49	6189-6193	LNIR	
29-50	6193-6194	;	
29-51	6195-6199	this	
29-52	6200-6204	gene	
29-53	6205-6212	encodes	
29-54	6213-6214	a	
29-55	6215-6221	signal	
29-56	6222-6229	peptide	
29-57	6229-6230	,	
29-58	6231-6245	immunoglobulin	
29-59	6245-6246	,	
29-60	6247-6261	immunoglobulin	
29-61	6262-6264	C2	
29-62	6265-6271	domain	
29-63	6272-6275	and	
29-64	6276-6279	one	
29-65	6280-6293	transmembrane	
29-66	6294-6300	domain	
29-67	6300-6301	.	

#Text=The transmembrane protein encoded by the gene is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
30-1	6302-6305	The	
30-2	6306-6319	transmembrane	
30-3	6320-6327	protein	
30-4	6328-6335	encoded	
30-5	6336-6338	by	
30-6	6339-6342	the	
30-7	6343-6347	gene	
30-8	6348-6350	is	
30-9	6351-6359	supposed	
30-10	6360-6362	to	
30-11	6363-6365	be	
30-12	6366-6380	over-expressed	
30-13	6381-6383	on	
30-14	6384-6387	the	
30-15	6388-6395	surface	
30-16	6396-6398	of	
30-17	6399-6404	tumor	
30-18	6405-6410	cells	
30-19	6411-6414	but	
30-20	6415-6418	not	
30-21	6419-6421	on	
30-22	6422-6428	normal	
30-23	6429-6434	cells	
30-24	6434-6435	.	

#Text=Thus, the gene may be a good target for receptor-targeted therapy or diagnosis. [0700] NSC 857: TIGD5; this gene encodes a Centromere Protein B (CENP-B).
31-1	6436-6440	Thus	
31-2	6440-6441	,	
31-3	6442-6445	the	
31-4	6446-6450	gene	
31-5	6451-6454	may	
31-6	6455-6457	be	
31-7	6458-6459	a	
31-8	6460-6464	good	
31-9	6465-6471	target	
31-10	6472-6475	for	
31-11	6476-6493	receptor-targeted	
31-12	6494-6501	therapy	
31-13	6502-6504	or	
31-14	6505-6514	diagnosis	
31-15	6514-6515	.	
31-16	6516-6517	[	
31-17	6517-6521	0700	
31-18	6521-6522	]	
31-19	6523-6526	NSC	
31-20	6527-6530	857	
31-21	6530-6531	:	
31-22	6532-6537	TIGD5	
31-23	6537-6538	;	
31-24	6539-6543	this	
31-25	6544-6548	gene	
31-26	6549-6556	encodes	
31-27	6557-6558	a	
31-28	6559-6569	Centromere	
31-29	6570-6577	Protein	
31-30	6578-6579	B	
31-31	6580-6581	(	
31-32	6581-6587	CENP-B	
31-33	6587-6588	)	
31-34	6588-6589	.	

#Text=CENP-B is a DNA-binding protein localized to the centromere.
32-1	6590-6596	CENP-B	
32-2	6597-6599	is	
32-3	6600-6601	a	
32-4	6602-6613	DNA-binding	
32-5	6614-6621	protein	
32-6	6622-6631	localized	
32-7	6632-6634	to	
32-8	6635-6638	the	
32-9	6639-6649	centromere	
32-10	6649-6650	.	

#Text=Within the N-terminal 125 residues of the protein, there is a DNA-binding domain, which binds to a corresponding 17 bp CENP-B box sequence.
33-1	6651-6657	Within	
33-2	6658-6661	the	
33-3	6662-6672	N-terminal	
33-4	6673-6676	125	
33-5	6677-6685	residues	
33-6	6686-6688	of	
33-7	6689-6692	the	
33-8	6693-6700	protein	
33-9	6700-6701	,	
33-10	6702-6707	there	
33-11	6708-6710	is	
33-12	6711-6712	a	
33-13	6713-6724	DNA-binding	
33-14	6725-6731	domain	
33-15	6731-6732	,	
33-16	6733-6738	which	
33-17	6739-6744	binds	
33-18	6745-6747	to	
33-19	6748-6749	a	
33-20	6750-6763	corresponding	
33-21	6764-6766	17	
33-22	6767-6769	bp	
33-23	6770-6776	CENP-B	
33-24	6777-6780	box	
33-25	6781-6789	sequence	
33-26	6789-6790	.	

#Text=In the C-terminal 59 residues, CENP-B has a dimerization domain.
34-1	6791-6793	In	
34-2	6794-6797	the	
34-3	6798-6808	C-terminal	
34-4	6809-6811	59	
34-5	6812-6820	residues	
34-6	6820-6821	,	
34-7	6822-6828	CENP-B	
34-8	6829-6832	has	
34-9	6833-6834	a	
34-10	6835-6847	dimerization	
34-11	6848-6854	domain	
34-12	6854-6855	.	

#Text=CENP-B dimers binds either a two separate DNA molecule or two CENP-B boxes on one DNA molecule, with the intervening stretch of DNA forming a loop structure.
35-1	6856-6862	CENP-B	
35-2	6863-6869	dimers	
35-3	6870-6875	binds	
35-4	6876-6882	either	
35-5	6883-6884	a	
35-6	6885-6888	two	
35-7	6889-6897	separate	
35-8	6898-6901	DNA	
35-9	6902-6910	molecule	
35-10	6911-6913	or	
35-11	6914-6917	two	
35-12	6918-6924	CENP-B	
35-13	6925-6930	boxes	
35-14	6931-6933	on	
35-15	6934-6937	one	
35-16	6938-6941	DNA	
35-17	6942-6950	molecule	
35-18	6950-6951	,	
35-19	6952-6956	with	
35-20	6957-6960	the	
35-21	6961-6972	intervening	
35-22	6973-6980	stretch	
35-23	6981-6983	of	
35-24	6984-6987	DNA	
35-25	6988-6995	forming	
35-26	6996-6997	a	
35-27	6998-7002	loop	
35-28	7003-7012	structure	
35-29	7012-7013	.	

#Text=This gene belongs to the tigger subfamily of the pogo superfamily of DNA-mediated transposons in humans.
36-1	7014-7018	This	
36-2	7019-7023	gene	
36-3	7024-7031	belongs	
36-4	7032-7034	to	
36-5	7035-7038	the	
36-6	7039-7045	tigger	
36-7	7046-7055	subfamily	
36-8	7056-7058	of	
36-9	7059-7062	the	
36-10	7063-7067	pogo	
36-11	7068-7079	superfamily	
36-12	7080-7082	of	
36-13	7083-7095	DNA-mediated	
36-14	7096-7107	transposons	
36-15	7108-7110	in	
36-16	7111-7117	humans	
36-17	7117-7118	.	

#Text=The proteins belonging to this subfamily are related to DNA transposons found in fungi and nematodes, and more distantly to the Tc1 and mariner transposases.
37-1	7119-7122	The	
37-2	7123-7131	proteins	
37-3	7132-7141	belonging	
37-4	7142-7144	to	
37-5	7145-7149	this	
37-6	7150-7159	subfamily	
37-7	7160-7163	are	
37-8	7164-7171	related	
37-9	7172-7174	to	
37-10	7175-7178	DNA	
37-11	7179-7190	transposons	
37-12	7191-7196	found	
37-13	7197-7199	in	
37-14	7200-7205	fungi	
37-15	7206-7209	and	
37-16	7210-7219	nematodes	
37-17	7219-7220	,	
37-18	7221-7224	and	
37-19	7225-7229	more	
37-20	7230-7239	distantly	
37-21	7240-7242	to	
37-22	7243-7246	the	
37-23	7247-7250	Tc1	
37-24	7251-7254	and	
37-25	7255-7262	mariner	
37-26	7263-7275	transposases	
37-27	7275-7276	.	

#Text=The protein encoded by the gene is also very similar to the major mammalian centromere protein B.
38-1	7277-7280	The	
38-2	7281-7288	protein	
38-3	7289-7296	encoded	
38-4	7297-7299	by	
38-5	7300-7303	the	
38-6	7304-7308	gene	
38-7	7309-7311	is	
38-8	7312-7316	also	
38-9	7317-7321	very	
38-10	7322-7329	similar	
38-11	7330-7332	to	
38-12	7333-7336	the	
38-13	7337-7342	major	
38-14	7343-7352	mammalian	
38-15	7353-7363	centromere	
38-16	7364-7371	protein	
38-17	7372-7373	B	
38-18	7373-7374	.	

#Text=The exact function of this gene is unknown.
39-1	7375-7378	The	
39-2	7379-7384	exact	
39-3	7385-7393	function	
39-4	7394-7396	of	
39-5	7397-7401	this	
39-6	7402-7406	gene	
39-7	7407-7409	is	
39-8	7410-7417	unknown	
39-9	7417-7418	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0701] NSC 859: URLC3; this gene does not encode any known domain, and the protein encoded by the gene has 70% similarity over 56 amino acids to an eukaryotic translation initiation factor 3 subunit (Homo sapiens).
40-1	7419-7422	The	
40-2	7423-7428	lower	
40-3	7429-7439	expression	
40-4	7440-7442	of	
40-5	7443-7447	this	
40-6	7448-7452	gene	
40-7	7453-7455	in	
40-8	7456-7462	normal	
40-9	7463-7470	tissues	
40-10	7470-7471	,	
40-11	7472-7476	high	
40-12	7477-7487	expression	
40-13	7488-7490	in	
40-14	7491-7497	NSCLCs	
40-15	7497-7498	,	
40-16	7499-7502	and	
40-17	7503-7510	reduced	
40-18	7511-7517	growth	
40-19	7517-7518	,	
40-20	7519-7532	proliferation	
40-21	7533-7536	and	
40-22	7536-7537	/	
40-23	7537-7539	or	
40-24	7540-7548	survival	
40-25	7549-7551	of	
40-26	7552-7555	the	
40-27	7556-7567	transfected	
40-28	7568-7573	cells	
40-29	7574-7576	by	
40-30	7577-7580	the	
40-31	7581-7592	suppression	
40-32	7593-7595	of	
40-33	7596-7600	this	
40-34	7601-7605	gene	
40-35	7606-7613	suggest	
40-36	7614-7618	that	
40-37	7619-7623	this	
40-38	7624-7628	gene	
40-39	7629-7634	might	
40-40	7635-7637	be	
40-41	7638-7644	useful	
40-42	7645-7647	as	
40-43	7648-7649	a	
40-44	7650-7655	novel	
40-45	7656-7666	diagnostic	
40-46	7667-7673	marker	
40-47	7674-7677	and	
40-48	7678-7684	target	
40-49	7685-7688	for	
40-50	7689-7692	new	
40-51	7693-7698	drugs	
40-52	7699-7702	and	
40-53	7703-7716	immunotherapy	
40-54	7716-7717	.	
40-55	7718-7719	[	
40-56	7719-7723	0701	
40-57	7723-7724	]	
40-58	7725-7728	NSC	
40-59	7729-7732	859	
40-60	7732-7733	:	
40-61	7734-7739	URLC3	
40-62	7739-7740	;	
40-63	7741-7745	this	
40-64	7746-7750	gene	
40-65	7751-7755	does	
40-66	7756-7759	not	
40-67	7760-7766	encode	
40-68	7767-7770	any	
40-69	7771-7776	known	
40-70	7777-7783	domain	
40-71	7783-7784	,	
40-72	7785-7788	and	
40-73	7789-7792	the	
40-74	7793-7800	protein	
40-75	7801-7808	encoded	
40-76	7809-7811	by	
40-77	7812-7815	the	
40-78	7816-7820	gene	
40-79	7821-7824	has	
40-80	7825-7828	70%	
40-81	7829-7839	similarity	
40-82	7840-7844	over	
40-83	7845-7847	56	
40-84	7848-7853	amino	
40-85	7854-7859	acids	
40-86	7860-7862	to	
40-87	7863-7865	an	
40-88	7866-7876	eukaryotic	
40-89	7877-7888	translation	
40-90	7889-7899	initiation	
40-91	7900-7906	factor	
40-92	7907-7908	3	
40-93	7909-7916	subunit	
40-94	7917-7918	(	
40-95	7918-7922	Homo	
40-96	7923-7930	sapiens	
40-97	7930-7931	)	
40-98	7931-7932	.	

#Text=The subunit binds to the 40s ribosome and promotes the binding of methionyl-tRNAi and mRNA (by similarity).
41-1	7933-7936	The	
41-2	7937-7944	subunit	
41-3	7945-7950	binds	
41-4	7951-7953	to	
41-5	7954-7957	the	
41-6	7958-7961	40s	
41-7	7962-7970	ribosome	
41-8	7971-7974	and	
41-9	7975-7983	promotes	
41-10	7984-7987	the	
41-11	7988-7995	binding	
41-12	7996-7998	of	
41-13	7999-8014	methionyl-tRNAi	
41-14	8015-8018	and	
41-15	8019-8023	mRNA	
41-16	8024-8025	(	
41-17	8025-8027	by	
41-18	8028-8038	similarity	
41-19	8038-8039	)	
41-20	8039-8040	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0702] NSC 885: BAG5; this gene encodes a BAG domain.
42-1	8041-8044	The	
42-2	8045-8050	lower	
42-3	8051-8061	expression	
42-4	8062-8064	of	
42-5	8065-8069	this	
42-6	8070-8074	gene	
42-7	8075-8077	in	
42-8	8078-8084	normal	
42-9	8085-8092	tissues	
42-10	8092-8093	,	
42-11	8094-8098	high	
42-12	8099-8109	expression	
42-13	8110-8112	in	
42-14	8113-8119	NSCLCs	
42-15	8119-8120	,	
42-16	8121-8124	and	
42-17	8125-8132	reduced	
42-18	8133-8139	growth	
42-19	8139-8140	,	
42-20	8141-8154	proliferation	
42-21	8155-8158	and	
42-22	8158-8159	/	
42-23	8159-8161	or	
42-24	8162-8170	survival	
42-25	8171-8173	of	
42-26	8174-8177	the	
42-27	8178-8189	transfected	
42-28	8190-8195	cells	
42-29	8196-8198	by	
42-30	8199-8202	the	
42-31	8203-8214	suppression	
42-32	8215-8217	of	
42-33	8218-8222	this	
42-34	8223-8227	gene	
42-35	8228-8235	suggest	
42-36	8236-8240	that	
42-37	8241-8245	this	
42-38	8246-8250	gene	
42-39	8251-8256	might	
42-40	8257-8259	be	
42-41	8260-8266	useful	
42-42	8267-8269	as	
42-43	8270-8271	a	
42-44	8272-8277	novel	
42-45	8278-8288	diagnostic	
42-46	8289-8295	marker	
42-47	8296-8299	and	
42-48	8300-8306	target	
42-49	8307-8310	for	
42-50	8311-8314	new	
42-51	8315-8320	drugs	
42-52	8321-8324	and	
42-53	8325-8338	immunotherapy	
42-54	8338-8339	.	
42-55	8340-8341	[	
42-56	8341-8345	0702	
42-57	8345-8346	]	
42-58	8347-8350	NSC	
42-59	8351-8354	885	
42-60	8354-8355	:	
42-61	8356-8360	BAG5	
42-62	8360-8361	;	
42-63	8362-8366	this	
42-64	8367-8371	gene	
42-65	8372-8379	encodes	
42-66	8380-8381	a	
42-67	8382-8385	BAG	
42-68	8386-8392	domain	
42-69	8392-8393	.	

#Text=Thus, the protein encoded by this gene is a member of the BAG1-related protein family.
43-1	8394-8398	Thus	
43-2	8398-8399	,	
43-3	8400-8403	the	
43-4	8404-8411	protein	
43-5	8412-8419	encoded	
43-6	8420-8422	by	
43-7	8423-8427	this	
43-8	8428-8432	gene	
43-9	8433-8435	is	
43-10	8436-8437	a	
43-11	8438-8444	member	
43-12	8445-8447	of	
43-13	8448-8451	the	
43-14	8452-8456	BAG1	
43-15	8456-8457	-	
43-16	8457-8464	related	
43-17	8465-8472	protein	
43-18	8473-8479	family	
43-19	8479-8480	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0703] NSC 893: MPHOSP1; this gene encodes a KISc domain and microtubule-dependent molecular motors that play important roles in intracellular transport of organelles and in cell division.
44-1	8481-8484	The	
44-2	8485-8490	lower	
44-3	8491-8501	expression	
44-4	8502-8504	of	
44-5	8505-8509	this	
44-6	8510-8514	gene	
44-7	8515-8517	in	
44-8	8518-8524	normal	
44-9	8525-8532	tissues	
44-10	8532-8533	,	
44-11	8534-8538	high	
44-12	8539-8549	expression	
44-13	8550-8552	in	
44-14	8553-8559	NSCLCs	
44-15	8559-8560	,	
44-16	8561-8564	and	
44-17	8565-8572	reduced	
44-18	8573-8579	growth	
44-19	8579-8580	,	
44-20	8581-8594	proliferation	
44-21	8595-8598	and	
44-22	8598-8599	/	
44-23	8599-8601	or	
44-24	8602-8610	survival	
44-25	8611-8613	of	
44-26	8614-8617	the	
44-27	8618-8629	transfected	
44-28	8630-8635	cells	
44-29	8636-8638	by	
44-30	8639-8642	the	
44-31	8643-8654	suppression	
44-32	8655-8657	of	
44-33	8658-8662	this	
44-34	8663-8667	gene	
44-35	8668-8675	suggest	
44-36	8676-8680	that	
44-37	8681-8685	this	
44-38	8686-8690	gene	
44-39	8691-8696	might	
44-40	8697-8699	be	
44-41	8700-8706	useful	
44-42	8707-8709	as	
44-43	8710-8711	a	
44-44	8712-8717	novel	
44-45	8718-8728	diagnostic	
44-46	8729-8735	marker	
44-47	8736-8739	and	
44-48	8740-8746	target	
44-49	8747-8750	for	
44-50	8751-8754	new	
44-51	8755-8760	drugs	
44-52	8761-8764	and	
44-53	8765-8778	immunotherapy	
44-54	8778-8779	.	
44-55	8780-8781	[	
44-56	8781-8785	0703	
44-57	8785-8786	]	
44-58	8787-8790	NSC	
44-59	8791-8794	893	
44-60	8794-8795	:	
44-61	8796-8803	MPHOSP1	
44-62	8803-8804	;	
44-63	8805-8809	this	
44-64	8810-8814	gene	
44-65	8815-8822	encodes	
44-66	8823-8824	a	
44-67	8825-8829	KISc	
44-68	8830-8836	domain	
44-69	8837-8840	and	
44-70	8841-8862	microtubule-dependent	
44-71	8863-8872	molecular	
44-72	8873-8879	motors	
44-73	8880-8884	that	
44-74	8885-8889	play	
44-75	8890-8899	important	
44-76	8900-8905	roles	
44-77	8906-8908	in	
44-78	8909-8922	intracellular	
44-79	8923-8932	transport	
44-80	8933-8935	of	
44-81	8936-8946	organelles	
44-82	8947-8950	and	
44-83	8951-8953	in	
44-84	8954-8958	cell	
44-85	8959-8967	division	
44-86	8967-8968	.	

#Text=The protein encoded by the gene belongs to the kinesin-like protein family and interacts with guanosine triphosphate (gtp)-bound forms of rab6a and rab6b.
45-1	8969-8972	The	
45-2	8973-8980	protein	
45-3	8981-8988	encoded	
45-4	8989-8991	by	
45-5	8992-8995	the	
45-6	8996-9000	gene	
45-7	9001-9008	belongs	
45-8	9009-9011	to	
45-9	9012-9015	the	
45-10	9016-9028	kinesin-like	
45-11	9029-9036	protein	
45-12	9037-9043	family	
45-13	9044-9047	and	
45-14	9048-9057	interacts	
45-15	9058-9062	with	
45-16	9063-9072	guanosine	
45-17	9073-9085	triphosphate	
45-18	9086-9087	(	
45-19	9087-9090	gtp	
45-20	9090-9091	)	
45-21	9091-9092	-	
45-22	9092-9097	bound	
45-23	9098-9103	forms	
45-24	9104-9106	of	
45-25	9107-9112	rab6a	
45-26	9113-9116	and	
45-27	9117-9122	rab6b	
45-28	9122-9123	.	

#Text=The protein may act as a motor required for the retrograde rab6 regulated transport of golgi membranes and associated vesicles along microtubules.
46-1	9124-9127	The	
46-2	9128-9135	protein	
46-3	9136-9139	may	
46-4	9140-9143	act	
46-5	9144-9146	as	
46-6	9147-9148	a	
46-7	9149-9154	motor	
46-8	9155-9163	required	
46-9	9164-9167	for	
46-10	9168-9171	the	
46-11	9172-9182	retrograde	
46-12	9183-9187	rab6	
46-13	9188-9197	regulated	
46-14	9198-9207	transport	
46-15	9208-9210	of	
46-16	9211-9216	golgi	
46-17	9217-9226	membranes	
46-18	9227-9230	and	
46-19	9231-9241	associated	
46-20	9242-9250	vesicles	
46-21	9251-9256	along	
46-22	9257-9269	microtubules	
46-23	9269-9270	.	

#Text=The protein has a microtubule plus end-directed motility, and is phosphorylated during the M-phase of the cell cycle.
47-1	9271-9274	The	
47-2	9275-9282	protein	
47-3	9283-9286	has	
47-4	9287-9288	a	
47-5	9289-9300	microtubule	
47-6	9301-9305	plus	
47-7	9306-9318	end-directed	
47-8	9319-9327	motility	
47-9	9327-9328	,	
47-10	9329-9332	and	
47-11	9333-9335	is	
47-12	9336-9350	phosphorylated	
47-13	9351-9357	during	
47-14	9358-9361	the	
47-15	9362-9369	M-phase	
47-16	9370-9372	of	
47-17	9373-9376	the	
47-18	9377-9381	cell	
47-19	9382-9387	cycle	
47-20	9387-9388	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0704] NSC 895: FAM3D; this gene encodes a protein having a signal peptide domain at the N-terminal end which is supposed to be a secretory protein, although its function remains to be elucidated.
48-1	9389-9392	The	
48-2	9393-9398	lower	
48-3	9399-9409	expression	
48-4	9410-9412	of	
48-5	9413-9417	this	
48-6	9418-9422	gene	
48-7	9423-9425	in	
48-8	9426-9432	normal	
48-9	9433-9440	tissues	
48-10	9440-9441	,	
48-11	9442-9446	high	
48-12	9447-9457	expression	
48-13	9458-9460	in	
48-14	9461-9467	NSCLCs	
48-15	9467-9468	,	
48-16	9469-9472	and	
48-17	9473-9480	reduced	
48-18	9481-9487	growth	
48-19	9487-9488	,	
48-20	9489-9502	proliferation	
48-21	9503-9506	and	
48-22	9506-9507	/	
48-23	9507-9509	or	
48-24	9510-9518	survival	
48-25	9519-9521	of	
48-26	9522-9525	the	
48-27	9526-9537	transfected	
48-28	9538-9543	cells	
48-29	9544-9546	by	
48-30	9547-9550	the	
48-31	9551-9562	suppression	
48-32	9563-9565	of	
48-33	9566-9570	this	
48-34	9571-9575	gene	
48-35	9576-9583	suggest	
48-36	9584-9588	that	
48-37	9589-9593	this	
48-38	9594-9598	gene	
48-39	9599-9604	might	
48-40	9605-9607	be	
48-41	9608-9614	useful	
48-42	9615-9617	as	
48-43	9618-9619	a	
48-44	9620-9625	novel	
48-45	9626-9636	diagnostic	
48-46	9637-9643	marker	
48-47	9644-9647	and	
48-48	9648-9654	target	
48-49	9655-9658	for	
48-50	9659-9662	new	
48-51	9663-9668	drugs	
48-52	9669-9672	and	
48-53	9673-9686	immunotherapy	
48-54	9686-9687	.	
48-55	9688-9689	[	
48-56	9689-9693	0704	
48-57	9693-9694	]	
48-58	9695-9698	NSC	
48-59	9699-9702	895	
48-60	9702-9703	:	
48-61	9704-9709	FAM3D	
48-62	9709-9710	;	
48-63	9711-9715	this	
48-64	9716-9720	gene	
48-65	9721-9728	encodes	
48-66	9729-9730	a	
48-67	9731-9738	protein	
48-68	9739-9745	having	
48-69	9746-9747	a	
48-70	9748-9754	signal	
48-71	9755-9762	peptide	
48-72	9763-9769	domain	
48-73	9770-9772	at	
48-74	9773-9776	the	
48-75	9777-9787	N-terminal	
48-76	9788-9791	end	
48-77	9792-9797	which	
48-78	9798-9800	is	
48-79	9801-9809	supposed	
48-80	9810-9812	to	
48-81	9813-9815	be	
48-82	9816-9817	a	
48-83	9818-9827	secretory	
48-84	9828-9835	protein	
48-85	9835-9836	,	
48-86	9837-9845	although	
48-87	9846-9849	its	
48-88	9850-9858	function	
48-89	9859-9866	remains	
48-90	9867-9869	to	
48-91	9870-9872	be	
48-92	9873-9883	elucidated	
48-93	9883-9884	.	

#Text=This protein was mainly detected in the cytoplasmic granules and golgi in the immunocytochemical analysis, suggesting that this protein might be secreted.
49-1	9885-9889	This	
49-2	9890-9897	protein	
49-3	9898-9901	was	
49-4	9902-9908	mainly	
49-5	9909-9917	detected	
49-6	9918-9920	in	
49-7	9921-9924	the	
49-8	9925-9936	cytoplasmic	
49-9	9937-9945	granules	
49-10	9946-9949	and	
49-11	9950-9955	golgi	
49-12	9956-9958	in	
49-13	9959-9962	the	
49-14	9963-9981	immunocytochemical	
49-15	9982-9990	analysis	
49-16	9990-9991	,	
49-17	9992-10002	suggesting	
49-18	10003-10007	that	
49-19	10008-10012	this	
49-20	10013-10020	protein	
49-21	10021-10026	might	
49-22	10027-10029	be	
49-23	10030-10038	secreted	
49-24	10038-10039	.	

#Text=The lower expression of this gene in normal tissues and high expression in NSCLCs suggest that this gene might be useful as a diagnostic marker (i.e., in the diagnosis using serum or sputum) for NSCLCs. [0705] NSC 898: URLC7; the protein encoded by this gene is localized in the nucleus and no known domain existed in the protein.
50-1	10040-10043	The	
50-2	10044-10049	lower	
50-3	10050-10060	expression	
50-4	10061-10063	of	
50-5	10064-10068	this	
50-6	10069-10073	gene	
50-7	10074-10076	in	
50-8	10077-10083	normal	
50-9	10084-10091	tissues	
50-10	10092-10095	and	
50-11	10096-10100	high	
50-12	10101-10111	expression	
50-13	10112-10114	in	
50-14	10115-10121	NSCLCs	
50-15	10122-10129	suggest	
50-16	10130-10134	that	
50-17	10135-10139	this	
50-18	10140-10144	gene	
50-19	10145-10150	might	
50-20	10151-10153	be	
50-21	10154-10160	useful	
50-22	10161-10163	as	
50-23	10164-10165	a	
50-24	10166-10176	diagnostic	
50-25	10177-10183	marker	
50-26	10184-10185	(	
50-27	10185-10188	i.e	
50-28	10188-10189	.	
50-29	10189-10190	,	
50-30	10191-10193	in	
50-31	10194-10197	the	
50-32	10198-10207	diagnosis	
50-33	10208-10213	using	
50-34	10214-10219	serum	
50-35	10220-10222	or	
50-36	10223-10229	sputum	
50-37	10229-10230	)	
50-38	10231-10234	for	
50-39	10235-10241	NSCLCs	
50-40	10241-10242	.	
50-41	10243-10244	[	
50-42	10244-10248	0705	
50-43	10248-10249	]	
50-44	10250-10253	NSC	
50-45	10254-10257	898	
50-46	10257-10258	:	
50-47	10259-10264	URLC7	
50-48	10264-10265	;	
50-49	10266-10269	the	
50-50	10270-10277	protein	
50-51	10278-10285	encoded	
50-52	10286-10288	by	
50-53	10289-10293	this	
50-54	10294-10298	gene	
50-55	10299-10301	is	
50-56	10302-10311	localized	
50-57	10312-10314	in	
50-58	10315-10318	the	
50-59	10319-10326	nucleus	
50-60	10327-10330	and	
50-61	10331-10333	no	
50-62	10334-10339	known	
50-63	10340-10346	domain	
50-64	10347-10354	existed	
50-65	10355-10357	in	
50-66	10358-10361	the	
50-67	10362-10369	protein	
50-68	10369-10370	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0706] NSC 903: URLC9; the protein encoded by this gene was localized in the nucleus and no known domain existed in the protein.
51-1	10371-10374	The	
51-2	10375-10380	lower	
51-3	10381-10391	expression	
51-4	10392-10394	of	
51-5	10395-10399	this	
51-6	10400-10404	gene	
51-7	10405-10407	in	
51-8	10408-10414	normal	
51-9	10415-10422	tissues	
51-10	10422-10423	,	
51-11	10424-10428	high	
51-12	10429-10439	expression	
51-13	10440-10442	in	
51-14	10443-10449	NSCLCs	
51-15	10449-10450	,	
51-16	10451-10454	and	
51-17	10455-10462	reduced	
51-18	10463-10469	growth	
51-19	10469-10470	,	
51-20	10471-10484	proliferation	
51-21	10485-10488	and	
51-22	10488-10489	/	
51-23	10489-10491	or	
51-24	10492-10500	survival	
51-25	10501-10503	of	
51-26	10504-10507	the	
51-27	10508-10519	transfected	
51-28	10520-10525	cells	
51-29	10526-10528	by	
51-30	10529-10532	the	
51-31	10533-10544	suppression	
51-32	10545-10547	of	
51-33	10548-10552	this	
51-34	10553-10557	gene	
51-35	10558-10565	suggest	
51-36	10566-10570	that	
51-37	10571-10575	this	
51-38	10576-10580	gene	
51-39	10581-10586	might	
51-40	10587-10589	be	
51-41	10590-10596	useful	
51-42	10597-10599	as	
51-43	10600-10601	a	
51-44	10602-10607	novel	
51-45	10608-10618	diagnostic	
51-46	10619-10625	marker	
51-47	10626-10629	and	
51-48	10630-10636	target	
51-49	10637-10640	for	
51-50	10641-10644	new	
51-51	10645-10650	drugs	
51-52	10651-10654	and	
51-53	10655-10668	immunotherapy	
51-54	10668-10669	.	
51-55	10670-10671	[	
51-56	10671-10675	0706	
51-57	10675-10676	]	
51-58	10677-10680	NSC	
51-59	10681-10684	903	
51-60	10684-10685	:	
51-61	10686-10691	URLC9	
51-62	10691-10692	;	
51-63	10693-10696	the	
51-64	10697-10704	protein	
51-65	10705-10712	encoded	
51-66	10713-10715	by	
51-67	10716-10720	this	
51-68	10721-10725	gene	
51-69	10726-10729	was	
51-70	10730-10739	localized	
51-71	10740-10742	in	
51-72	10743-10746	the	
51-73	10747-10754	nucleus	
51-74	10755-10758	and	
51-75	10759-10761	no	
51-76	10762-10767	known	
51-77	10768-10774	domain	
51-78	10775-10782	existed	
51-79	10783-10785	in	
51-80	10786-10789	the	
51-81	10790-10797	protein	
51-82	10797-10798	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0707] NSC 905: URLC1; this gene encodes a TUDOR domain, for which several putative functions have been suggested: (1) RNA-binding; and (2) nucleic acid binding.
52-1	10799-10802	The	
52-2	10803-10808	lower	
52-3	10809-10819	expression	
52-4	10820-10822	of	
52-5	10823-10827	this	
52-6	10828-10832	gene	
52-7	10833-10835	in	
52-8	10836-10842	normal	
52-9	10843-10850	tissues	
52-10	10850-10851	,	
52-11	10852-10856	high	
52-12	10857-10867	expression	
52-13	10868-10870	in	
52-14	10871-10877	NSCLCs	
52-15	10877-10878	,	
52-16	10879-10882	and	
52-17	10883-10890	reduced	
52-18	10891-10897	growth	
52-19	10897-10898	,	
52-20	10899-10912	proliferation	
52-21	10913-10916	and	
52-22	10916-10917	/	
52-23	10917-10919	or	
52-24	10920-10928	survival	
52-25	10929-10931	of	
52-26	10932-10935	the	
52-27	10936-10947	transfected	
52-28	10948-10953	cells	
52-29	10954-10956	by	
52-30	10957-10960	the	
52-31	10961-10972	suppression	
52-32	10973-10975	of	
52-33	10976-10980	this	
52-34	10981-10985	gene	
52-35	10986-10993	suggest	
52-36	10994-10998	that	
52-37	10999-11003	this	
52-38	11004-11008	gene	
52-39	11009-11014	might	
52-40	11015-11017	be	
52-41	11018-11024	useful	
52-42	11025-11027	as	
52-43	11028-11029	a	
52-44	11030-11035	novel	
52-45	11036-11046	diagnostic	
52-46	11047-11053	marker	
52-47	11054-11057	and	
52-48	11058-11064	target	
52-49	11065-11068	for	
52-50	11069-11072	new	
52-51	11073-11078	drugs	
52-52	11079-11082	and	
52-53	11083-11096	immunotherapy	
52-54	11096-11097	.	
52-55	11098-11099	[	
52-56	11099-11103	0707	
52-57	11103-11104	]	
52-58	11105-11108	NSC	
52-59	11109-11112	905	
52-60	11112-11113	:	
52-61	11114-11119	URLC1	
52-62	11119-11120	;	
52-63	11121-11125	this	
52-64	11126-11130	gene	
52-65	11131-11138	encodes	
52-66	11139-11140	a	
52-67	11141-11146	TUDOR	
52-68	11147-11153	domain	
52-69	11153-11154	,	
52-70	11155-11158	for	
52-71	11159-11164	which	
52-72	11165-11172	several	
52-73	11173-11181	putative	
52-74	11182-11191	functions	
52-75	11192-11196	have	
52-76	11197-11201	been	
52-77	11202-11211	suggested	
52-78	11211-11212	:	
52-79	11213-11214	(	
52-80	11214-11215	1	
52-81	11215-11216	)	
52-82	11217-11228	RNA-binding	
52-83	11228-11229	;	
52-84	11230-11233	and	
52-85	11234-11235	(	
52-86	11235-11236	2	
52-87	11236-11237	)	
52-88	11238-11245	nucleic	
52-89	11246-11250	acid	
52-90	11251-11258	binding	
52-91	11258-11259	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0708] NSC 909: CDCA8; the protein encoded by this gene was localized in the nucleus and no known domain existed in the protein.
53-1	11260-11263	The	
53-2	11264-11269	lower	
53-3	11270-11280	expression	
53-4	11281-11283	of	
53-5	11284-11288	this	
53-6	11289-11293	gene	
53-7	11294-11296	in	
53-8	11297-11303	normal	
53-9	11304-11311	tissues	
53-10	11311-11312	,	
53-11	11313-11317	high	
53-12	11318-11328	expression	
53-13	11329-11331	in	
53-14	11332-11338	NSCLCs	
53-15	11338-11339	,	
53-16	11340-11343	and	
53-17	11344-11351	reduced	
53-18	11352-11358	growth	
53-19	11358-11359	,	
53-20	11360-11373	proliferation	
53-21	11374-11377	and	
53-22	11377-11378	/	
53-23	11378-11380	or	
53-24	11381-11389	survival	
53-25	11390-11392	of	
53-26	11393-11396	the	
53-27	11397-11408	transfected	
53-28	11409-11414	cells	
53-29	11415-11417	by	
53-30	11418-11421	the	
53-31	11422-11433	suppression	
53-32	11434-11436	of	
53-33	11437-11441	this	
53-34	11442-11446	gene	
53-35	11447-11454	suggest	
53-36	11455-11459	that	
53-37	11460-11464	this	
53-38	11465-11469	gene	
53-39	11470-11475	might	
53-40	11476-11478	be	
53-41	11479-11485	useful	
53-42	11486-11488	as	
53-43	11489-11490	a	
53-44	11491-11496	novel	
53-45	11497-11507	diagnostic	
53-46	11508-11514	marker	
53-47	11515-11518	and	
53-48	11519-11525	target	
53-49	11526-11529	for	
53-50	11530-11533	new	
53-51	11534-11539	drugs	
53-52	11540-11543	and	
53-53	11544-11557	immunotherapy	
53-54	11557-11558	.	
53-55	11559-11560	[	
53-56	11560-11564	0708	
53-57	11564-11565	]	
53-58	11566-11569	NSC	
53-59	11570-11573	909	
53-60	11573-11574	:	
53-61	11575-11580	CDCA8	
53-62	11580-11581	;	
53-63	11582-11585	the	
53-64	11586-11593	protein	
53-65	11594-11601	encoded	
53-66	11602-11604	by	
53-67	11605-11609	this	
53-68	11610-11614	gene	
53-69	11615-11618	was	
53-70	11619-11628	localized	
53-71	11629-11631	in	
53-72	11632-11635	the	
53-73	11636-11643	nucleus	
53-74	11644-11647	and	
53-75	11648-11650	no	
53-76	11651-11656	known	
53-77	11657-11663	domain	
53-78	11664-11671	existed	
53-79	11672-11674	in	
53-80	11675-11678	the	
53-81	11679-11686	protein	
53-82	11686-11687	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0709] NSC 915: URLC10; this gene encodes 2 transmembrane domains.
54-1	11688-11691	The	
54-2	11692-11697	lower	
54-3	11698-11708	expression	
54-4	11709-11711	of	
54-5	11712-11716	this	
54-6	11717-11721	gene	
54-7	11722-11724	in	
54-8	11725-11731	normal	
54-9	11732-11739	tissues	
54-10	11739-11740	,	
54-11	11741-11745	high	
54-12	11746-11756	expression	
54-13	11757-11759	in	
54-14	11760-11766	NSCLCs	
54-15	11766-11767	,	
54-16	11768-11771	and	
54-17	11772-11779	reduced	
54-18	11780-11786	growth	
54-19	11786-11787	,	
54-20	11788-11801	proliferation	
54-21	11802-11805	and	
54-22	11805-11806	/	
54-23	11806-11808	or	
54-24	11809-11817	survival	
54-25	11818-11820	of	
54-26	11821-11824	the	
54-27	11825-11836	transfected	
54-28	11837-11842	cells	
54-29	11843-11845	by	
54-30	11846-11849	the	
54-31	11850-11861	suppression	
54-32	11862-11864	of	
54-33	11865-11869	this	
54-34	11870-11874	gene	
54-35	11875-11882	suggest	
54-36	11883-11887	that	
54-37	11888-11892	this	
54-38	11893-11897	gene	
54-39	11898-11903	might	
54-40	11904-11906	be	
54-41	11907-11913	useful	
54-42	11914-11916	as	
54-43	11917-11918	a	
54-44	11919-11924	novel	
54-45	11925-11935	diagnostic	
54-46	11936-11942	marker	
54-47	11943-11946	and	
54-48	11947-11953	target	
54-49	11954-11957	for	
54-50	11958-11961	new	
54-51	11962-11967	drugs	
54-52	11968-11971	and	
54-53	11972-11985	immunotherapy	
54-54	11985-11986	.	
54-55	11987-11988	[	
54-56	11988-11992	0709	
54-57	11992-11993	]	
54-58	11994-11997	NSC	
54-59	11998-12001	915	
54-60	12001-12002	:	
54-61	12003-12009	URLC10	
54-62	12009-12010	;	
54-63	12011-12015	this	
54-64	12016-12020	gene	
54-65	12021-12028	encodes	
54-66	12029-12030	2	
54-67	12031-12044	transmembrane	
54-68	12045-12052	domains	
54-69	12052-12053	.	

#Text=The protein encoded by the gene has a region with low similarity to GML.
55-1	12054-12057	The	
55-2	12058-12065	protein	
55-3	12066-12073	encoded	
55-4	12074-12076	by	
55-5	12077-12080	the	
55-6	12081-12085	gene	
55-7	12086-12089	has	
55-8	12090-12091	a	
55-9	12092-12098	region	
55-10	12099-12103	with	
55-11	12104-12107	low	
55-12	12108-12118	similarity	
55-13	12119-12121	to	
55-14	12122-12125	GML	
55-15	12125-12126	.	

#Text=The protein was mainly detected in the cytoplasmic granule and golgi, and as dots on the surface of the cytoplasmic membrane by immunocytochemical analysis.
56-1	12127-12130	The	
56-2	12131-12138	protein	
56-3	12139-12142	was	
56-4	12143-12149	mainly	
56-5	12150-12158	detected	
56-6	12159-12161	in	
56-7	12162-12165	the	
56-8	12166-12177	cytoplasmic	
56-9	12178-12185	granule	
56-10	12186-12189	and	
56-11	12190-12195	golgi	
56-12	12195-12196	,	
56-13	12197-12200	and	
56-14	12201-12203	as	
56-15	12204-12208	dots	
56-16	12209-12211	on	
56-17	12212-12215	the	
56-18	12216-12223	surface	
56-19	12224-12226	of	
56-20	12227-12230	the	
56-21	12231-12242	cytoplasmic	
56-22	12243-12251	membrane	
56-23	12252-12254	by	
56-24	12255-12273	immunocytochemical	
56-25	12274-12282	analysis	
56-26	12282-12283	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
57-1	12284-12288	This	
57-2	12289-12302	transmembrane	
57-3	12303-12310	protein	
57-4	12311-12313	is	
57-5	12314-12322	supposed	
57-6	12323-12325	to	
57-7	12326-12328	be	
57-8	12329-12343	over-expressed	
57-9	12344-12346	on	
57-10	12347-12350	the	
57-11	12351-12358	surface	
57-12	12359-12361	of	
57-13	12362-12367	tumor	
57-14	12368-12373	cells	
57-15	12374-12377	but	
57-16	12378-12381	not	
57-17	12382-12384	on	
57-18	12385-12391	normal	
57-19	12392-12397	cells	
57-20	12397-12398	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0710] NSC 920: CHAF1A; no known domain has been detected to be encoded by the gene.
58-1	12399-12403	Thus	
58-2	12403-12404	,	
58-3	12405-12408	the	
58-4	12409-12416	protein	
58-5	12417-12420	may	
58-6	12421-12426	serve	
58-7	12427-12429	as	
58-8	12430-12431	a	
58-9	12432-12436	good	
58-10	12437-12443	target	
58-11	12444-12447	for	
58-12	12448-12465	receptor-targeted	
58-13	12466-12473	therapy	
58-14	12474-12476	or	
58-15	12477-12486	diagnosis	
58-16	12486-12487	.	
58-17	12488-12489	[	
58-18	12489-12493	0710	
58-19	12493-12494	]	
58-20	12495-12498	NSC	
58-21	12499-12502	920	
58-22	12502-12503	:	
58-23	12504-12510	CHAF1A	
58-24	12510-12511	;	
58-25	12512-12514	no	
58-26	12515-12520	known	
58-27	12521-12527	domain	
58-28	12528-12531	has	
58-29	12532-12536	been	
58-30	12537-12545	detected	
58-31	12546-12548	to	
58-32	12549-12551	be	
58-33	12552-12559	encoded	
58-34	12560-12562	by	
58-35	12563-12566	the	
58-36	12567-12571	gene	
58-37	12571-12572	.	

#Text=The protein encoded by the gene has a 150 kDa subunit of chromatin assembly factor 1, which helps deposit of histones H3 acetylated H4 onto replicating DNA.
59-1	12573-12576	The	
59-2	12577-12584	protein	
59-3	12585-12592	encoded	
59-4	12593-12595	by	
59-5	12596-12599	the	
59-6	12600-12604	gene	
59-7	12605-12608	has	
59-8	12609-12610	a	
59-9	12611-12614	150	
59-10	12615-12618	kDa	
59-11	12619-12626	subunit	
59-12	12627-12629	of	
59-13	12630-12639	chromatin	
59-14	12640-12648	assembly	
59-15	12649-12655	factor	
59-16	12656-12657	1	
59-17	12657-12658	,	
59-18	12659-12664	which	
59-19	12665-12670	helps	
59-20	12671-12678	deposit	
59-21	12679-12681	of	
59-22	12682-12690	histones	
59-23	12691-12693	H3	
59-24	12694-12704	acetylated	
59-25	12705-12707	H4	
59-26	12708-12712	onto	
59-27	12713-12724	replicating	
59-28	12725-12728	DNA	
59-29	12728-12729	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0711] NSC 947: PKP3; the gene encodes an armadillo/beta-catenin-like repeats domain (ARM).
60-1	12730-12733	The	
60-2	12734-12739	lower	
60-3	12740-12750	expression	
60-4	12751-12753	of	
60-5	12754-12758	this	
60-6	12759-12763	gene	
60-7	12764-12766	in	
60-8	12767-12773	normal	
60-9	12774-12781	tissues	
60-10	12781-12782	,	
60-11	12783-12787	high	
60-12	12788-12798	expression	
60-13	12799-12801	in	
60-14	12802-12808	NSCLCs	
60-15	12808-12809	,	
60-16	12810-12813	and	
60-17	12814-12821	reduced	
60-18	12822-12828	growth	
60-19	12828-12829	,	
60-20	12830-12843	proliferation	
60-21	12844-12847	and	
60-22	12847-12848	/	
60-23	12848-12850	or	
60-24	12851-12859	survival	
60-25	12860-12862	of	
60-26	12863-12866	the	
60-27	12867-12878	transfected	
60-28	12879-12884	cells	
60-29	12885-12887	by	
60-30	12888-12891	the	
60-31	12892-12903	suppression	
60-32	12904-12906	of	
60-33	12907-12911	this	
60-34	12912-12916	gene	
60-35	12917-12924	suggest	
60-36	12925-12929	that	
60-37	12930-12934	this	
60-38	12935-12939	gene	
60-39	12940-12945	might	
60-40	12946-12948	be	
60-41	12949-12955	useful	
60-42	12956-12958	as	
60-43	12959-12960	a	
60-44	12961-12966	novel	
60-45	12967-12977	diagnostic	
60-46	12978-12984	marker	
60-47	12985-12988	and	
60-48	12989-12995	target	
60-49	12996-12999	for	
60-50	13000-13003	new	
60-51	13004-13009	drugs	
60-52	13010-13013	and	
60-53	13014-13027	immunotherapy	
60-54	13027-13028	.	
60-55	13029-13030	[	
60-56	13030-13034	0711	
60-57	13034-13035	]	
60-58	13036-13039	NSC	
60-59	13040-13043	947	
60-60	13043-13044	:	
60-61	13045-13049	PKP3	
60-62	13049-13050	;	
60-63	13051-13054	the	
60-64	13055-13059	gene	
60-65	13060-13067	encodes	
60-66	13068-13070	an	
60-67	13071-13080	armadillo	
60-68	13080-13081	/	
60-69	13081-13098	beta-catenin-like	
60-70	13099-13106	repeats	
60-71	13107-13113	domain	
60-72	13114-13115	(	
60-73	13115-13118	ARM	
60-74	13118-13119	)	
60-75	13119-13120	.	

#Text=The armadillo repeat is an approximately 40 amino acid long tandemly repeated sequence motif first identified in the Drosphia segment polarity gene armadillo.
61-1	13121-13124	The	
61-2	13125-13134	armadillo	
61-3	13135-13141	repeat	
61-4	13142-13144	is	
61-5	13145-13147	an	
61-6	13148-13161	approximately	
61-7	13162-13164	40	
61-8	13165-13170	amino	
61-9	13171-13175	acid	
61-10	13176-13180	long	
61-11	13181-13189	tandemly	
61-12	13190-13198	repeated	
61-13	13199-13207	sequence	
61-14	13208-13213	motif	
61-15	13214-13219	first	
61-16	13220-13230	identified	
61-17	13231-13233	in	
61-18	13234-13237	the	
61-19	13238-13246	Drosphia	
61-20	13247-13254	segment	
61-21	13255-13263	polarity	
61-22	13264-13268	gene	
61-23	13269-13278	armadillo	
61-24	13278-13279	.	

#Text=Similar repeats were later found in the mammalian armadillo homolog beta-catenin, the junctional plaque protein plakoglobin, the adenomatous polyposis coli (APC) tumor suppressor protein and a number of other proteins.
62-1	13280-13287	Similar	
62-2	13288-13295	repeats	
62-3	13296-13300	were	
62-4	13301-13306	later	
62-5	13307-13312	found	
62-6	13313-13315	in	
62-7	13316-13319	the	
62-8	13320-13329	mammalian	
62-9	13330-13339	armadillo	
62-10	13340-13347	homolog	
62-11	13348-13360	beta-catenin	
62-12	13360-13361	,	
62-13	13362-13365	the	
62-14	13366-13376	junctional	
62-15	13377-13383	plaque	
62-16	13384-13391	protein	
62-17	13392-13403	plakoglobin	
62-18	13403-13404	,	
62-19	13405-13408	the	
62-20	13409-13420	adenomatous	
62-21	13421-13430	polyposis	
62-22	13431-13435	coli	
62-23	13436-13437	(	
62-24	13437-13440	APC	
62-25	13440-13441	)	
62-26	13442-13447	tumor	
62-27	13448-13458	suppressor	
62-28	13459-13466	protein	
62-29	13467-13470	and	
62-30	13471-13472	a	
62-31	13473-13479	number	
62-32	13480-13482	of	
62-33	13483-13488	other	
62-34	13489-13497	proteins	
62-35	13497-13498	.	

#Text=The protein encoded by the gene function as a plakophillin 3, which mediates protein-protein interactions and is a member of the armadilloprotein family.
63-1	13499-13502	The	
63-2	13503-13510	protein	
63-3	13511-13518	encoded	
63-4	13519-13521	by	
63-5	13522-13525	the	
63-6	13526-13530	gene	
63-7	13531-13539	function	
63-8	13540-13542	as	
63-9	13543-13544	a	
63-10	13545-13557	plakophillin	
63-11	13558-13559	3	
63-12	13559-13560	,	
63-13	13561-13566	which	
63-14	13567-13575	mediates	
63-15	13576-13591	protein-protein	
63-16	13592-13604	interactions	
63-17	13605-13608	and	
63-18	13609-13611	is	
63-19	13612-13613	a	
63-20	13614-13620	member	
63-21	13621-13623	of	
63-22	13624-13627	the	
63-23	13628-13644	armadilloprotein	
63-24	13645-13651	family	
63-25	13651-13652	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy.
64-1	13653-13656	The	
64-2	13657-13662	lower	
64-3	13663-13673	expression	
64-4	13674-13676	of	
64-5	13677-13681	this	
64-6	13682-13686	gene	
64-7	13687-13689	in	
64-8	13690-13696	normal	
64-9	13697-13704	tissues	
64-10	13704-13705	,	
64-11	13706-13710	high	
64-12	13711-13721	expression	
64-13	13722-13724	in	
64-14	13725-13731	NSCLCs	
64-15	13731-13732	,	
64-16	13733-13736	and	
64-17	13737-13744	reduced	
64-18	13745-13751	growth	
64-19	13751-13752	,	
64-20	13753-13766	proliferation	
64-21	13767-13770	and	
64-22	13770-13771	/	
64-23	13771-13773	or	
64-24	13774-13782	survival	
64-25	13783-13785	of	
64-26	13786-13789	the	
64-27	13790-13801	transfected	
64-28	13802-13807	cells	
64-29	13808-13810	by	
64-30	13811-13814	the	
64-31	13815-13826	suppression	
64-32	13827-13829	of	
64-33	13830-13834	this	
64-34	13835-13839	gene	
64-35	13840-13847	suggest	
64-36	13848-13852	that	
64-37	13853-13857	this	
64-38	13858-13862	gene	
64-39	13863-13868	might	
64-40	13869-13871	be	
64-41	13872-13878	useful	
64-42	13879-13881	as	
64-43	13882-13883	a	
64-44	13884-13889	novel	
64-45	13890-13900	diagnostic	
64-46	13901-13907	marker	
64-47	13908-13911	and	
64-48	13912-13918	target	
64-49	13919-13922	for	
64-50	13923-13926	new	
64-51	13927-13932	drugs	
64-52	13933-13936	and	
64-53	13937-13950	immunotherapy	
64-54	13950-13951	.	

#Text=The immunohistochemical staining demonstrated that PKP3 is strongly stained in the cytoplasm of squamous cell carcinoma cells.
65-1	13952-13955	The	
65-2	13956-13975	immunohistochemical	
65-3	13976-13984	staining	
65-4	13985-13997	demonstrated	
65-5	13998-14002	that	
65-6	14003-14007	PKP3	
65-7	14008-14010	is	
65-8	14011-14019	strongly	
65-9	14020-14027	stained	
65-10	14028-14030	in	
65-11	14031-14034	the	
65-12	14035-14044	cytoplasm	
65-13	14045-14047	of	
65-14	14048-14056	squamous	
65-15	14057-14061	cell	
65-16	14062-14071	carcinoma	
65-17	14072-14077	cells	
65-18	14077-14078	.	

#Text=These data suggest that PKP3 may be a promising therapeutic and diagnostic target for treating lung cancers. [0712] NSC 948: TASK-2; this gene encodes an ion transporter domain, signal peptide (SOSUI).
66-1	14079-14084	These	
66-2	14085-14089	data	
66-3	14090-14097	suggest	
66-4	14098-14102	that	
66-5	14103-14107	PKP3	
66-6	14108-14111	may	
66-7	14112-14114	be	
66-8	14115-14116	a	
66-9	14117-14126	promising	
66-10	14127-14138	therapeutic	
66-11	14139-14142	and	
66-12	14143-14153	diagnostic	
66-13	14154-14160	target	
66-14	14161-14164	for	
66-15	14165-14173	treating	
66-16	14174-14178	lung	
66-17	14179-14186	cancers	
66-18	14186-14187	.	
66-19	14188-14189	[	
66-20	14189-14193	0712	
66-21	14193-14194	]	
66-22	14195-14198	NSC	
66-23	14199-14202	948	
66-24	14202-14203	:	
66-25	14204-14208	TASK	
66-26	14208-14209	-	
66-27	14209-14210	2	
66-28	14210-14211	;	
66-29	14212-14216	this	
66-30	14217-14221	gene	
66-31	14222-14229	encodes	
66-32	14230-14232	an	
66-33	14233-14236	ion	
66-34	14237-14248	transporter	
66-35	14249-14255	domain	
66-36	14255-14256	,	
66-37	14257-14263	signal	
66-38	14264-14271	peptide	
66-39	14272-14273	(	
66-40	14273-14278	SOSUI	
66-41	14278-14279	)	
66-42	14279-14280	.	

#Text=This gene encodes a protein belonging to the superfamily of potassium channel proteins containing two pore-forming P domains. mRNA of this gene is mainly expressed in the cortical distal tubules and collecting ducts of the kidney.
67-1	14281-14285	This	
67-2	14286-14290	gene	
67-3	14291-14298	encodes	
67-4	14299-14300	a	
67-5	14301-14308	protein	
67-6	14309-14318	belonging	
67-7	14319-14321	to	
67-8	14322-14325	the	
67-9	14326-14337	superfamily	
67-10	14338-14340	of	
67-11	14341-14350	potassium	
67-12	14351-14358	channel	
67-13	14359-14367	proteins	
67-14	14368-14378	containing	
67-15	14379-14382	two	
67-16	14383-14395	pore-forming	
67-17	14396-14397	P	
67-18	14398-14405	domains	
67-19	14405-14406	.	
67-20	14407-14411	mRNA	
67-21	14412-14414	of	
67-22	14415-14419	this	
67-23	14420-14424	gene	
67-24	14425-14427	is	
67-25	14428-14434	mainly	
67-26	14435-14444	expressed	
67-27	14445-14447	in	
67-28	14448-14451	the	
67-29	14452-14460	cortical	
67-30	14461-14467	distal	
67-31	14468-14475	tubules	
67-32	14476-14479	and	
67-33	14480-14490	collecting	
67-34	14491-14496	ducts	
67-35	14497-14499	of	
67-36	14500-14503	the	
67-37	14504-14510	kidney	
67-38	14510-14511	.	

#Text=The protein encoded by the gene is highly sensitive to external pH and this, in combination with its expression pattern, suggests that it may play an important role in renal potassium transport.
68-1	14512-14515	The	
68-2	14516-14523	protein	
68-3	14524-14531	encoded	
68-4	14532-14534	by	
68-5	14535-14538	the	
68-6	14539-14543	gene	
68-7	14544-14546	is	
68-8	14547-14553	highly	
68-9	14554-14563	sensitive	
68-10	14564-14566	to	
68-11	14567-14575	external	
68-12	14576-14578	pH	
68-13	14579-14582	and	
68-14	14583-14587	this	
68-15	14587-14588	,	
68-16	14589-14591	in	
68-17	14592-14603	combination	
68-18	14604-14608	with	
68-19	14609-14612	its	
68-20	14613-14623	expression	
68-21	14624-14631	pattern	
68-22	14631-14632	,	
68-23	14633-14641	suggests	
68-24	14642-14646	that	
68-25	14647-14649	it	
68-26	14650-14653	may	
68-27	14654-14658	play	
68-28	14659-14661	an	
68-29	14662-14671	important	
68-30	14672-14676	role	
68-31	14677-14679	in	
68-32	14680-14685	renal	
68-33	14686-14695	potassium	
68-34	14696-14705	transport	
68-35	14705-14706	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
69-1	14707-14711	This	
69-2	14712-14725	transmembrane	
69-3	14726-14733	protein	
69-4	14734-14736	is	
69-5	14737-14745	supposed	
69-6	14746-14748	to	
69-7	14749-14751	be	
69-8	14752-14766	over-expressed	
69-9	14767-14769	on	
69-10	14770-14773	the	
69-11	14774-14781	surface	
69-12	14782-14784	of	
69-13	14785-14790	tumor	
69-14	14791-14796	cells	
69-15	14797-14800	but	
69-16	14801-14804	not	
69-17	14805-14807	on	
69-18	14808-14814	normal	
69-19	14815-14820	cells	
69-20	14820-14821	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0713] NSC 956: SIAHBP1; this gene encodes an RNA recognition motif (RRM) domain, which is known as a nucleic acid binding domain.
70-1	14822-14826	Thus	
70-2	14826-14827	,	
70-3	14828-14831	the	
70-4	14832-14839	protein	
70-5	14840-14843	may	
70-6	14844-14849	serve	
70-7	14850-14852	as	
70-8	14853-14854	a	
70-9	14855-14859	good	
70-10	14860-14866	target	
70-11	14867-14870	for	
70-12	14871-14888	receptor-targeted	
70-13	14889-14896	therapy	
70-14	14897-14899	or	
70-15	14900-14909	diagnosis	
70-16	14909-14910	.	
70-17	14911-14912	[	
70-18	14912-14916	0713	
70-19	14916-14917	]	
70-20	14918-14921	NSC	
70-21	14922-14925	956	
70-22	14925-14926	:	
70-23	14927-14934	SIAHBP1	
70-24	14934-14935	;	
70-25	14936-14940	this	
70-26	14941-14945	gene	
70-27	14946-14953	encodes	
70-28	14954-14956	an	
70-29	14957-14960	RNA	
70-30	14961-14972	recognition	
70-31	14973-14978	motif	
70-32	14979-14980	(	
70-33	14980-14983	RRM	
70-34	14983-14984	)	
70-35	14985-14991	domain	
70-36	14991-14992	,	
70-37	14993-14998	which	
70-38	14999-15001	is	
70-39	15002-15007	known	
70-40	15008-15010	as	
70-41	15011-15012	a	
70-42	15013-15020	nucleic	
70-43	15021-15025	acid	
70-44	15026-15033	binding	
70-45	15034-15040	domain	
70-46	15040-15041	.	

#Text=The protein encoded by this gene is a Ro RNS-binding protein.
71-1	15042-15045	The	
71-2	15046-15053	protein	
71-3	15054-15061	encoded	
71-4	15062-15064	by	
71-5	15065-15069	this	
71-6	15070-15074	gene	
71-7	15075-15077	is	
71-8	15078-15079	a	
71-9	15080-15082	Ro	
71-10	15083-15094	RNS-binding	
71-11	15095-15102	protein	
71-12	15102-15103	.	

#Text=It interacts with Ro RNPs to activate the function of Ro RNPs.
72-1	15104-15106	It	
72-2	15107-15116	interacts	
72-3	15117-15121	with	
72-4	15122-15124	Ro	
72-5	15125-15129	RNPs	
72-6	15130-15132	to	
72-7	15133-15141	activate	
72-8	15142-15145	the	
72-9	15146-15154	function	
72-10	15155-15157	of	
72-11	15158-15160	Ro	
72-12	15161-15165	RNPs	
72-13	15165-15166	.	

#Text=The protein also forms a ternary complex with a far upstream element (FUSE) and FUSE-binding protein.
73-1	15167-15170	The	
73-2	15171-15178	protein	
73-3	15179-15183	also	
73-4	15184-15189	forms	
73-5	15190-15191	a	
73-6	15192-15199	ternary	
73-7	15200-15207	complex	
73-8	15208-15212	with	
73-9	15213-15214	a	
73-10	15215-15218	far	
73-11	15219-15227	upstream	
73-12	15228-15235	element	
73-13	15236-15237	(	
73-14	15237-15241	FUSE	
73-15	15241-15242	)	
73-16	15243-15246	and	
73-17	15247-15259	FUSE-binding	
73-18	15260-15267	protein	
73-19	15267-15268	.	

#Text=It can repress a c-myc reporter via the binding with FUSE.
74-1	15269-15271	It	
74-2	15272-15275	can	
74-3	15276-15283	repress	
74-4	15284-15285	a	
74-5	15286-15291	c-myc	
74-6	15292-15300	reporter	
74-7	15301-15304	via	
74-8	15305-15308	the	
74-9	15309-15316	binding	
74-10	15317-15321	with	
74-11	15322-15326	FUSE	
74-12	15326-15327	.	

#Text=The transcription factor IIH is also known as the target of the protein and the protein inhibits activated transcription.
75-1	15328-15331	The	
75-2	15332-15345	transcription	
75-3	15346-15352	factor	
75-4	15353-15356	IIH	
75-5	15357-15359	is	
75-6	15360-15364	also	
75-7	15365-15370	known	
75-8	15371-15373	as	
75-9	15374-15377	the	
75-10	15378-15384	target	
75-11	15385-15387	of	
75-12	15388-15391	the	
75-13	15392-15399	protein	
75-14	15400-15403	and	
75-15	15404-15407	the	
75-16	15408-15415	protein	
75-17	15416-15424	inhibits	
75-18	15425-15434	activated	
75-19	15435-15448	transcription	
75-20	15448-15449	.	

#Text=This gene is implicated in the xeroderma pigmentosum disorder.
76-1	15450-15454	This	
76-2	15455-15459	gene	
76-3	15460-15462	is	
76-4	15463-15473	implicated	
76-5	15474-15476	in	
76-6	15477-15480	the	
76-7	15481-15490	xeroderma	
76-8	15491-15502	pigmentosum	
76-9	15503-15511	disorder	
76-10	15511-15512	.	

#Text=Two alternatively spliced transcript variants exist for this gene that encode different isoforms.
77-1	15513-15516	Two	
77-2	15517-15530	alternatively	
77-3	15531-15538	spliced	
77-4	15539-15549	transcript	
77-5	15550-15558	variants	
77-6	15559-15564	exist	
77-7	15565-15568	for	
77-8	15569-15573	this	
77-9	15574-15578	gene	
77-10	15579-15583	that	
77-11	15584-15590	encode	
77-12	15591-15600	different	
77-13	15601-15609	isoforms	
77-14	15609-15610	.	

#Text=Multiple polyadenyllation sites seem to exist on this gene.
78-1	15611-15619	Multiple	
78-2	15620-15636	polyadenyllation	
78-3	15637-15642	sites	
78-4	15643-15647	seem	
78-5	15648-15650	to	
78-6	15651-15656	exist	
78-7	15657-15659	on	
78-8	15660-15664	this	
78-9	15665-15669	gene	
78-10	15669-15670	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy.
#Text=[0714] NSC 991: DOLPP1; this gene encodes a transmembrane domain and an acid phosphatase homologues domain.
79-1	15671-15674	The	
79-2	15675-15680	lower	
79-3	15681-15691	expression	
79-4	15692-15694	of	
79-5	15695-15699	this	
79-6	15700-15704	gene	
79-7	15705-15707	in	
79-8	15708-15714	normal	
79-9	15715-15722	tissues	
79-10	15722-15723	,	
79-11	15724-15728	high	
79-12	15729-15739	expression	
79-13	15740-15742	in	
79-14	15743-15749	NSCLCs	
79-15	15749-15750	,	
79-16	15751-15754	and	
79-17	15755-15762	reduced	
79-18	15763-15769	growth	
79-19	15769-15770	,	
79-20	15771-15784	proliferation	
79-21	15785-15788	and	
79-22	15788-15789	/	
79-23	15789-15791	or	
79-24	15792-15800	survival	
79-25	15801-15803	of	
79-26	15804-15807	the	
79-27	15808-15819	transfected	
79-28	15820-15825	cells	
79-29	15826-15828	by	
79-30	15829-15832	the	
79-31	15833-15844	suppression	
79-32	15845-15847	of	
79-33	15848-15852	this	
79-34	15853-15857	gene	
79-35	15858-15865	suggest	
79-36	15866-15870	that	
79-37	15871-15875	this	
79-38	15876-15880	gene	
79-39	15881-15886	might	
79-40	15887-15889	be	
79-41	15890-15896	useful	
79-42	15897-15899	as	
79-43	15900-15901	a	
79-44	15902-15907	novel	
79-45	15908-15918	diagnostic	
79-46	15919-15925	marker	
79-47	15926-15929	and	
79-48	15930-15936	target	
79-49	15937-15940	for	
79-50	15941-15944	new	
79-51	15945-15950	drugs	
79-52	15951-15954	and	
79-53	15955-15968	immunotherapy	
79-54	15968-15969	.	
79-55	15970-15971	[	
79-56	15971-15975	0714	
79-57	15975-15976	]	
79-58	15977-15980	NSC	
79-59	15981-15984	991	
79-60	15984-15985	:	
79-61	15986-15992	DOLPP1	
79-62	15992-15993	;	
79-63	15994-15998	this	
79-64	15999-16003	gene	
79-65	16004-16011	encodes	
79-66	16012-16013	a	
79-67	16014-16027	transmembrane	
79-68	16028-16034	domain	
79-69	16035-16038	and	
79-70	16039-16041	an	
79-71	16042-16046	acid	
79-72	16047-16058	phosphatase	
79-73	16059-16069	homologues	
79-74	16070-16076	domain	
79-75	16076-16077	.	

#Text=The transmembrane protein encoded by the gene is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
80-1	16078-16081	The	
80-2	16082-16095	transmembrane	
80-3	16096-16103	protein	
80-4	16104-16111	encoded	
80-5	16112-16114	by	
80-6	16115-16118	the	
80-7	16119-16123	gene	
80-8	16124-16126	is	
80-9	16127-16135	supposed	
80-10	16136-16138	to	
80-11	16139-16141	be	
80-12	16142-16156	over-expressed	
80-13	16157-16159	on	
80-14	16160-16163	the	
80-15	16164-16171	surface	
80-16	16172-16174	of	
80-17	16175-16180	tumor	
80-18	16181-16186	cells	
80-19	16187-16190	but	
80-20	16191-16194	not	
80-21	16195-16197	on	
80-22	16198-16204	normal	
80-23	16205-16210	cells	
80-24	16210-16211	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0715] NSC 994: DKFZP434E2318; this gene encodes a BTB/POZ domain and a Kelch domain.
81-1	16212-16216	Thus	
81-2	16216-16217	,	
81-3	16218-16221	the	
81-4	16222-16229	protein	
81-5	16230-16233	may	
81-6	16234-16239	serve	
81-7	16240-16242	as	
81-8	16243-16244	a	
81-9	16245-16249	good	
81-10	16250-16256	target	
81-11	16257-16260	for	
81-12	16261-16278	receptor-targeted	
81-13	16279-16286	therapy	
81-14	16287-16289	or	
81-15	16290-16299	diagnosis	
81-16	16299-16300	.	
81-17	16301-16302	[	
81-18	16302-16306	0715	
81-19	16306-16307	]	
81-20	16308-16311	NSC	
81-21	16312-16315	994	
81-22	16315-16316	:	
81-23	16317-16330	DKFZP434E2318	
81-24	16330-16331	;	
81-25	16332-16336	this	
81-26	16337-16341	gene	
81-27	16342-16349	encodes	
81-28	16350-16351	a	
81-29	16352-16355	BTB	
81-30	16355-16356	/	
81-31	16356-16359	POZ	
81-32	16360-16366	domain	
81-33	16367-16370	and	
81-34	16371-16372	a	
81-35	16373-16378	Kelch	
81-36	16379-16385	domain	
81-37	16385-16386	.	

#Text=The BTB/POZ domain is known to be a protein-protein interaction motif.
82-1	16387-16390	The	
82-2	16391-16394	BTB	
82-3	16394-16395	/	
82-4	16395-16398	POZ	
82-5	16399-16405	domain	
82-6	16406-16408	is	
82-7	16409-16414	known	
82-8	16415-16417	to	
82-9	16418-16420	be	
82-10	16421-16422	a	
82-11	16423-16438	protein-protein	
82-12	16439-16450	interaction	
82-13	16451-16456	motif	
82-14	16456-16457	.	

#Text=The BTB/POZ domain mediates homomeric dimerization and also, in some instances, heteromeric dimerization.
83-1	16458-16461	The	
83-2	16462-16465	BTB	
83-3	16465-16466	/	
83-4	16466-16469	POZ	
83-5	16470-16476	domain	
83-6	16477-16485	mediates	
83-7	16486-16495	homomeric	
83-8	16496-16508	dimerization	
83-9	16509-16512	and	
83-10	16513-16517	also	
83-11	16517-16518	,	
83-12	16519-16521	in	
83-13	16522-16526	some	
83-14	16527-16536	instances	
83-15	16536-16537	,	
83-16	16538-16549	heteromeric	
83-17	16550-16562	dimerization	
83-18	16562-16563	.	

#Text=The POZ domain of several zinc finger proteins have been shown to mediate transcriptional repression and to interact components of histone deacetylase co-repressor complexes including N-CoR and SMART.
84-1	16564-16567	The	
84-2	16568-16571	POZ	
84-3	16572-16578	domain	
84-4	16579-16581	of	
84-5	16582-16589	several	
84-6	16590-16594	zinc	
84-7	16595-16601	finger	
84-8	16602-16610	proteins	
84-9	16611-16615	have	
84-10	16616-16620	been	
84-11	16621-16626	shown	
84-12	16627-16629	to	
84-13	16630-16637	mediate	
84-14	16638-16653	transcriptional	
84-15	16654-16664	repression	
84-16	16665-16668	and	
84-17	16669-16671	to	
84-18	16672-16680	interact	
84-19	16681-16691	components	
84-20	16692-16694	of	
84-21	16695-16702	histone	
84-22	16703-16714	deacetylase	
84-23	16715-16727	co-repressor	
84-24	16728-16737	complexes	
84-25	16738-16747	including	
84-26	16748-16753	N-CoR	
84-27	16754-16757	and	
84-28	16758-16763	SMART	
84-29	16763-16764	.	

#Text=The Kelch domain is a beta propeller domain involved in protein-protein interactions and have some enzymatic activities like glycolate oxidase.
85-1	16765-16768	The	
85-2	16769-16774	Kelch	
85-3	16775-16781	domain	
85-4	16782-16784	is	
85-5	16785-16786	a	
85-6	16787-16791	beta	
85-7	16792-16801	propeller	
85-8	16802-16808	domain	
85-9	16809-16817	involved	
85-10	16818-16820	in	
85-11	16821-16836	protein-protein	
85-12	16837-16849	interactions	
85-13	16850-16853	and	
85-14	16854-16858	have	
85-15	16859-16863	some	
85-16	16864-16873	enzymatic	
85-17	16874-16884	activities	
85-18	16885-16889	like	
85-19	16890-16899	glycolate	
85-20	16900-16907	oxidase	
85-21	16907-16908	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0716] NSC 1000: PSK-1; this gene encodes a signal peptide, a CUB domain, a Sushi domain (SCR repeat) and one transmembrane domain.
86-1	16909-16912	The	
86-2	16913-16918	lower	
86-3	16919-16929	expression	
86-4	16930-16932	of	
86-5	16933-16937	this	
86-6	16938-16942	gene	
86-7	16943-16945	in	
86-8	16946-16952	normal	
86-9	16953-16960	tissues	
86-10	16960-16961	,	
86-11	16962-16966	high	
86-12	16967-16977	expression	
86-13	16978-16980	in	
86-14	16981-16987	NSCLCs	
86-15	16987-16988	,	
86-16	16989-16992	and	
86-17	16993-17000	reduced	
86-18	17001-17007	growth	
86-19	17007-17008	,	
86-20	17009-17022	proliferation	
86-21	17023-17026	and	
86-22	17026-17027	/	
86-23	17027-17029	or	
86-24	17030-17038	survival	
86-25	17039-17041	of	
86-26	17042-17045	the	
86-27	17046-17057	transfected	
86-28	17058-17063	cells	
86-29	17064-17066	by	
86-30	17067-17070	the	
86-31	17071-17082	suppression	
86-32	17083-17085	of	
86-33	17086-17090	this	
86-34	17091-17095	gene	
86-35	17096-17103	suggest	
86-36	17104-17108	that	
86-37	17109-17113	this	
86-38	17114-17118	gene	
86-39	17119-17124	might	
86-40	17125-17127	be	
86-41	17128-17134	useful	
86-42	17135-17137	as	
86-43	17138-17139	a	
86-44	17140-17145	novel	
86-45	17146-17156	diagnostic	
86-46	17157-17163	marker	
86-47	17164-17167	and	
86-48	17168-17174	target	
86-49	17175-17178	for	
86-50	17179-17182	new	
86-51	17183-17188	drugs	
86-52	17189-17192	and	
86-53	17193-17206	immunotherapy	
86-54	17206-17207	.	
86-55	17208-17209	[	
86-56	17209-17213	0716	
86-57	17213-17214	]	
86-58	17215-17218	NSC	
86-59	17219-17223	1000	
86-60	17223-17224	:	
86-61	17225-17228	PSK	
86-62	17228-17229	-	
86-63	17229-17230	1	
86-64	17230-17231	;	
86-65	17232-17236	this	
86-66	17237-17241	gene	
86-67	17242-17249	encodes	
86-68	17250-17251	a	
86-69	17252-17258	signal	
86-70	17259-17266	peptide	
86-71	17266-17267	,	
86-72	17268-17269	a	
86-73	17270-17273	CUB	
86-74	17274-17280	domain	
86-75	17280-17281	,	
86-76	17282-17283	a	
86-77	17284-17289	Sushi	
86-78	17290-17296	domain	
86-79	17297-17298	(	
86-80	17298-17301	SCR	
86-81	17302-17308	repeat	
86-82	17308-17309	)	
86-83	17310-17313	and	
86-84	17314-17317	one	
86-85	17318-17331	transmembrane	
86-86	17332-17338	domain	
86-87	17338-17339	.	

#Text=The protein encoded by the gene is highly similar to murin Sez6, an adhesion protein which contains five sushi (SCR) domains and an extracellular CUB domain.
87-1	17340-17343	The	
87-2	17344-17351	protein	
87-3	17352-17359	encoded	
87-4	17360-17362	by	
87-5	17363-17366	the	
87-6	17367-17371	gene	
87-7	17372-17374	is	
87-8	17375-17381	highly	
87-9	17382-17389	similar	
87-10	17390-17392	to	
87-11	17393-17398	murin	
87-12	17399-17403	Sez6	
87-13	17403-17404	,	
87-14	17405-17407	an	
87-15	17408-17416	adhesion	
87-16	17417-17424	protein	
87-17	17425-17430	which	
87-18	17431-17439	contains	
87-19	17440-17444	five	
87-20	17445-17450	sushi	
87-21	17451-17452	(	
87-22	17452-17455	SCR	
87-23	17455-17456	)	
87-24	17457-17464	domains	
87-25	17465-17468	and	
87-26	17469-17471	an	
87-27	17472-17485	extracellular	
87-28	17486-17489	CUB	
87-29	17490-17496	domain	
87-30	17496-17497	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
88-1	17498-17502	This	
88-2	17503-17516	transmembrane	
88-3	17517-17524	protein	
88-4	17525-17527	is	
88-5	17528-17536	supposed	
88-6	17537-17539	to	
88-7	17540-17542	be	
88-8	17543-17557	over-expressed	
88-9	17558-17560	on	
88-10	17561-17564	the	
88-11	17565-17572	surface	
88-12	17573-17575	of	
88-13	17576-17581	tumor	
88-14	17582-17587	cells	
88-15	17588-17591	but	
88-16	17592-17595	not	
88-17	17596-17598	on	
88-18	17599-17605	normal	
88-19	17606-17611	cells	
88-20	17611-17612	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0717] NSC 1066: MCM8; this gene encodes an ATPase associated with a variety of cellular activities (AAA) domain and a minichromosome maintenance protein (MCM) domain.
89-1	17613-17617	Thus	
89-2	17617-17618	,	
89-3	17619-17622	the	
89-4	17623-17630	protein	
89-5	17631-17634	may	
89-6	17635-17640	serve	
89-7	17641-17643	as	
89-8	17644-17645	a	
89-9	17646-17650	good	
89-10	17651-17657	target	
89-11	17658-17661	for	
89-12	17662-17679	receptor-targeted	
89-13	17680-17687	therapy	
89-14	17688-17690	or	
89-15	17691-17700	diagnosis	
89-16	17700-17701	.	
89-17	17702-17703	[	
89-18	17703-17707	0717	
89-19	17707-17708	]	
89-20	17709-17712	NSC	
89-21	17713-17717	1066	
89-22	17717-17718	:	
89-23	17719-17723	MCM8	
89-24	17723-17724	;	
89-25	17725-17729	this	
89-26	17730-17734	gene	
89-27	17735-17742	encodes	
89-28	17743-17745	an	
89-29	17746-17752	ATPase	
89-30	17753-17763	associated	
89-31	17764-17768	with	
89-32	17769-17770	a	
89-33	17771-17778	variety	
89-34	17779-17781	of	
89-35	17782-17790	cellular	
89-36	17791-17801	activities	
89-37	17802-17803	(	
89-38	17803-17806	AAA	
89-39	17806-17807	)	
89-40	17808-17814	domain	
89-41	17815-17818	and	
89-42	17819-17820	a	
89-43	17821-17835	minichromosome	
89-44	17836-17847	maintenance	
89-45	17848-17855	protein	
89-46	17856-17857	(	
89-47	17857-17860	MCM	
89-48	17860-17861	)	
89-49	17862-17868	domain	
89-50	17868-17869	.	

#Text=The lower expression of this gene in normal tissues and high expression in NSCLCs suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0718] NSC 1075: URLC4; no known domain was detected to be encoded by the gene.
90-1	17870-17873	The	
90-2	17874-17879	lower	
90-3	17880-17890	expression	
90-4	17891-17893	of	
90-5	17894-17898	this	
90-6	17899-17903	gene	
90-7	17904-17906	in	
90-8	17907-17913	normal	
90-9	17914-17921	tissues	
90-10	17922-17925	and	
90-11	17926-17930	high	
90-12	17931-17941	expression	
90-13	17942-17944	in	
90-14	17945-17951	NSCLCs	
90-15	17952-17959	suggest	
90-16	17960-17964	that	
90-17	17965-17969	this	
90-18	17970-17974	gene	
90-19	17975-17980	might	
90-20	17981-17983	be	
90-21	17984-17990	useful	
90-22	17991-17993	as	
90-23	17994-17995	a	
90-24	17996-18001	novel	
90-25	18002-18012	diagnostic	
90-26	18013-18019	marker	
90-27	18020-18023	and	
90-28	18024-18030	target	
90-29	18031-18034	for	
90-30	18035-18038	new	
90-31	18039-18044	drugs	
90-32	18045-18048	and	
90-33	18049-18062	immunotherapy	
90-34	18062-18063	.	
90-35	18064-18065	[	
90-36	18065-18069	0718	
90-37	18069-18070	]	
90-38	18071-18074	NSC	
90-39	18075-18079	1075	
90-40	18079-18080	:	
90-41	18081-18086	URLC4	
90-42	18086-18087	;	
90-43	18088-18090	no	
90-44	18091-18096	known	
90-45	18097-18103	domain	
90-46	18104-18107	was	
90-47	18108-18116	detected	
90-48	18117-18119	to	
90-49	18120-18122	be	
90-50	18123-18130	encoded	
90-51	18131-18133	by	
90-52	18134-18137	the	
90-53	18138-18142	gene	
90-54	18142-18143	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0719] NSC 1103: KCNK1; this gene encodes a protein belonging to the superfamily of potassium channel proteins containing two pore-forming P domain.
91-1	18144-18147	The	
91-2	18148-18153	lower	
91-3	18154-18164	expression	
91-4	18165-18167	of	
91-5	18168-18172	this	
91-6	18173-18177	gene	
91-7	18178-18180	in	
91-8	18181-18187	normal	
91-9	18188-18195	tissues	
91-10	18195-18196	,	
91-11	18197-18201	high	
91-12	18202-18212	expression	
91-13	18213-18215	in	
91-14	18216-18222	NSCLCs	
91-15	18222-18223	,	
91-16	18224-18227	and	
91-17	18228-18235	reduced	
91-18	18236-18242	growth	
91-19	18242-18243	,	
91-20	18244-18257	proliferation	
91-21	18258-18261	and	
91-22	18261-18262	/	
91-23	18262-18264	or	
91-24	18265-18273	survival	
91-25	18274-18276	of	
91-26	18277-18280	the	
91-27	18281-18292	transfected	
91-28	18293-18298	cells	
91-29	18299-18301	by	
91-30	18302-18305	the	
91-31	18306-18317	suppression	
91-32	18318-18320	of	
91-33	18321-18325	this	
91-34	18326-18330	gene	
91-35	18331-18338	suggest	
91-36	18339-18343	that	
91-37	18344-18348	this	
91-38	18349-18353	gene	
91-39	18354-18359	might	
91-40	18360-18362	be	
91-41	18363-18369	useful	
91-42	18370-18372	as	
91-43	18373-18374	a	
91-44	18375-18380	novel	
91-45	18381-18391	diagnostic	
91-46	18392-18398	marker	
91-47	18399-18402	and	
91-48	18403-18409	target	
91-49	18410-18413	for	
91-50	18414-18417	new	
91-51	18418-18423	drugs	
91-52	18424-18427	and	
91-53	18428-18441	immunotherapy	
91-54	18441-18442	.	
91-55	18443-18444	[	
91-56	18444-18448	0719	
91-57	18448-18449	]	
91-58	18450-18453	NSC	
91-59	18454-18458	1103	
91-60	18458-18459	:	
91-61	18460-18465	KCNK1	
91-62	18465-18466	;	
91-63	18467-18471	this	
91-64	18472-18476	gene	
91-65	18477-18484	encodes	
91-66	18485-18486	a	
91-67	18487-18494	protein	
91-68	18495-18504	belonging	
91-69	18505-18507	to	
91-70	18508-18511	the	
91-71	18512-18523	superfamily	
91-72	18524-18526	of	
91-73	18527-18536	potassium	
91-74	18537-18544	channel	
91-75	18545-18553	proteins	
91-76	18554-18564	containing	
91-77	18565-18568	two	
91-78	18569-18581	pore-forming	
91-79	18582-18583	P	
91-80	18584-18590	domain	
91-81	18590-18591	.	

#Text=The product of this gene has not been shown to be a functional channel.
92-1	18592-18595	The	
92-2	18596-18603	product	
92-3	18604-18606	of	
92-4	18607-18611	this	
92-5	18612-18616	gene	
92-6	18617-18620	has	
92-7	18621-18624	not	
92-8	18625-18629	been	
92-9	18630-18635	shown	
92-10	18636-18638	to	
92-11	18639-18641	be	
92-12	18642-18643	a	
92-13	18644-18654	functional	
92-14	18655-18662	channel	
92-15	18662-18663	.	

#Text=Other non-pore-forming proteins may be necessary for the activity as the functional channel.
93-1	18664-18669	Other	
93-2	18670-18686	non-pore-forming	
93-3	18687-18695	proteins	
93-4	18696-18699	may	
93-5	18700-18702	be	
93-6	18703-18712	necessary	
93-7	18713-18716	for	
93-8	18717-18720	the	
93-9	18721-18729	activity	
93-10	18730-18732	as	
93-11	18733-18736	the	
93-12	18737-18747	functional	
93-13	18748-18755	channel	
93-14	18755-18756	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
94-1	18757-18761	This	
94-2	18762-18775	transmembrane	
94-3	18776-18783	protein	
94-4	18784-18786	is	
94-5	18787-18795	supposed	
94-6	18796-18798	to	
94-7	18799-18801	be	
94-8	18802-18816	over-expressed	
94-9	18817-18819	on	
94-10	18820-18823	the	
94-11	18824-18831	surface	
94-12	18832-18834	of	
94-13	18835-18840	tumor	
94-14	18841-18846	cells	
94-15	18847-18850	but	
94-16	18851-18854	not	
94-17	18855-18857	on	
94-18	18858-18864	normal	
94-19	18865-18870	cells	
94-20	18870-18871	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0720] NSC 1107: URLC8; this gene encodes a double-strand RNA binding motif (DSRM) domain.
95-1	18872-18876	Thus	
95-2	18876-18877	,	
95-3	18878-18881	the	
95-4	18882-18889	protein	
95-5	18890-18893	may	
95-6	18894-18899	serve	
95-7	18900-18902	as	
95-8	18903-18904	a	
95-9	18905-18909	good	
95-10	18910-18916	target	
95-11	18917-18920	for	
95-12	18921-18938	receptor-targeted	
95-13	18939-18946	therapy	
95-14	18947-18949	or	
95-15	18950-18959	diagnosis	
95-16	18959-18960	.	
95-17	18961-18962	[	
95-18	18962-18966	0720	
95-19	18966-18967	]	
95-20	18968-18971	NSC	
95-21	18972-18976	1107	
95-22	18976-18977	:	
95-23	18978-18983	URLC8	
95-24	18983-18984	;	
95-25	18985-18989	this	
95-26	18990-18994	gene	
95-27	18995-19002	encodes	
95-28	19003-19004	a	
95-29	19005-19018	double-strand	
95-30	19019-19022	RNA	
95-31	19023-19030	binding	
95-32	19031-19036	motif	
95-33	19037-19038	(	
95-34	19038-19042	DSRM	
95-35	19042-19043	)	
95-36	19044-19050	domain	
95-37	19050-19051	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0721] NSC 1113: URLC5; no known domain was detected to be encoded by the gene.
96-1	19052-19055	The	
96-2	19056-19061	lower	
96-3	19062-19072	expression	
96-4	19073-19075	of	
96-5	19076-19080	this	
96-6	19081-19085	gene	
96-7	19086-19088	in	
96-8	19089-19095	normal	
96-9	19096-19103	tissues	
96-10	19103-19104	,	
96-11	19105-19109	high	
96-12	19110-19120	expression	
96-13	19121-19123	in	
96-14	19124-19130	NSCLCs	
96-15	19130-19131	,	
96-16	19132-19135	and	
96-17	19136-19143	reduced	
96-18	19144-19150	growth	
96-19	19150-19151	,	
96-20	19152-19165	proliferation	
96-21	19166-19169	and	
96-22	19169-19170	/	
96-23	19170-19172	or	
96-24	19173-19181	survival	
96-25	19182-19184	of	
96-26	19185-19188	the	
96-27	19189-19200	transfected	
96-28	19201-19206	cells	
96-29	19207-19209	by	
96-30	19210-19213	the	
96-31	19214-19225	suppression	
96-32	19226-19228	of	
96-33	19229-19233	this	
96-34	19234-19238	gene	
96-35	19239-19246	suggest	
96-36	19247-19251	that	
96-37	19252-19256	this	
96-38	19257-19261	gene	
96-39	19262-19267	might	
96-40	19268-19270	be	
96-41	19271-19277	useful	
96-42	19278-19280	as	
96-43	19281-19282	a	
96-44	19283-19288	novel	
96-45	19289-19299	diagnostic	
96-46	19300-19306	marker	
96-47	19307-19310	and	
96-48	19311-19317	target	
96-49	19318-19321	for	
96-50	19322-19325	new	
96-51	19326-19331	drugs	
96-52	19332-19335	and	
96-53	19336-19349	immunotherapy	
96-54	19349-19350	.	
96-55	19351-19352	[	
96-56	19352-19356	0721	
96-57	19356-19357	]	
96-58	19358-19361	NSC	
96-59	19362-19366	1113	
96-60	19366-19367	:	
96-61	19368-19373	URLC5	
96-62	19373-19374	;	
96-63	19375-19377	no	
96-64	19378-19383	known	
96-65	19384-19390	domain	
96-66	19391-19394	was	
96-67	19395-19403	detected	
96-68	19404-19406	to	
96-69	19407-19409	be	
96-70	19410-19417	encoded	
96-71	19418-19420	by	
96-72	19421-19424	the	
96-73	19425-19429	gene	
96-74	19429-19430	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0722] NSC 1131:SYNJ2BP; this gene encodes a PDZ transmembrane domain.
97-1	19431-19434	The	
97-2	19435-19440	lower	
97-3	19441-19451	expression	
97-4	19452-19454	of	
97-5	19455-19459	this	
97-6	19460-19464	gene	
97-7	19465-19467	in	
97-8	19468-19474	normal	
97-9	19475-19482	tissues	
97-10	19482-19483	,	
97-11	19484-19488	high	
97-12	19489-19499	expression	
97-13	19500-19502	in	
97-14	19503-19509	NSCLCs	
97-15	19509-19510	,	
97-16	19511-19514	and	
97-17	19515-19522	reduced	
97-18	19523-19529	growth	
97-19	19529-19530	,	
97-20	19531-19544	proliferation	
97-21	19545-19548	and	
97-22	19548-19549	/	
97-23	19549-19551	or	
97-24	19552-19560	survival	
97-25	19561-19563	of	
97-26	19564-19567	the	
97-27	19568-19579	transfected	
97-28	19580-19585	cells	
97-29	19586-19588	by	
97-30	19589-19592	the	
97-31	19593-19604	suppression	
97-32	19605-19607	of	
97-33	19608-19612	this	
97-34	19613-19617	gene	
97-35	19618-19625	suggest	
97-36	19626-19630	that	
97-37	19631-19635	this	
97-38	19636-19640	gene	
97-39	19641-19646	might	
97-40	19647-19649	be	
97-41	19650-19656	useful	
97-42	19657-19659	as	
97-43	19660-19661	a	
97-44	19662-19667	novel	
97-45	19668-19678	diagnostic	
97-46	19679-19685	marker	
97-47	19686-19689	and	
97-48	19690-19696	target	
97-49	19697-19700	for	
97-50	19701-19704	new	
97-51	19705-19710	drugs	
97-52	19711-19714	and	
97-53	19715-19728	immunotherapy	
97-54	19728-19729	.	
97-55	19730-19731	[	
97-56	19731-19735	0722	
97-57	19735-19736	]	
97-58	19737-19740	NSC	
97-59	19741-19745	1131	
97-60	19745-19746	:	
97-61	19746-19753	SYNJ2BP	
97-62	19753-19754	;	
97-63	19755-19759	this	
97-64	19760-19764	gene	
97-65	19765-19772	encodes	
97-66	19773-19774	a	
97-67	19775-19778	PDZ	
97-68	19779-19792	transmembrane	
97-69	19793-19799	domain	
97-70	19799-19800	.	

#Text=The protein encoded by the gene may be a membrane-targeted signaling protein, containing a PDZ domain.
98-1	19801-19804	The	
98-2	19805-19812	protein	
98-3	19813-19820	encoded	
98-4	19821-19823	by	
98-5	19824-19827	the	
98-6	19828-19832	gene	
98-7	19833-19836	may	
98-8	19837-19839	be	
98-9	19840-19841	a	
98-10	19842-19859	membrane-targeted	
98-11	19860-19869	signaling	
98-12	19870-19877	protein	
98-13	19877-19878	,	
98-14	19879-19889	containing	
98-15	19890-19891	a	
98-16	19892-19895	PDZ	
98-17	19896-19902	domain	
98-18	19902-19903	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0723] NSC 1141: URLC11; this gene encodes 9 transmembrane domains.
99-1	19904-19907	The	
99-2	19908-19913	lower	
99-3	19914-19924	expression	
99-4	19925-19927	of	
99-5	19928-19932	this	
99-6	19933-19937	gene	
99-7	19938-19940	in	
99-8	19941-19947	normal	
99-9	19948-19955	tissues	
99-10	19955-19956	,	
99-11	19957-19961	high	
99-12	19962-19972	expression	
99-13	19973-19975	in	
99-14	19976-19982	NSCLCs	
99-15	19982-19983	,	
99-16	19984-19987	and	
99-17	19988-19995	reduced	
99-18	19996-20002	growth	
99-19	20002-20003	,	
99-20	20004-20017	proliferation	
99-21	20018-20021	and	
99-22	20021-20022	/	
99-23	20022-20024	or	
99-24	20025-20033	survival	
99-25	20034-20036	of	
99-26	20037-20040	the	
99-27	20041-20052	transfected	
99-28	20053-20058	cells	
99-29	20059-20061	by	
99-30	20062-20065	the	
99-31	20066-20077	suppression	
99-32	20078-20080	of	
99-33	20081-20085	this	
99-34	20086-20090	gene	
99-35	20091-20098	suggest	
99-36	20099-20103	that	
99-37	20104-20108	this	
99-38	20109-20113	gene	
99-39	20114-20119	might	
99-40	20120-20122	be	
99-41	20123-20129	useful	
99-42	20130-20132	as	
99-43	20133-20134	a	
99-44	20135-20140	novel	
99-45	20141-20151	diagnostic	
99-46	20152-20158	marker	
99-47	20159-20162	and	
99-48	20163-20169	target	
99-49	20170-20173	for	
99-50	20174-20177	new	
99-51	20178-20183	drugs	
99-52	20184-20187	and	
99-53	20188-20201	immunotherapy	
99-54	20201-20202	.	
99-55	20203-20204	[	
99-56	20204-20208	0723	
99-57	20208-20209	]	
99-58	20210-20213	NSC	
99-59	20214-20218	1141	
99-60	20218-20219	:	
99-61	20220-20226	URLC11	
99-62	20226-20227	;	
99-63	20228-20232	this	
99-64	20233-20237	gene	
99-65	20238-20245	encodes	
99-66	20246-20247	9	
99-67	20248-20261	transmembrane	
99-68	20262-20269	domains	
99-69	20269-20270	.	

#Text=The transmembrane protein encoded by the gene is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
100-1	20271-20274	The	
100-2	20275-20288	transmembrane	
100-3	20289-20296	protein	
100-4	20297-20304	encoded	
100-5	20305-20307	by	
100-6	20308-20311	the	
100-7	20312-20316	gene	
100-8	20317-20319	is	
100-9	20320-20328	supposed	
100-10	20329-20331	to	
100-11	20332-20334	be	
100-12	20335-20349	over-expressed	
100-13	20350-20352	on	
100-14	20353-20356	the	
100-15	20357-20364	surface	
100-16	20365-20367	of	
100-17	20368-20373	tumor	
100-18	20374-20379	cells	
100-19	20380-20383	but	
100-20	20384-20387	not	
100-21	20388-20390	on	
100-22	20391-20397	normal	
100-23	20398-20403	cells	
100-24	20403-20404	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0724] NSC 1142: NAPG; no known domain was detected to be encoded by the gene.
101-1	20405-20409	Thus	
101-2	20409-20410	,	
101-3	20411-20414	the	
101-4	20415-20422	protein	
101-5	20423-20426	may	
101-6	20427-20432	serve	
101-7	20433-20435	as	
101-8	20436-20437	a	
101-9	20438-20442	good	
101-10	20443-20449	target	
101-11	20450-20453	for	
101-12	20454-20471	receptor-targeted	
101-13	20472-20479	therapy	
101-14	20480-20482	or	
101-15	20483-20492	diagnosis	
101-16	20492-20493	.	
101-17	20494-20495	[	
101-18	20495-20499	0724	
101-19	20499-20500	]	
101-20	20501-20504	NSC	
101-21	20505-20509	1142	
101-22	20509-20510	:	
101-23	20511-20515	NAPG	
101-24	20515-20516	;	
101-25	20517-20519	no	
101-26	20520-20525	known	
101-27	20526-20532	domain	
101-28	20533-20536	was	
101-29	20537-20545	detected	
101-30	20546-20548	to	
101-31	20549-20551	be	
101-32	20552-20559	encoded	
101-33	20560-20562	by	
101-34	20563-20566	the	
101-35	20567-20571	gene	
101-36	20571-20572	.	

#Text=The sequence of the predicted 312-amino acid human protein encoded by NAPG is 95% identical to bovine gamma-SNAP.
102-1	20573-20576	The	
102-2	20577-20585	sequence	
102-3	20586-20588	of	
102-4	20589-20592	the	
102-5	20593-20602	predicted	
102-6	20603-20606	312	
102-7	20606-20607	-	
102-8	20607-20612	amino	
102-9	20613-20617	acid	
102-10	20618-20623	human	
102-11	20624-20631	protein	
102-12	20632-20639	encoded	
102-13	20640-20642	by	
102-14	20643-20647	NAPG	
102-15	20648-20650	is	
102-16	20651-20654	95%	
102-17	20655-20664	identical	
102-18	20665-20667	to	
102-19	20668-20674	bovine	
102-20	20675-20685	gamma-SNAP	
102-21	20685-20686	.	

#Text=The NAPG protein mediates platelet exocytosis and controls the membrane fusion event of this process.
103-1	20687-20690	The	
103-2	20691-20695	NAPG	
103-3	20696-20703	protein	
103-4	20704-20712	mediates	
103-5	20713-20721	platelet	
103-6	20722-20732	exocytosis	
103-7	20733-20736	and	
103-8	20737-20745	controls	
103-9	20746-20749	the	
103-10	20750-20758	membrane	
103-11	20759-20765	fusion	
103-12	20766-20771	event	
103-13	20772-20774	of	
103-14	20775-20779	this	
103-15	20780-20787	process	
103-16	20787-20788	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0725] NSC 1164: NPTX1; this gene encodes a Pentaxin/C-reactive protein.
104-1	20789-20792	The	
104-2	20793-20798	lower	
104-3	20799-20809	expression	
104-4	20810-20812	of	
104-5	20813-20817	this	
104-6	20818-20822	gene	
104-7	20823-20825	in	
104-8	20826-20832	normal	
104-9	20833-20840	tissues	
104-10	20840-20841	,	
104-11	20842-20846	high	
104-12	20847-20857	expression	
104-13	20858-20860	in	
104-14	20861-20867	NSCLCs	
104-15	20867-20868	,	
104-16	20869-20872	and	
104-17	20873-20880	reduced	
104-18	20881-20887	growth	
104-19	20887-20888	,	
104-20	20889-20902	proliferation	
104-21	20903-20906	and	
104-22	20906-20907	/	
104-23	20907-20909	or	
104-24	20910-20918	survival	
104-25	20919-20921	of	
104-26	20922-20925	the	
104-27	20926-20937	transfected	
104-28	20938-20943	cells	
104-29	20944-20946	by	
104-30	20947-20950	the	
104-31	20951-20962	suppression	
104-32	20963-20965	of	
104-33	20966-20970	this	
104-34	20971-20975	gene	
104-35	20976-20983	suggest	
104-36	20984-20988	that	
104-37	20989-20993	this	
104-38	20994-20998	gene	
104-39	20999-21004	might	
104-40	21005-21007	be	
104-41	21008-21014	useful	
104-42	21015-21017	as	
104-43	21018-21019	a	
104-44	21020-21025	novel	
104-45	21026-21036	diagnostic	
104-46	21037-21043	marker	
104-47	21044-21047	and	
104-48	21048-21054	target	
104-49	21055-21058	for	
104-50	21059-21062	new	
104-51	21063-21068	drugs	
104-52	21069-21072	and	
104-53	21073-21086	immunotherapy	
104-54	21086-21087	.	
104-55	21088-21089	[	
104-56	21089-21093	0725	
104-57	21093-21094	]	
104-58	21095-21098	NSC	
104-59	21099-21103	1164	
104-60	21103-21104	:	
104-61	21105-21110	NPTX1	
104-62	21110-21111	;	
104-63	21112-21116	this	
104-64	21117-21121	gene	
104-65	21122-21129	encodes	
104-66	21130-21131	a	
104-67	21132-21140	Pentaxin	
104-68	21140-21141	/	
104-69	21141-21151	C-reactive	
104-70	21152-21159	protein	
104-71	21159-21160	.	

#Text=NPTX1 is a member of the neuronal pentraxin gene family.
105-1	21161-21166	NPTX1	
105-2	21167-21169	is	
105-3	21170-21171	a	
105-4	21172-21178	member	
105-5	21179-21181	of	
105-6	21182-21185	the	
105-7	21186-21194	neuronal	
105-8	21195-21204	pentraxin	
105-9	21205-21209	gene	
105-10	21210-21216	family	
105-11	21216-21217	.	

#Text=Neuronal pentraxin 1 is similar to the rat NP1 gene which encodes a binding protein for the snake venom toxin taipoxin.
106-1	21218-21226	Neuronal	
106-2	21227-21236	pentraxin	
106-3	21237-21238	1	
106-4	21239-21241	is	
106-5	21242-21249	similar	
106-6	21250-21252	to	
106-7	21253-21256	the	
106-8	21257-21260	rat	
106-9	21261-21264	NP1	
106-10	21265-21269	gene	
106-11	21270-21275	which	
106-12	21276-21283	encodes	
106-13	21284-21285	a	
106-14	21286-21293	binding	
106-15	21294-21301	protein	
106-16	21302-21305	for	
106-17	21306-21309	the	
106-18	21310-21315	snake	
106-19	21316-21321	venom	
106-20	21322-21327	toxin	
106-21	21328-21336	taipoxin	
106-22	21336-21337	.	

#Text=The protein encoded by the gene was mainly detected in the cytoplasmic granules by the immunocytochemical analysis.
107-1	21338-21341	The	
107-2	21342-21349	protein	
107-3	21350-21357	encoded	
107-4	21358-21360	by	
107-5	21361-21364	the	
107-6	21365-21369	gene	
107-7	21370-21373	was	
107-8	21374-21380	mainly	
107-9	21381-21389	detected	
107-10	21390-21392	in	
107-11	21393-21396	the	
107-12	21397-21408	cytoplasmic	
107-13	21409-21417	granules	
107-14	21418-21420	by	
107-15	21421-21424	the	
107-16	21425-21443	immunocytochemical	
107-17	21444-21452	analysis	
107-18	21452-21453	.	

#Text=The lower expression of this gene in normal tissues and high expression in NSCLCs suggest that this gene might be useful as a diagnostic marker (i.e., for diagnosis using serum or sputum) and therapeutic target for NSCLCs.
108-1	21454-21457	The	
108-2	21458-21463	lower	
108-3	21464-21474	expression	
108-4	21475-21477	of	
108-5	21478-21482	this	
108-6	21483-21487	gene	
108-7	21488-21490	in	
108-8	21491-21497	normal	
108-9	21498-21505	tissues	
108-10	21506-21509	and	
108-11	21510-21514	high	
108-12	21515-21525	expression	
108-13	21526-21528	in	
108-14	21529-21535	NSCLCs	
108-15	21536-21543	suggest	
108-16	21544-21548	that	
108-17	21549-21553	this	
108-18	21554-21558	gene	
108-19	21559-21564	might	
108-20	21565-21567	be	
108-21	21568-21574	useful	
108-22	21575-21577	as	
108-23	21578-21579	a	
108-24	21580-21590	diagnostic	
108-25	21591-21597	marker	
108-26	21598-21599	(	
108-27	21599-21602	i.e	
108-28	21602-21603	.	
108-29	21603-21604	,	
108-30	21605-21608	for	
108-31	21609-21618	diagnosis	
108-32	21619-21624	using	
108-33	21625-21630	serum	
108-34	21631-21633	or	
108-35	21634-21640	sputum	
108-36	21640-21641	)	
108-37	21642-21645	and	
108-38	21646-21657	therapeutic	
108-39	21658-21664	target	
108-40	21665-21668	for	
108-41	21669-21675	NSCLCs	
108-42	21675-21676	.	

#Text=The immunohistochemical staining demonstrated that NPTX1 is strongly stained in the cytoplasm of adenocarcinoma cells.
109-1	21677-21680	The	
109-2	21681-21700	immunohistochemical	
109-3	21701-21709	staining	
109-4	21710-21722	demonstrated	
109-5	21723-21727	that	
109-6	21728-21733	NPTX1	
109-7	21734-21736	is	
109-8	21737-21745	strongly	
109-9	21746-21753	stained	
109-10	21754-21756	in	
109-11	21757-21760	the	
109-12	21761-21770	cytoplasm	
109-13	21771-21773	of	
109-14	21774-21788	adenocarcinoma	
109-15	21789-21794	cells	
109-16	21794-21795	.	

#Text=These data suggested that NPTX1 might be a promising therapeutic and diagnostic target for treating lung cancers. [0726] NSC 1183: BYSL; no known domain was detected to be encoded by the gene.
110-1	21796-21801	These	
110-2	21802-21806	data	
110-3	21807-21816	suggested	
110-4	21817-21821	that	
110-5	21822-21827	NPTX1	
110-6	21828-21833	might	
110-7	21834-21836	be	
110-8	21837-21838	a	
110-9	21839-21848	promising	
110-10	21849-21860	therapeutic	
110-11	21861-21864	and	
110-12	21865-21875	diagnostic	
110-13	21876-21882	target	
110-14	21883-21886	for	
110-15	21887-21895	treating	
110-16	21896-21900	lung	
110-17	21901-21908	cancers	
110-18	21908-21909	.	
110-19	21910-21911	[	
110-20	21911-21915	0726	
110-21	21915-21916	]	
110-22	21917-21920	NSC	
110-23	21921-21925	1183	
110-24	21925-21926	:	
110-25	21927-21931	BYSL	
110-26	21931-21932	;	
110-27	21933-21935	no	
110-28	21936-21941	known	
110-29	21942-21948	domain	
110-30	21949-21952	was	
110-31	21953-21961	detected	
110-32	21962-21964	to	
110-33	21965-21967	be	
110-34	21968-21975	encoded	
110-35	21976-21978	by	
110-36	21979-21982	the	
110-37	21983-21987	gene	
110-38	21987-21988	.	

#Text=The protein encoded by the gene has a function of bystin, which forms a cell adhesion molecule complex with trophinin (TRO) and TASTIN that may be important for the embryo implantation.
111-1	21989-21992	The	
111-2	21993-22000	protein	
111-3	22001-22008	encoded	
111-4	22009-22011	by	
111-5	22012-22015	the	
111-6	22016-22020	gene	
111-7	22021-22024	has	
111-8	22025-22026	a	
111-9	22027-22035	function	
111-10	22036-22038	of	
111-11	22039-22045	bystin	
111-12	22045-22046	,	
111-13	22047-22052	which	
111-14	22053-22058	forms	
111-15	22059-22060	a	
111-16	22061-22065	cell	
111-17	22066-22074	adhesion	
111-18	22075-22083	molecule	
111-19	22084-22091	complex	
111-20	22092-22096	with	
111-21	22097-22106	trophinin	
111-22	22107-22108	(	
111-23	22108-22111	TRO	
111-24	22111-22112	)	
111-25	22113-22116	and	
111-26	22117-22123	TASTIN	
111-27	22124-22128	that	
111-28	22129-22132	may	
111-29	22133-22135	be	
111-30	22136-22145	important	
111-31	22146-22149	for	
111-32	22150-22153	the	
111-33	22154-22160	embryo	
111-34	22161-22173	implantation	
111-35	22173-22174	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0727] NSC 1185: URLC6; this gene encodes a zinc finger RNA recognition motif domain.
112-1	22175-22178	The	
112-2	22179-22184	lower	
112-3	22185-22195	expression	
112-4	22196-22198	of	
112-5	22199-22203	this	
112-6	22204-22208	gene	
112-7	22209-22211	in	
112-8	22212-22218	normal	
112-9	22219-22226	tissues	
112-10	22226-22227	,	
112-11	22228-22232	high	
112-12	22233-22243	expression	
112-13	22244-22246	in	
112-14	22247-22253	NSCLCs	
112-15	22253-22254	,	
112-16	22255-22258	and	
112-17	22259-22266	reduced	
112-18	22267-22273	growth	
112-19	22273-22274	,	
112-20	22275-22288	proliferation	
112-21	22289-22292	and	
112-22	22292-22293	/	
112-23	22293-22295	or	
112-24	22296-22304	survival	
112-25	22305-22307	of	
112-26	22308-22311	the	
112-27	22312-22323	transfected	
112-28	22324-22329	cells	
112-29	22330-22332	by	
112-30	22333-22336	the	
112-31	22337-22348	suppression	
112-32	22349-22351	of	
112-33	22352-22356	this	
112-34	22357-22361	gene	
112-35	22362-22369	suggest	
112-36	22370-22374	that	
112-37	22375-22379	this	
112-38	22380-22384	gene	
112-39	22385-22390	might	
112-40	22391-22393	be	
112-41	22394-22400	useful	
112-42	22401-22403	as	
112-43	22404-22405	a	
112-44	22406-22411	novel	
112-45	22412-22422	diagnostic	
112-46	22423-22429	marker	
112-47	22430-22433	and	
112-48	22434-22440	target	
112-49	22441-22444	for	
112-50	22445-22448	new	
112-51	22449-22454	drugs	
112-52	22455-22458	and	
112-53	22459-22472	immunotherapy	
112-54	22472-22473	.	
112-55	22474-22475	[	
112-56	22475-22479	0727	
112-57	22479-22480	]	
112-58	22481-22484	NSC	
112-59	22485-22489	1185	
112-60	22489-22490	:	
112-61	22491-22496	URLC6	
112-62	22496-22497	;	
112-63	22498-22502	this	
112-64	22503-22507	gene	
112-65	22508-22515	encodes	
112-66	22516-22517	a	
112-67	22518-22522	zinc	
112-68	22523-22529	finger	
112-69	22530-22533	RNA	
112-70	22534-22545	recognition	
112-71	22546-22551	motif	
112-72	22552-22558	domain	
112-73	22558-22559	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0728] NSC 1191: COX17; the protein encoded by this gene localizes in the mitochondrial intermembrane space (by similarity) and may function to transport copper to the mitochondria.
113-1	22560-22563	The	
113-2	22564-22569	lower	
113-3	22570-22580	expression	
113-4	22581-22583	of	
113-5	22584-22588	this	
113-6	22589-22593	gene	
113-7	22594-22596	in	
113-8	22597-22603	normal	
113-9	22604-22611	tissues	
113-10	22611-22612	,	
113-11	22613-22617	high	
113-12	22618-22628	expression	
113-13	22629-22631	in	
113-14	22632-22638	NSCLCs	
113-15	22638-22639	,	
113-16	22640-22643	and	
113-17	22644-22651	reduced	
113-18	22652-22658	growth	
113-19	22658-22659	,	
113-20	22660-22673	proliferation	
113-21	22674-22677	and	
113-22	22677-22678	/	
113-23	22678-22680	or	
113-24	22681-22689	survival	
113-25	22690-22692	of	
113-26	22693-22696	the	
113-27	22697-22708	transfected	
113-28	22709-22714	cells	
113-29	22715-22717	by	
113-30	22718-22721	the	
113-31	22722-22733	suppression	
113-32	22734-22736	of	
113-33	22737-22741	this	
113-34	22742-22746	gene	
113-35	22747-22754	suggest	
113-36	22755-22759	that	
113-37	22760-22764	this	
113-38	22765-22769	gene	
113-39	22770-22775	might	
113-40	22776-22778	be	
113-41	22779-22785	useful	
113-42	22786-22788	as	
113-43	22789-22790	a	
113-44	22791-22796	novel	
113-45	22797-22807	diagnostic	
113-46	22808-22814	marker	
113-47	22815-22818	and	
113-48	22819-22825	target	
113-49	22826-22829	for	
113-50	22830-22833	new	
113-51	22834-22839	drugs	
113-52	22840-22843	and	
113-53	22844-22857	immunotherapy	
113-54	22857-22858	.	
113-55	22859-22860	[	
113-56	22860-22864	0728	
113-57	22864-22865	]	
113-58	22866-22869	NSC	
113-59	22870-22874	1191	
113-60	22874-22875	:	
113-61	22876-22881	COX17	
113-62	22881-22882	;	
113-63	22883-22886	the	
113-64	22887-22894	protein	
113-65	22895-22902	encoded	
113-66	22903-22905	by	
113-67	22906-22910	this	
113-68	22911-22915	gene	
113-69	22916-22925	localizes	
113-70	22926-22928	in	
113-71	22929-22932	the	
113-72	22933-22946	mitochondrial	
113-73	22947-22960	intermembrane	
113-74	22961-22966	space	
113-75	22967-22968	(	
113-76	22968-22970	by	
113-77	22971-22981	similarity	
113-78	22981-22982	)	
113-79	22983-22986	and	
113-80	22987-22990	may	
113-81	22991-22999	function	
113-82	23000-23002	to	
113-83	23003-23012	transport	
113-84	23013-23019	copper	
113-85	23020-23022	to	
113-86	23023-23026	the	
113-87	23027-23039	mitochondria	
113-88	23039-23040	.	

#Text=Further, the protein may be required for the expression of cytochrome oxidase.
114-1	23041-23048	Further	
114-2	23048-23049	,	
114-3	23050-23053	the	
114-4	23054-23061	protein	
114-5	23062-23065	may	
114-6	23066-23068	be	
114-7	23069-23077	required	
114-8	23078-23081	for	
114-9	23082-23085	the	
114-10	23086-23096	expression	
114-11	23097-23099	of	
114-12	23100-23110	cytochrome	
114-13	23111-23118	oxidase	
114-14	23118-23119	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0729] NSC 1201: SLC7A1; this gene encodes 14 transmembrane domains.
115-1	23120-23123	The	
115-2	23124-23129	lower	
115-3	23130-23140	expression	
115-4	23141-23143	of	
115-5	23144-23148	this	
115-6	23149-23153	gene	
115-7	23154-23156	in	
115-8	23157-23163	normal	
115-9	23164-23171	tissues	
115-10	23171-23172	,	
115-11	23173-23177	high	
115-12	23178-23188	expression	
115-13	23189-23191	in	
115-14	23192-23198	NSCLCs	
115-15	23198-23199	,	
115-16	23200-23203	and	
115-17	23204-23211	reduced	
115-18	23212-23218	growth	
115-19	23218-23219	,	
115-20	23220-23233	proliferation	
115-21	23234-23237	and	
115-22	23237-23238	/	
115-23	23238-23240	or	
115-24	23241-23249	survival	
115-25	23250-23252	of	
115-26	23253-23256	the	
115-27	23257-23268	transfected	
115-28	23269-23274	cells	
115-29	23275-23277	by	
115-30	23278-23281	the	
115-31	23282-23293	suppression	
115-32	23294-23296	of	
115-33	23297-23301	this	
115-34	23302-23306	gene	
115-35	23307-23314	suggest	
115-36	23315-23319	that	
115-37	23320-23324	this	
115-38	23325-23329	gene	
115-39	23330-23335	might	
115-40	23336-23338	be	
115-41	23339-23345	useful	
115-42	23346-23348	as	
115-43	23349-23350	a	
115-44	23351-23356	novel	
115-45	23357-23367	diagnostic	
115-46	23368-23374	marker	
115-47	23375-23378	and	
115-48	23379-23385	target	
115-49	23386-23389	for	
115-50	23390-23393	new	
115-51	23394-23399	drugs	
115-52	23400-23403	and	
115-53	23404-23417	immunotherapy	
115-54	23417-23418	.	
115-55	23419-23420	[	
115-56	23420-23424	0729	
115-57	23424-23425	]	
115-58	23426-23429	NSC	
115-59	23430-23434	1201	
115-60	23434-23435	:	
115-61	23436-23442	SLC7A1	
115-62	23442-23443	;	
115-63	23444-23448	this	
115-64	23449-23453	gene	
115-65	23454-23461	encodes	
115-66	23462-23464	14	
115-67	23465-23478	transmembrane	
115-68	23479-23486	domains	
115-69	23486-23487	.	

#Text=The protein encoded by this gene has strong similarity to the murine Rec-1 (Atrc 1) that functions as a cationic amino acid transporter (ecotropic retroviral receptor) which transports arginine, lysine and ornithine across the plasma membrane.
116-1	23488-23491	The	
116-2	23492-23499	protein	
116-3	23500-23507	encoded	
116-4	23508-23510	by	
116-5	23511-23515	this	
116-6	23516-23520	gene	
116-7	23521-23524	has	
116-8	23525-23531	strong	
116-9	23532-23542	similarity	
116-10	23543-23545	to	
116-11	23546-23549	the	
116-12	23550-23556	murine	
116-13	23557-23560	Rec	
116-14	23560-23561	-	
116-15	23561-23562	1	
116-16	23563-23564	(	
116-17	23564-23568	Atrc	
116-18	23569-23570	1	
116-19	23570-23571	)	
116-20	23572-23576	that	
116-21	23577-23586	functions	
116-22	23587-23589	as	
116-23	23590-23591	a	
116-24	23592-23600	cationic	
116-25	23601-23606	amino	
116-26	23607-23611	acid	
116-27	23612-23623	transporter	
116-28	23624-23625	(	
116-29	23625-23634	ecotropic	
116-30	23635-23645	retroviral	
116-31	23646-23654	receptor	
116-32	23654-23655	)	
116-33	23656-23661	which	
116-34	23662-23672	transports	
116-35	23673-23681	arginine	
116-36	23681-23682	,	
116-37	23683-23689	lysine	
116-38	23690-23693	and	
116-39	23694-23703	ornithine	
116-40	23704-23710	across	
116-41	23711-23714	the	
116-42	23715-23721	plasma	
116-43	23722-23730	membrane	
116-44	23730-23731	.	

#Text=This protein was mainly detected in the cytoplasmic membrane and golgi by the immunocytochemical analysis.
117-1	23732-23736	This	
117-2	23737-23744	protein	
117-3	23745-23748	was	
117-4	23749-23755	mainly	
117-5	23756-23764	detected	
117-6	23765-23767	in	
117-7	23768-23771	the	
117-8	23772-23783	cytoplasmic	
117-9	23784-23792	membrane	
117-10	23793-23796	and	
117-11	23797-23802	golgi	
117-12	23803-23805	by	
117-13	23806-23809	the	
117-14	23810-23828	immunocytochemical	
117-15	23829-23837	analysis	
117-16	23837-23838	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
118-1	23839-23843	This	
118-2	23844-23857	transmembrane	
118-3	23858-23865	protein	
118-4	23866-23868	is	
118-5	23869-23877	supposed	
118-6	23878-23880	to	
118-7	23881-23883	be	
118-8	23884-23898	over-expressed	
118-9	23899-23901	on	
118-10	23902-23905	the	
118-11	23906-23913	surface	
118-12	23914-23916	of	
118-13	23917-23922	tumor	
118-14	23923-23928	cells	
118-15	23929-23932	but	
118-16	23933-23936	not	
118-17	23937-23939	on	
118-18	23940-23946	normal	
118-19	23947-23952	cells	
118-20	23952-23953	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0730] NSC 1240: FLJ00159; this gene encodes 4 transmembrane domains.
119-1	23954-23958	Thus	
119-2	23958-23959	,	
119-3	23960-23963	the	
119-4	23964-23971	protein	
119-5	23972-23975	may	
119-6	23976-23981	serve	
119-7	23982-23984	as	
119-8	23985-23986	a	
119-9	23987-23991	good	
119-10	23992-23998	target	
119-11	23999-24002	for	
119-12	24003-24020	receptor-targeted	
119-13	24021-24028	therapy	
119-14	24029-24031	or	
119-15	24032-24041	diagnosis	
119-16	24041-24042	.	
119-17	24043-24044	[	
119-18	24044-24048	0730	
119-19	24048-24049	]	
119-20	24050-24053	NSC	
119-21	24054-24058	1240	
119-22	24058-24059	:	
119-23	24060-24068	FLJ00159	
119-24	24068-24069	;	
119-25	24070-24074	this	
119-26	24075-24079	gene	
119-27	24080-24087	encodes	
119-28	24088-24089	4	
119-29	24090-24103	transmembrane	
119-30	24104-24111	domains	
119-31	24111-24112	.	

#Text=The transmembrane protein encoded by this gene is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
120-1	24113-24116	The	
120-2	24117-24130	transmembrane	
120-3	24131-24138	protein	
120-4	24139-24146	encoded	
120-5	24147-24149	by	
120-6	24150-24154	this	
120-7	24155-24159	gene	
120-8	24160-24162	is	
120-9	24163-24171	supposed	
120-10	24172-24174	to	
120-11	24175-24177	be	
120-12	24178-24192	over-expressed	
120-13	24193-24195	on	
120-14	24196-24199	the	
120-15	24200-24207	surface	
120-16	24208-24210	of	
120-17	24211-24216	tumor	
120-18	24217-24222	cells	
120-19	24223-24226	but	
120-20	24227-24230	not	
120-21	24231-24233	on	
120-22	24234-24240	normal	
120-23	24241-24246	cells	
120-24	24246-24247	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0731] NSC 1246: SUPT3H; this gene encodes a transcription initiation factor .alpha.D, a 18 kD subunit.
121-1	24248-24252	Thus	
121-2	24252-24253	,	
121-3	24254-24257	the	
121-4	24258-24265	protein	
121-5	24266-24269	may	
121-6	24270-24275	serve	
121-7	24276-24278	as	
121-8	24279-24280	a	
121-9	24281-24285	good	
121-10	24286-24292	target	
121-11	24293-24296	for	
121-12	24297-24314	receptor-targeted	
121-13	24315-24322	therapy	
121-14	24323-24325	or	
121-15	24326-24335	diagnosis	
121-16	24335-24336	.	
121-17	24337-24338	[	
121-18	24338-24342	0731	
121-19	24342-24343	]	
121-20	24344-24347	NSC	
121-21	24348-24352	1246	
121-22	24352-24353	:	
121-23	24354-24360	SUPT3H	
121-24	24360-24361	;	
121-25	24362-24366	this	
121-26	24367-24371	gene	
121-27	24372-24379	encodes	
121-28	24380-24381	a	
121-29	24382-24395	transcription	
121-30	24396-24406	initiation	
121-31	24407-24413	factor	
121-32	24414-24415	.	
121-33	24415-24422	alpha.D	
121-34	24422-24423	,	
121-35	24424-24425	a	
121-36	24426-24428	18	
121-37	24429-24431	kD	
121-38	24432-24439	subunit	
121-39	24439-24440	.	

#Text=The family including the protein encoded by the gene includes the Spt3 yeast transcription factors and the 18 kD subunit of the human transcription initiation factor .alpha.D (TF.alpha.D-18).
122-1	24441-24444	The	
122-2	24445-24451	family	
122-3	24452-24461	including	
122-4	24462-24465	the	
122-5	24466-24473	protein	
122-6	24474-24481	encoded	
122-7	24482-24484	by	
122-8	24485-24488	the	
122-9	24489-24493	gene	
122-10	24494-24502	includes	
122-11	24503-24506	the	
122-12	24507-24511	Spt3	
122-13	24512-24517	yeast	
122-14	24518-24531	transcription	
122-15	24532-24539	factors	
122-16	24540-24543	and	
122-17	24544-24547	the	
122-18	24548-24550	18	
122-19	24551-24553	kD	
122-20	24554-24561	subunit	
122-21	24562-24564	of	
122-22	24565-24568	the	
122-23	24569-24574	human	
122-24	24575-24588	transcription	
122-25	24589-24599	initiation	
122-26	24600-24606	factor	
122-27	24607-24608	.	
122-28	24608-24615	alpha.D	
122-29	24616-24617	(	
122-30	24617-24627	TF.alpha.D	
122-31	24627-24628	-	
122-32	24628-24630	18	
122-33	24630-24631	)	
122-34	24631-24632	.	

#Text=The determination of the crystal structure revealed an atypical histone fold.
123-1	24633-24636	The	
123-2	24637-24650	determination	
123-3	24651-24653	of	
123-4	24654-24657	the	
123-5	24658-24665	crystal	
123-6	24666-24675	structure	
123-7	24676-24684	revealed	
123-8	24685-24687	an	
123-9	24688-24696	atypical	
123-10	24697-24704	histone	
123-11	24705-24709	fold	
123-12	24709-24710	.	

#Text=The lower expression of this gene in normal tissues and high expression in NSCLCs suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0732] NSC 1254: FLJ10815; this gene encodes a transmembrane amino acid transporter protein.
124-1	24711-24714	The	
124-2	24715-24720	lower	
124-3	24721-24731	expression	
124-4	24732-24734	of	
124-5	24735-24739	this	
124-6	24740-24744	gene	
124-7	24745-24747	in	
124-8	24748-24754	normal	
124-9	24755-24762	tissues	
124-10	24763-24766	and	
124-11	24767-24771	high	
124-12	24772-24782	expression	
124-13	24783-24785	in	
124-14	24786-24792	NSCLCs	
124-15	24793-24800	suggest	
124-16	24801-24805	that	
124-17	24806-24810	this	
124-18	24811-24815	gene	
124-19	24816-24821	might	
124-20	24822-24824	be	
124-21	24825-24831	useful	
124-22	24832-24834	as	
124-23	24835-24836	a	
124-24	24837-24842	novel	
124-25	24843-24853	diagnostic	
124-26	24854-24860	marker	
124-27	24861-24864	and	
124-28	24865-24871	target	
124-29	24872-24875	for	
124-30	24876-24879	new	
124-31	24880-24885	drugs	
124-32	24886-24889	and	
124-33	24890-24903	immunotherapy	
124-34	24903-24904	.	
124-35	24905-24906	[	
124-36	24906-24910	0732	
124-37	24910-24911	]	
124-38	24912-24915	NSC	
124-39	24916-24920	1254	
124-40	24920-24921	:	
124-41	24922-24930	FLJ10815	
124-42	24930-24931	;	
124-43	24932-24936	this	
124-44	24937-24941	gene	
124-45	24942-24949	encodes	
124-46	24950-24951	a	
124-47	24952-24965	transmembrane	
124-48	24966-24971	amino	
124-49	24972-24976	acid	
124-50	24977-24988	transporter	
124-51	24989-24996	protein	
124-52	24996-24997	.	

#Text=This transmembrane region is found in many amino acid transporters including UNC-47 and MTR.
125-1	24998-25002	This	
125-2	25003-25016	transmembrane	
125-3	25017-25023	region	
125-4	25024-25026	is	
125-5	25027-25032	found	
125-6	25033-25035	in	
125-7	25036-25040	many	
125-8	25041-25046	amino	
125-9	25047-25051	acid	
125-10	25052-25064	transporters	
125-11	25065-25074	including	
125-12	25075-25078	UNC	
125-13	25078-25079	-	
125-14	25079-25081	47	
125-15	25082-25085	and	
125-16	25086-25089	MTR	
125-17	25089-25090	.	

#Text=UNC-47 encodes a vesicular amino butyric acid (GABA) transporter, (VGAT).
126-1	25091-25094	UNC	
126-2	25094-25095	-	
126-3	25095-25097	47	
126-4	25098-25105	encodes	
126-5	25106-25107	a	
126-6	25108-25117	vesicular	
126-7	25118-25123	amino	
126-8	25124-25131	butyric	
126-9	25132-25136	acid	
126-10	25137-25138	(	
126-11	25138-25142	GABA	
126-12	25142-25143	)	
126-13	25144-25155	transporter	
126-14	25155-25156	,	
126-15	25157-25158	(	
126-16	25158-25162	VGAT	
126-17	25162-25163	)	
126-18	25163-25164	.	

#Text=The protein encode by the gene has a function a little similar to the membrane transporters of the amino acid/auxin permease (AAAP) family.
127-1	25165-25168	The	
127-2	25169-25176	protein	
127-3	25177-25183	encode	
127-4	25184-25186	by	
127-5	25187-25190	the	
127-6	25191-25195	gene	
127-7	25196-25199	has	
127-8	25200-25201	a	
127-9	25202-25210	function	
127-10	25211-25212	a	
127-11	25213-25219	little	
127-12	25220-25227	similar	
127-13	25228-25230	to	
127-14	25231-25234	the	
127-15	25235-25243	membrane	
127-16	25244-25256	transporters	
127-17	25257-25259	of	
127-18	25260-25263	the	
127-19	25264-25269	amino	
127-20	25270-25274	acid	
127-21	25274-25275	/	
127-22	25275-25280	auxin	
127-23	25281-25289	permease	
127-24	25290-25291	(	
127-25	25291-25295	AAAP	
127-26	25295-25296	)	
127-27	25297-25303	family	
127-28	25303-25304	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
128-1	25305-25309	This	
128-2	25310-25323	transmembrane	
128-3	25324-25331	protein	
128-4	25332-25334	is	
128-5	25335-25343	supposed	
128-6	25344-25346	to	
128-7	25347-25349	be	
128-8	25350-25364	over-expressed	
128-9	25365-25367	on	
128-10	25368-25371	the	
128-11	25372-25379	surface	
128-12	25380-25382	of	
128-13	25383-25388	tumor	
128-14	25389-25394	cells	
128-15	25395-25398	but	
128-16	25399-25402	not	
128-17	25403-25405	on	
128-18	25406-25412	normal	
128-19	25413-25418	cells	
128-20	25418-25419	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0733] NSC 1265: SLC28A2; this gene encodes an Na+ dependent nucleoside transporter.
129-1	25420-25424	Thus	
129-2	25424-25425	,	
129-3	25426-25429	the	
129-4	25430-25437	protein	
129-5	25438-25441	may	
129-6	25442-25447	serve	
129-7	25448-25450	as	
129-8	25451-25452	a	
129-9	25453-25457	good	
129-10	25458-25464	target	
129-11	25465-25468	for	
129-12	25469-25486	receptor-targeted	
129-13	25487-25494	therapy	
129-14	25495-25497	or	
129-15	25498-25507	diagnosis	
129-16	25507-25508	.	
129-17	25509-25510	[	
129-18	25510-25514	0733	
129-19	25514-25515	]	
129-20	25516-25519	NSC	
129-21	25520-25524	1265	
129-22	25524-25525	:	
129-23	25526-25533	SLC28A2	
129-24	25533-25534	;	
129-25	25535-25539	this	
129-26	25540-25544	gene	
129-27	25545-25552	encodes	
129-28	25553-25555	an	
129-29	25556-25558	Na	
129-30	25558-25559	+	
129-31	25560-25569	dependent	
129-32	25570-25580	nucleoside	
129-33	25581-25592	transporter	
129-34	25592-25593	.	

#Text=The protein encoded by this gene functions as a sodium-coupled nucleoside transporter 2, which transports purine nucleosides and uridine.
130-1	25594-25597	The	
130-2	25598-25605	protein	
130-3	25606-25613	encoded	
130-4	25614-25616	by	
130-5	25617-25621	this	
130-6	25622-25626	gene	
130-7	25627-25636	functions	
130-8	25637-25639	as	
130-9	25640-25641	a	
130-10	25642-25656	sodium-coupled	
130-11	25657-25667	nucleoside	
130-12	25668-25679	transporter	
130-13	25680-25681	2	
130-14	25681-25682	,	
130-15	25683-25688	which	
130-16	25689-25699	transports	
130-17	25700-25706	purine	
130-18	25707-25718	nucleosides	
130-19	25719-25722	and	
130-20	25723-25730	uridine	
130-21	25730-25731	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
131-1	25732-25736	This	
131-2	25737-25750	transmembrane	
131-3	25751-25758	protein	
131-4	25759-25761	is	
131-5	25762-25770	supposed	
131-6	25771-25773	to	
131-7	25774-25776	be	
131-8	25777-25791	over-expressed	
131-9	25792-25794	on	
131-10	25795-25798	the	
131-11	25799-25806	surface	
131-12	25807-25809	of	
131-13	25810-25815	tumor	
131-14	25816-25821	cells	
131-15	25822-25825	but	
131-16	25826-25829	not	
131-17	25830-25832	on	
131-18	25833-25839	normal	
131-19	25840-25845	cells	
131-20	25845-25846	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0734] NSC 1273: FLJ32549; no known domain was detected to be encoded by the gene.
132-1	25847-25851	Thus	
132-2	25851-25852	,	
132-3	25853-25856	the	
132-4	25857-25864	protein	
132-5	25865-25868	may	
132-6	25869-25874	serve	
132-7	25875-25877	as	
132-8	25878-25879	a	
132-9	25880-25884	good	
132-10	25885-25891	target	
132-11	25892-25895	for	
132-12	25896-25913	receptor-targeted	
132-13	25914-25921	therapy	
132-14	25922-25924	or	
132-15	25925-25934	diagnosis	
132-16	25934-25935	.	
132-17	25936-25937	[	
132-18	25937-25941	0734	
132-19	25941-25942	]	
132-20	25943-25946	NSC	
132-21	25947-25951	1273	
132-22	25951-25952	:	
132-23	25953-25961	FLJ32549	
132-24	25961-25962	;	
132-25	25963-25965	no	
132-26	25966-25971	known	
132-27	25972-25978	domain	
132-28	25979-25982	was	
132-29	25983-25991	detected	
132-30	25992-25994	to	
132-31	25995-25997	be	
132-32	25998-26005	encoded	
132-33	26006-26008	by	
132-34	26009-26012	the	
132-35	26013-26017	gene	
132-36	26017-26018	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0735] NSC 1288: PTGFRN; this gene encodes a signal peptide, six immunoglobulin domains and one transmembrane domain.
133-1	26019-26022	The	
133-2	26023-26028	lower	
133-3	26029-26039	expression	
133-4	26040-26042	of	
133-5	26043-26047	this	
133-6	26048-26052	gene	
133-7	26053-26055	in	
133-8	26056-26062	normal	
133-9	26063-26070	tissues	
133-10	26070-26071	,	
133-11	26072-26076	high	
133-12	26077-26087	expression	
133-13	26088-26090	in	
133-14	26091-26097	NSCLCs	
133-15	26097-26098	,	
133-16	26099-26102	and	
133-17	26103-26110	reduced	
133-18	26111-26117	growth	
133-19	26117-26118	,	
133-20	26119-26132	proliferation	
133-21	26133-26136	and	
133-22	26136-26137	/	
133-23	26137-26139	or	
133-24	26140-26148	survival	
133-25	26149-26151	of	
133-26	26152-26155	the	
133-27	26156-26167	transfected	
133-28	26168-26173	cells	
133-29	26174-26176	by	
133-30	26177-26180	the	
133-31	26181-26192	suppression	
133-32	26193-26195	of	
133-33	26196-26200	this	
133-34	26201-26205	gene	
133-35	26206-26213	suggest	
133-36	26214-26218	that	
133-37	26219-26223	this	
133-38	26224-26228	gene	
133-39	26229-26234	might	
133-40	26235-26237	be	
133-41	26238-26244	useful	
133-42	26245-26247	as	
133-43	26248-26249	a	
133-44	26250-26255	novel	
133-45	26256-26266	diagnostic	
133-46	26267-26273	marker	
133-47	26274-26277	and	
133-48	26278-26284	target	
133-49	26285-26288	for	
133-50	26289-26292	new	
133-51	26293-26298	drugs	
133-52	26299-26302	and	
133-53	26303-26316	immunotherapy	
133-54	26316-26317	.	
133-55	26318-26319	[	
133-56	26319-26323	0735	
133-57	26323-26324	]	
133-58	26325-26328	NSC	
133-59	26329-26333	1288	
133-60	26333-26334	:	
133-61	26335-26341	PTGFRN	
133-62	26341-26342	;	
133-63	26343-26347	this	
133-64	26348-26352	gene	
133-65	26353-26360	encodes	
133-66	26361-26362	a	
133-67	26363-26369	signal	
133-68	26370-26377	peptide	
133-69	26377-26378	,	
133-70	26379-26382	six	
133-71	26383-26397	immunoglobulin	
133-72	26398-26405	domains	
133-73	26406-26409	and	
133-74	26410-26413	one	
133-75	26414-26427	transmembrane	
133-76	26428-26434	domain	
133-77	26434-26435	.	

#Text=The protein encoded by this gene inhibits the binding of prostaglandin f2-alpha (pgf2-alpha) to its specific fp receptor by decreasing the receptor number rather than the affinity constant.
134-1	26436-26439	The	
134-2	26440-26447	protein	
134-3	26448-26455	encoded	
134-4	26456-26458	by	
134-5	26459-26463	this	
134-6	26464-26468	gene	
134-7	26469-26477	inhibits	
134-8	26478-26481	the	
134-9	26482-26489	binding	
134-10	26490-26492	of	
134-11	26493-26506	prostaglandin	
134-12	26507-26509	f2	
134-13	26509-26510	-	
134-14	26510-26515	alpha	
134-15	26516-26517	(	
134-16	26517-26521	pgf2	
134-17	26521-26522	-	
134-18	26522-26527	alpha	
134-19	26527-26528	)	
134-20	26529-26531	to	
134-21	26532-26535	its	
134-22	26536-26544	specific	
134-23	26545-26547	fp	
134-24	26548-26556	receptor	
134-25	26557-26559	by	
134-26	26560-26570	decreasing	
134-27	26571-26574	the	
134-28	26575-26583	receptor	
134-29	26584-26590	number	
134-30	26591-26597	rather	
134-31	26598-26602	than	
134-32	26603-26606	the	
134-33	26607-26615	affinity	
134-34	26616-26624	constant	
134-35	26624-26625	.	

#Text=The protein seems to functionally couple with the prostaglandin f2-alpha receptor.
135-1	26626-26629	The	
135-2	26630-26637	protein	
135-3	26638-26643	seems	
135-4	26644-26646	to	
135-5	26647-26659	functionally	
135-6	26660-26666	couple	
135-7	26667-26671	with	
135-8	26672-26675	the	
135-9	26676-26689	prostaglandin	
135-10	26690-26692	f2	
135-11	26692-26693	-	
135-12	26693-26698	alpha	
135-13	26699-26707	receptor	
135-14	26707-26708	.	

#Text=This protein was mainly detected in the cytoplasmic membrane and golgi by the immunocytochemical analysis.
136-1	26709-26713	This	
136-2	26714-26721	protein	
136-3	26722-26725	was	
136-4	26726-26732	mainly	
136-5	26733-26741	detected	
136-6	26742-26744	in	
136-7	26745-26748	the	
136-8	26749-26760	cytoplasmic	
136-9	26761-26769	membrane	
136-10	26770-26773	and	
136-11	26774-26779	golgi	
136-12	26780-26782	by	
136-13	26783-26786	the	
136-14	26787-26805	immunocytochemical	
136-15	26806-26814	analysis	
136-16	26814-26815	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
137-1	26816-26820	This	
137-2	26821-26834	transmembrane	
137-3	26835-26842	protein	
137-4	26843-26845	is	
137-5	26846-26854	supposed	
137-6	26855-26857	to	
137-7	26858-26860	be	
137-8	26861-26875	over-expressed	
137-9	26876-26878	on	
137-10	26879-26882	the	
137-11	26883-26890	surface	
137-12	26891-26893	of	
137-13	26894-26899	tumor	
137-14	26900-26905	cells	
137-15	26906-26909	but	
137-16	26910-26913	not	
137-17	26914-26916	on	
137-18	26917-26923	normal	
137-19	26924-26929	cells	
137-20	26929-26930	.	

#Text=Thus, the protein may server as a good target for receptor-targeted therapy or diagnosis. [0736] NSC 1292: C17orf26; this gene encodes 3 transmembrane domains, a Zinc transporter domain and a signal peptide (SOSUI).
138-1	26931-26935	Thus	
138-2	26935-26936	,	
138-3	26937-26940	the	
138-4	26941-26948	protein	
138-5	26949-26952	may	
138-6	26953-26959	server	
138-7	26960-26962	as	
138-8	26963-26964	a	
138-9	26965-26969	good	
138-10	26970-26976	target	
138-11	26977-26980	for	
138-12	26981-26998	receptor-targeted	
138-13	26999-27006	therapy	
138-14	27007-27009	or	
138-15	27010-27019	diagnosis	
138-16	27019-27020	.	
138-17	27021-27022	[	
138-18	27022-27026	0736	
138-19	27026-27027	]	
138-20	27028-27031	NSC	
138-21	27032-27036	1292	
138-22	27036-27037	:	
138-23	27038-27046	C17orf26	
138-24	27046-27047	;	
138-25	27048-27052	this	
138-26	27053-27057	gene	
138-27	27058-27065	encodes	
138-28	27066-27067	3	
138-29	27068-27081	transmembrane	
138-30	27082-27089	domains	
138-31	27089-27090	,	
138-32	27091-27092	a	
138-33	27093-27097	Zinc	
138-34	27098-27109	transporter	
138-35	27110-27116	domain	
138-36	27117-27120	and	
138-37	27121-27122	a	
138-38	27123-27129	signal	
138-39	27130-27137	peptide	
138-40	27138-27139	(	
138-41	27139-27144	SOSUI	
138-42	27144-27145	)	
138-43	27145-27146	.	

#Text=The transmembrane protein encoded by the gene is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
139-1	27147-27150	The	
139-2	27151-27164	transmembrane	
139-3	27165-27172	protein	
139-4	27173-27180	encoded	
139-5	27181-27183	by	
139-6	27184-27187	the	
139-7	27188-27192	gene	
139-8	27193-27195	is	
139-9	27196-27204	supposed	
139-10	27205-27207	to	
139-11	27208-27210	be	
139-12	27211-27225	over-expressed	
139-13	27226-27228	on	
139-14	27229-27232	the	
139-15	27233-27240	surface	
139-16	27241-27243	of	
139-17	27244-27249	tumor	
139-18	27250-27255	cells	
139-19	27256-27259	but	
139-20	27260-27263	not	
139-21	27264-27266	on	
139-22	27267-27273	normal	
139-23	27274-27279	cells	
139-24	27279-27280	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0737] NSC 1295: ADAM8; this gene encodes a protein homologous to snake disintegrins, Reprolysin family propeptide and Reprolysin (M12B) family zinc metalloprotease.
140-1	27281-27285	Thus	
140-2	27285-27286	,	
140-3	27287-27290	the	
140-4	27291-27298	protein	
140-5	27299-27302	may	
140-6	27303-27308	serve	
140-7	27309-27311	as	
140-8	27312-27313	a	
140-9	27314-27318	good	
140-10	27319-27325	target	
140-11	27326-27329	for	
140-12	27330-27347	receptor-targeted	
140-13	27348-27355	therapy	
140-14	27356-27358	or	
140-15	27359-27368	diagnosis	
140-16	27368-27369	.	
140-17	27370-27371	[	
140-18	27371-27375	0737	
140-19	27375-27376	]	
140-20	27377-27380	NSC	
140-21	27381-27385	1295	
140-22	27385-27386	:	
140-23	27387-27392	ADAM8	
140-24	27392-27393	;	
140-25	27394-27398	this	
140-26	27399-27403	gene	
140-27	27404-27411	encodes	
140-28	27412-27413	a	
140-29	27414-27421	protein	
140-30	27422-27432	homologous	
140-31	27433-27435	to	
140-32	27436-27441	snake	
140-33	27442-27454	disintegrins	
140-34	27454-27455	,	
140-35	27456-27466	Reprolysin	
140-36	27467-27473	family	
140-37	27474-27484	propeptide	
140-38	27485-27488	and	
140-39	27489-27499	Reprolysin	
140-40	27500-27501	(	
140-41	27501-27505	M12B	
140-42	27505-27506	)	
140-43	27507-27513	family	
140-44	27514-27518	zinc	
140-45	27519-27534	metalloprotease	
140-46	27534-27535	.	

#Text=Members of the ADAM family are cell surface proteins with a unique structure possessing both potential adhesion and protease domains.
141-1	27536-27543	Members	
141-2	27544-27546	of	
141-3	27547-27550	the	
141-4	27551-27555	ADAM	
141-5	27556-27562	family	
141-6	27563-27566	are	
141-7	27567-27571	cell	
141-8	27572-27579	surface	
141-9	27580-27588	proteins	
141-10	27589-27593	with	
141-11	27594-27595	a	
141-12	27596-27602	unique	
141-13	27603-27612	structure	
141-14	27613-27623	possessing	
141-15	27624-27628	both	
141-16	27629-27638	potential	
141-17	27639-27647	adhesion	
141-18	27648-27651	and	
141-19	27652-27660	protease	
141-20	27661-27668	domains	
141-21	27668-27669	.	

#Text=The extracellular region of ADAM8 shows significant amino acid sequence homology to the hemorrhagic snake venom proteins, including the metalloprotease and disintegrin domains.
142-1	27670-27673	The	
142-2	27674-27687	extracellular	
142-3	27688-27694	region	
142-4	27695-27697	of	
142-5	27698-27703	ADAM8	
142-6	27704-27709	shows	
142-7	27710-27721	significant	
142-8	27722-27727	amino	
142-9	27728-27732	acid	
142-10	27733-27741	sequence	
142-11	27742-27750	homology	
142-12	27751-27753	to	
142-13	27754-27757	the	
142-14	27758-27769	hemorrhagic	
142-15	27770-27775	snake	
142-16	27776-27781	venom	
142-17	27782-27790	proteins	
142-18	27790-27791	,	
142-19	27792-27801	including	
142-20	27802-27805	the	
142-21	27806-27821	metalloprotease	
142-22	27822-27825	and	
142-23	27826-27837	disintegrin	
142-24	27838-27845	domains	
142-25	27845-27846	.	

#Text=The lower expression of this gene in normal tissues and high expression in NSCLCs suggest that this gene might be useful as a diagnostic marker (i.e., for diagnosis using serum or sputum) and therapeutic target for NSCLCs.
143-1	27847-27850	The	
143-2	27851-27856	lower	
143-3	27857-27867	expression	
143-4	27868-27870	of	
143-5	27871-27875	this	
143-6	27876-27880	gene	
143-7	27881-27883	in	
143-8	27884-27890	normal	
143-9	27891-27898	tissues	
143-10	27899-27902	and	
143-11	27903-27907	high	
143-12	27908-27918	expression	
143-13	27919-27921	in	
143-14	27922-27928	NSCLCs	
143-15	27929-27936	suggest	
143-16	27937-27941	that	
143-17	27942-27946	this	
143-18	27947-27951	gene	
143-19	27952-27957	might	
143-20	27958-27960	be	
143-21	27961-27967	useful	
143-22	27968-27970	as	
143-23	27971-27972	a	
143-24	27973-27983	diagnostic	
143-25	27984-27990	marker	
143-26	27991-27992	(	
143-27	27992-27995	i.e	
143-28	27995-27996	.	
143-29	27996-27997	,	
143-30	27998-28001	for	
143-31	28002-28011	diagnosis	
143-32	28012-28017	using	
143-33	28018-28023	serum	
143-34	28024-28026	or	
143-35	28027-28033	sputum	
143-36	28033-28034	)	
143-37	28035-28038	and	
143-38	28039-28050	therapeutic	
143-39	28051-28057	target	
143-40	28058-28061	for	
143-41	28062-28068	NSCLCs	
143-42	28068-28069	.	

#Text=The immunohistochemical staining demonstrated that ADAM8 is strongly stained in adenocarcinoma cells.
144-1	28070-28073	The	
144-2	28074-28093	immunohistochemical	
144-3	28094-28102	staining	
144-4	28103-28115	demonstrated	
144-5	28116-28120	that	
144-6	28121-28126	ADAM8	
144-7	28127-28129	is	
144-8	28130-28138	strongly	
144-9	28139-28146	stained	
144-10	28147-28149	in	
144-11	28150-28164	adenocarcinoma	
144-12	28165-28170	cells	
144-13	28170-28171	.	

#Text=These data suggested that ADAM8 might be a promising therapeutic and diagnostic target for treating lung cancers. [0738] NSC 1306: ABCA4; this gene encodes a signal peptide and an AAA domain.
145-1	28172-28177	These	
145-2	28178-28182	data	
145-3	28183-28192	suggested	
145-4	28193-28197	that	
145-5	28198-28203	ADAM8	
145-6	28204-28209	might	
145-7	28210-28212	be	
145-8	28213-28214	a	
145-9	28215-28224	promising	
145-10	28225-28236	therapeutic	
145-11	28237-28240	and	
145-12	28241-28251	diagnostic	
145-13	28252-28258	target	
145-14	28259-28262	for	
145-15	28263-28271	treating	
145-16	28272-28276	lung	
145-17	28277-28284	cancers	
145-18	28284-28285	.	
145-19	28286-28287	[	
145-20	28287-28291	0738	
145-21	28291-28292	]	
145-22	28293-28296	NSC	
145-23	28297-28301	1306	
145-24	28301-28302	:	
145-25	28303-28308	ABCA4	
145-26	28308-28309	;	
145-27	28310-28314	this	
145-28	28315-28319	gene	
145-29	28320-28327	encodes	
145-30	28328-28329	a	
145-31	28330-28336	signal	
145-32	28337-28344	peptide	
145-33	28345-28348	and	
145-34	28349-28351	an	
145-35	28352-28355	AAA	
145-36	28356-28362	domain	
145-37	28362-28363	.	

#Text=The membrane-associated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters.
146-1	28364-28367	The	
146-2	28368-28387	membrane-associated	
146-3	28388-28395	protein	
146-4	28396-28403	encoded	
146-5	28404-28406	by	
146-6	28407-28411	this	
146-7	28412-28416	gene	
146-8	28417-28419	is	
146-9	28420-28421	a	
146-10	28422-28428	member	
146-11	28429-28431	of	
146-12	28432-28435	the	
146-13	28436-28447	superfamily	
146-14	28448-28450	of	
146-15	28451-28462	ATP-binding	
146-16	28463-28471	cassette	
146-17	28472-28473	(	
146-18	28473-28476	ABC	
146-19	28476-28477	)	
146-20	28478-28490	transporters	
146-21	28490-28491	.	

#Text=The ABC proteins transport various molecules across extra- and intracellular membranes.
147-1	28492-28495	The	
147-2	28496-28499	ABC	
147-3	28500-28508	proteins	
147-4	28509-28518	transport	
147-5	28519-28526	various	
147-6	28527-28536	molecules	
147-7	28537-28543	across	
147-8	28544-28549	extra	
147-9	28549-28550	-	
147-10	28551-28554	and	
147-11	28555-28568	intracellular	
147-12	28569-28578	membranes	
147-13	28578-28579	.	

#Text=The ABC genes are divided into seven distinct subfamilies (ABC1, MDR/TAP, MRP, ALD, OABP, GCN20 and White).
148-1	28580-28583	The	
148-2	28584-28587	ABC	
148-3	28588-28593	genes	
148-4	28594-28597	are	
148-5	28598-28605	divided	
148-6	28606-28610	into	
148-7	28611-28616	seven	
148-8	28617-28625	distinct	
148-9	28626-28637	subfamilies	
148-10	28638-28639	(	
148-11	28639-28643	ABC1	
148-12	28643-28644	,	
148-13	28645-28648	MDR	
148-14	28648-28649	/	
148-15	28649-28652	TAP	
148-16	28652-28653	,	
148-17	28654-28657	MRP	
148-18	28657-28658	,	
148-19	28659-28662	ALD	
148-20	28662-28663	,	
148-21	28664-28668	OABP	
148-22	28668-28669	,	
148-23	28670-28675	GCN20	
148-24	28676-28679	and	
148-25	28680-28685	White	
148-26	28685-28686	)	
148-27	28686-28687	.	

#Text=The protein encoded by this gene is a member of the ABC1 subfamily.
149-1	28688-28691	The	
149-2	28692-28699	protein	
149-3	28700-28707	encoded	
149-4	28708-28710	by	
149-5	28711-28715	this	
149-6	28716-28720	gene	
149-7	28721-28723	is	
149-8	28724-28725	a	
149-9	28726-28732	member	
149-10	28733-28735	of	
149-11	28736-28739	the	
149-12	28740-28744	ABC1	
149-13	28745-28754	subfamily	
149-14	28754-28755	.	

#Text=Members of the ABC1 subfamily comprise the only major ABC subfamily found exclusively in multicellular eukaryotes.
150-1	28756-28763	Members	
150-2	28764-28766	of	
150-3	28767-28770	the	
150-4	28771-28775	ABC1	
150-5	28776-28785	subfamily	
150-6	28786-28794	comprise	
150-7	28795-28798	the	
150-8	28799-28803	only	
150-9	28804-28809	major	
150-10	28810-28813	ABC	
150-11	28814-28823	subfamily	
150-12	28824-28829	found	
150-13	28830-28841	exclusively	
150-14	28842-28844	in	
150-15	28845-28858	multicellular	
150-16	28859-28869	eukaryotes	
150-17	28869-28870	.	

#Text=This protein is a retina-specific ABC transporter which uses N-retinylidene-PE as a substrate.
151-1	28871-28875	This	
151-2	28876-28883	protein	
151-3	28884-28886	is	
151-4	28887-28888	a	
151-5	28889-28904	retina-specific	
151-6	28905-28908	ABC	
151-7	28909-28920	transporter	
151-8	28921-28926	which	
151-9	28927-28931	uses	
151-10	28932-28949	N-retinylidene-PE	
151-11	28950-28952	as	
151-12	28953-28954	a	
151-13	28955-28964	substrate	
151-14	28964-28965	.	

#Text=The protein is exclusively expressed in retina photoreceptor cell, indicating the gene product mediates transport of an essential molecule across the photoreceptor cell membrane.
152-1	28966-28969	The	
152-2	28970-28977	protein	
152-3	28978-28980	is	
152-4	28981-28992	exclusively	
152-5	28993-29002	expressed	
152-6	29003-29005	in	
152-7	29006-29012	retina	
152-8	29013-29026	photoreceptor	
152-9	29027-29031	cell	
152-10	29031-29032	,	
152-11	29033-29043	indicating	
152-12	29044-29047	the	
152-13	29048-29052	gene	
152-14	29053-29060	product	
152-15	29061-29069	mediates	
152-16	29070-29079	transport	
152-17	29080-29082	of	
152-18	29083-29085	an	
152-19	29086-29095	essential	
152-20	29096-29104	molecule	
152-21	29105-29111	across	
152-22	29112-29115	the	
152-23	29116-29129	photoreceptor	
152-24	29130-29134	cell	
152-25	29135-29143	membrane	
152-26	29143-29144	.	

#Text=Mutations in this gene are found in patients who are diagnosed as having Stargardt disease and are associated with retinitis pigmentosa-19 and macular degeneration age-related 2.
153-1	29145-29154	Mutations	
153-2	29155-29157	in	
153-3	29158-29162	this	
153-4	29163-29167	gene	
153-5	29168-29171	are	
153-6	29172-29177	found	
153-7	29178-29180	in	
153-8	29181-29189	patients	
153-9	29190-29193	who	
153-10	29194-29197	are	
153-11	29198-29207	diagnosed	
153-12	29208-29210	as	
153-13	29211-29217	having	
153-14	29218-29227	Stargardt	
153-15	29228-29235	disease	
153-16	29236-29239	and	
153-17	29240-29243	are	
153-18	29244-29254	associated	
153-19	29255-29259	with	
153-20	29260-29269	retinitis	
153-21	29270-29280	pigmentosa	
153-22	29280-29281	-	
153-23	29281-29283	19	
153-24	29284-29287	and	
153-25	29288-29295	macular	
153-26	29296-29308	degeneration	
153-27	29309-29320	age-related	
153-28	29321-29322	2	
153-29	29322-29323	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
154-1	29324-29328	This	
154-2	29329-29342	transmembrane	
154-3	29343-29350	protein	
154-4	29351-29353	is	
154-5	29354-29362	supposed	
154-6	29363-29365	to	
154-7	29366-29368	be	
154-8	29369-29383	over-expressed	
154-9	29384-29386	on	
154-10	29387-29390	the	
154-11	29391-29398	surface	
154-12	29399-29401	of	
154-13	29402-29407	tumor	
154-14	29408-29413	cells	
154-15	29414-29417	but	
154-16	29418-29421	not	
154-17	29422-29424	on	
154-18	29425-29431	normal	
154-19	29432-29437	cells	
154-20	29437-29438	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0739] NSC 1343: GPR49; this gene encodes a signal peptide, a Leucine rich repeat N-terminal domain and a 7 transmembrane receptor (rhodopsin family).
155-1	29439-29443	Thus	
155-2	29443-29444	,	
155-3	29445-29448	the	
155-4	29449-29456	protein	
155-5	29457-29460	may	
155-6	29461-29466	serve	
155-7	29467-29469	as	
155-8	29470-29471	a	
155-9	29472-29476	good	
155-10	29477-29483	target	
155-11	29484-29487	for	
155-12	29488-29505	receptor-targeted	
155-13	29506-29513	therapy	
155-14	29514-29516	or	
155-15	29517-29526	diagnosis	
155-16	29526-29527	.	
155-17	29528-29529	[	
155-18	29529-29533	0739	
155-19	29533-29534	]	
155-20	29535-29538	NSC	
155-21	29539-29543	1343	
155-22	29543-29544	:	
155-23	29545-29550	GPR49	
155-24	29550-29551	;	
155-25	29552-29556	this	
155-26	29557-29561	gene	
155-27	29562-29569	encodes	
155-28	29570-29571	a	
155-29	29572-29578	signal	
155-30	29579-29586	peptide	
155-31	29586-29587	,	
155-32	29588-29589	a	
155-33	29590-29597	Leucine	
155-34	29598-29602	rich	
155-35	29603-29609	repeat	
155-36	29610-29620	N-terminal	
155-37	29621-29627	domain	
155-38	29628-29631	and	
155-39	29632-29633	a	
155-40	29634-29635	7	
155-41	29636-29649	transmembrane	
155-42	29650-29658	receptor	
155-43	29659-29660	(	
155-44	29660-29669	rhodopsin	
155-45	29670-29676	family	
155-46	29676-29677	)	
155-47	29677-29678	.	

#Text=The protein encoded by this gene belongs to the G protein-coupled receptor family, which members have a large extracellular region containing leucine-rich receptor.
156-1	29679-29682	The	
156-2	29683-29690	protein	
156-3	29691-29698	encoded	
156-4	29699-29701	by	
156-5	29702-29706	this	
156-6	29707-29711	gene	
156-7	29712-29719	belongs	
156-8	29720-29722	to	
156-9	29723-29726	the	
156-10	29727-29728	G	
156-11	29729-29744	protein-coupled	
156-12	29745-29753	receptor	
156-13	29754-29760	family	
156-14	29760-29761	,	
156-15	29762-29767	which	
156-16	29768-29775	members	
156-17	29776-29780	have	
156-18	29781-29782	a	
156-19	29783-29788	large	
156-20	29789-29802	extracellular	
156-21	29803-29809	region	
156-22	29810-29820	containing	
156-23	29821-29833	leucine-rich	
156-24	29834-29842	receptor	
156-25	29842-29843	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
157-1	29844-29848	This	
157-2	29849-29862	transmembrane	
157-3	29863-29870	protein	
157-4	29871-29873	is	
157-5	29874-29882	supposed	
157-6	29883-29885	to	
157-7	29886-29888	be	
157-8	29889-29903	over-expressed	
157-9	29904-29906	on	
157-10	29907-29910	the	
157-11	29911-29918	surface	
157-12	29919-29921	of	
157-13	29922-29927	tumor	
157-14	29928-29933	cells	
157-15	29934-29937	but	
157-16	29938-29941	not	
157-17	29942-29944	on	
157-18	29945-29951	normal	
157-19	29952-29957	cells	
157-20	29957-29958	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0740] NSC 1362: SCAMP5; this gene encodes 4 transmembrane domains.
158-1	29959-29963	Thus	
158-2	29963-29964	,	
158-3	29965-29968	the	
158-4	29969-29976	protein	
158-5	29977-29980	may	
158-6	29981-29986	serve	
158-7	29987-29989	as	
158-8	29990-29991	a	
158-9	29992-29996	good	
158-10	29997-30003	target	
158-11	30004-30007	for	
158-12	30008-30025	receptor-targeted	
158-13	30026-30033	therapy	
158-14	30034-30036	or	
158-15	30037-30046	diagnosis	
158-16	30046-30047	.	
158-17	30048-30049	[	
158-18	30049-30053	0740	
158-19	30053-30054	]	
158-20	30055-30058	NSC	
158-21	30059-30063	1362	
158-22	30063-30064	:	
158-23	30065-30071	SCAMP5	
158-24	30071-30072	;	
158-25	30073-30077	this	
158-26	30078-30082	gene	
158-27	30083-30090	encodes	
158-28	30091-30092	4	
158-29	30093-30106	transmembrane	
158-30	30107-30114	domains	
158-31	30114-30115	.	

#Text=The transmembrane protein encoded by the gene is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
159-1	30116-30119	The	
159-2	30120-30133	transmembrane	
159-3	30134-30141	protein	
159-4	30142-30149	encoded	
159-5	30150-30152	by	
159-6	30153-30156	the	
159-7	30157-30161	gene	
159-8	30162-30164	is	
159-9	30165-30173	supposed	
159-10	30174-30176	to	
159-11	30177-30179	be	
159-12	30180-30194	over-expressed	
159-13	30195-30197	on	
159-14	30198-30201	the	
159-15	30202-30209	surface	
159-16	30210-30212	of	
159-17	30213-30218	tumor	
159-18	30219-30224	cells	
159-19	30225-30228	but	
159-20	30229-30232	not	
159-21	30233-30235	on	
159-22	30236-30242	normal	
159-23	30243-30248	cells	
159-24	30248-30249	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0741] NSC 1389: NMU; this gene encodes an NMU domain.
160-1	30250-30254	Thus	
160-2	30254-30255	,	
160-3	30256-30259	the	
160-4	30260-30267	protein	
160-5	30268-30271	may	
160-6	30272-30277	serve	
160-7	30278-30280	as	
160-8	30281-30282	a	
160-9	30283-30287	good	
160-10	30288-30294	target	
160-11	30295-30298	for	
160-12	30299-30316	receptor-targeted	
160-13	30317-30324	therapy	
160-14	30325-30327	or	
160-15	30328-30337	diagnosis	
160-16	30337-30338	.	
160-17	30339-30340	[	
160-18	30340-30344	0741	
160-19	30344-30345	]	
160-20	30346-30349	NSC	
160-21	30350-30354	1389	
160-22	30354-30355	:	
160-23	30356-30359	NMU	
160-24	30359-30360	;	
160-25	30361-30365	this	
160-26	30366-30370	gene	
160-27	30371-30378	encodes	
160-28	30379-30381	an	
160-29	30382-30385	NMU	
160-30	30386-30392	domain	
160-31	30392-30393	.	

#Text=Like most active peptides, the protein encoded by this gene is proteolytically processed from a larger precursor protein.
161-1	30394-30398	Like	
161-2	30399-30403	most	
161-3	30404-30410	active	
161-4	30411-30419	peptides	
161-5	30419-30420	,	
161-6	30421-30424	the	
161-7	30425-30432	protein	
161-8	30433-30440	encoded	
161-9	30441-30443	by	
161-10	30444-30448	this	
161-11	30449-30453	gene	
161-12	30454-30456	is	
161-13	30457-30472	proteolytically	
161-14	30473-30482	processed	
161-15	30483-30487	from	
161-16	30488-30489	a	
161-17	30490-30496	larger	
161-18	30497-30506	precursor	
161-19	30507-30514	protein	
161-20	30514-30515	.	

#Text=The mature peptides of the protein are 8 to 25 residues long and its C-terminus is amidated.
162-1	30516-30519	The	
162-2	30520-30526	mature	
162-3	30527-30535	peptides	
162-4	30536-30538	of	
162-5	30539-30542	the	
162-6	30543-30550	protein	
162-7	30551-30554	are	
162-8	30555-30556	8	
162-9	30557-30559	to	
162-10	30560-30562	25	
162-11	30563-30571	residues	
162-12	30572-30576	long	
162-13	30577-30580	and	
162-14	30581-30584	its	
162-15	30585-30595	C-terminus	
162-16	30596-30598	is	
162-17	30599-30607	amidated	
162-18	30607-30608	.	

#Text=The protein stimulates muscle contractions, specifically, that of the gastrointestinal tract and inhibit feeding.
163-1	30609-30612	The	
163-2	30613-30620	protein	
163-3	30621-30631	stimulates	
163-4	30632-30638	muscle	
163-5	30639-30651	contractions	
163-6	30651-30652	,	
163-7	30653-30665	specifically	
163-8	30665-30666	,	
163-9	30667-30671	that	
163-10	30672-30674	of	
163-11	30675-30678	the	
163-12	30679-30695	gastrointestinal	
163-13	30696-30701	tract	
163-14	30702-30705	and	
163-15	30706-30713	inhibit	
163-16	30714-30721	feeding	
163-17	30721-30722	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy.
164-1	30723-30726	The	
164-2	30727-30732	lower	
164-3	30733-30743	expression	
164-4	30744-30746	of	
164-5	30747-30751	this	
164-6	30752-30756	gene	
164-7	30757-30759	in	
164-8	30760-30766	normal	
164-9	30767-30774	tissues	
164-10	30774-30775	,	
164-11	30776-30780	high	
164-12	30781-30791	expression	
164-13	30792-30794	in	
164-14	30795-30801	NSCLCs	
164-15	30801-30802	,	
164-16	30803-30806	and	
164-17	30807-30814	reduced	
164-18	30815-30821	growth	
164-19	30821-30822	,	
164-20	30823-30836	proliferation	
164-21	30837-30840	and	
164-22	30840-30841	/	
164-23	30841-30843	or	
164-24	30844-30852	survival	
164-25	30853-30855	of	
164-26	30856-30859	the	
164-27	30860-30871	transfected	
164-28	30872-30877	cells	
164-29	30878-30880	by	
164-30	30881-30884	the	
164-31	30885-30896	suppression	
164-32	30897-30899	of	
164-33	30900-30904	this	
164-34	30905-30909	gene	
164-35	30910-30917	suggest	
164-36	30918-30922	that	
164-37	30923-30927	this	
164-38	30928-30932	gene	
164-39	30933-30938	might	
164-40	30939-30941	be	
164-41	30942-30948	useful	
164-42	30949-30951	as	
164-43	30952-30953	a	
164-44	30954-30959	novel	
164-45	30960-30970	diagnostic	
164-46	30971-30977	marker	
164-47	30978-30981	and	
164-48	30982-30988	target	
164-49	30989-30992	for	
164-50	30993-30996	new	
164-51	30997-31002	drugs	
164-52	31003-31006	and	
164-53	31007-31020	immunotherapy	
164-54	31020-31021	.	

#Text=According to the present study, the NMU protein secreted into the culture medium by stable transfectant, or the active form of the NMU peptides added into the medium promoted the growth of COS-7 cells in a dose dependent manner.
165-1	31022-31031	According	
165-2	31032-31034	to	
165-3	31035-31038	the	
165-4	31039-31046	present	
165-5	31047-31052	study	
165-6	31052-31053	,	
165-7	31054-31057	the	
165-8	31058-31061	NMU	
165-9	31062-31069	protein	
165-10	31070-31078	secreted	
165-11	31079-31083	into	
165-12	31084-31087	the	
165-13	31088-31095	culture	
165-14	31096-31102	medium	
165-15	31103-31105	by	
165-16	31106-31112	stable	
165-17	31113-31125	transfectant	
165-18	31125-31126	,	
165-19	31127-31129	or	
165-20	31130-31133	the	
165-21	31134-31140	active	
165-22	31141-31145	form	
165-23	31146-31148	of	
165-24	31149-31152	the	
165-25	31153-31156	NMU	
165-26	31157-31165	peptides	
165-27	31166-31171	added	
165-28	31172-31176	into	
165-29	31177-31180	the	
165-30	31181-31187	medium	
165-31	31188-31196	promoted	
165-32	31197-31200	the	
165-33	31201-31207	growth	
165-34	31208-31210	of	
165-35	31211-31214	COS	
165-36	31214-31215	-	
165-37	31215-31216	7	
165-38	31217-31222	cells	
165-39	31223-31225	in	
165-40	31226-31227	a	
165-41	31228-31232	dose	
165-42	31233-31242	dependent	
165-43	31243-31249	manner	
165-44	31249-31250	.	

#Text=According to the immunohistochemical staining, the NMU protein was strongly stained in the cytoplasm of both adenocarcinoma and squamous cell carcinoma cells.
166-1	31251-31260	According	
166-2	31261-31263	to	
166-3	31264-31267	the	
166-4	31268-31287	immunohistochemical	
166-5	31288-31296	staining	
166-6	31296-31297	,	
166-7	31298-31301	the	
166-8	31302-31305	NMU	
166-9	31306-31313	protein	
166-10	31314-31317	was	
166-11	31318-31326	strongly	
166-12	31327-31334	stained	
166-13	31335-31337	in	
166-14	31338-31341	the	
166-15	31342-31351	cytoplasm	
166-16	31352-31354	of	
166-17	31355-31359	both	
166-18	31360-31374	adenocarcinoma	
166-19	31375-31378	and	
166-20	31379-31387	squamous	
166-21	31388-31392	cell	
166-22	31393-31402	carcinoma	
166-23	31403-31408	cells	
166-24	31408-31409	.	

#Text=These data revealed that NMU might be an important autocrine growth factor for NSCLC and suggested that a promising therapeutic and diagnostic strategy for treating lung cancers may be developed by focusing on the NMU ligand-receptor system.
167-1	31410-31415	These	
167-2	31416-31420	data	
167-3	31421-31429	revealed	
167-4	31430-31434	that	
167-5	31435-31438	NMU	
167-6	31439-31444	might	
167-7	31445-31447	be	
167-8	31448-31450	an	
167-9	31451-31460	important	
167-10	31461-31470	autocrine	
167-11	31471-31477	growth	
167-12	31478-31484	factor	
167-13	31485-31488	for	
167-14	31489-31494	NSCLC	
167-15	31495-31498	and	
167-16	31499-31508	suggested	
167-17	31509-31513	that	
167-18	31514-31515	a	
167-19	31516-31525	promising	
167-20	31526-31537	therapeutic	
167-21	31538-31541	and	
167-22	31542-31552	diagnostic	
167-23	31553-31561	strategy	
167-24	31562-31565	for	
167-25	31566-31574	treating	
167-26	31575-31579	lung	
167-27	31580-31587	cancers	
167-28	31588-31591	may	
167-29	31592-31594	be	
167-30	31595-31604	developed	
167-31	31605-31607	by	
167-32	31608-31616	focusing	
167-33	31617-31619	on	
167-34	31620-31623	the	
167-35	31624-31627	NMU	
167-36	31628-31643	ligand-receptor	
167-37	31644-31650	system	
167-38	31650-31651	.	

#Text=Furthermore, the suppression of NMU induced apoptosis in LC319 cells.
168-1	31652-31663	Furthermore	
168-2	31663-31664	,	
168-3	31665-31668	the	
168-4	31669-31680	suppression	
168-5	31681-31683	of	
168-6	31684-31687	NMU	
168-7	31688-31695	induced	
168-8	31696-31705	apoptosis	
168-9	31706-31708	in	
168-10	31709-31714	LC319	
168-11	31715-31720	cells	
168-12	31720-31721	.	

#Text=Moreover, the suppression of NMU protein by anti-NMU antibody induced growth suppression compared with controls in LC319 cells.
169-1	31722-31730	Moreover	
169-2	31730-31731	,	
169-3	31732-31735	the	
169-4	31736-31747	suppression	
169-5	31748-31750	of	
169-6	31751-31754	NMU	
169-7	31755-31762	protein	
169-8	31763-31765	by	
169-9	31766-31774	anti-NMU	
169-10	31775-31783	antibody	
169-11	31784-31791	induced	
169-12	31792-31798	growth	
169-13	31799-31810	suppression	
169-14	31811-31819	compared	
169-15	31820-31824	with	
169-16	31825-31833	controls	
169-17	31834-31836	in	
169-18	31837-31842	LC319	
169-19	31843-31848	cells	
169-20	31848-31849	.	

#Text=These results suggest that lung cancer may be treated using antibody or siRNA targeting NMU.
#Text=[0742] NSC 1395: FBN2; this gene encodes a Calcium-binding EGF-like (EGF CA) domain and an EGF like (unclassified subfamily) domain.
170-1	31850-31855	These	
170-2	31856-31863	results	
170-3	31864-31871	suggest	
170-4	31872-31876	that	
170-5	31877-31881	lung	
170-6	31882-31888	cancer	
170-7	31889-31892	may	
170-8	31893-31895	be	
170-9	31896-31903	treated	
170-10	31904-31909	using	
170-11	31910-31918	antibody	
170-12	31919-31921	or	
170-13	31922-31927	siRNA	
170-14	31928-31937	targeting	
170-15	31938-31941	NMU	
170-16	31941-31942	.	
170-17	31943-31944	[	
170-18	31944-31948	0742	
170-19	31948-31949	]	
170-20	31950-31953	NSC	
170-21	31954-31958	1395	
170-22	31958-31959	:	
170-23	31960-31964	FBN2	
170-24	31964-31965	;	
170-25	31966-31970	this	
170-26	31971-31975	gene	
170-27	31976-31983	encodes	
170-28	31984-31985	a	
170-29	31986-32001	Calcium-binding	
170-30	32002-32010	EGF-like	
170-31	32011-32012	(	
170-32	32012-32015	EGF	
170-33	32016-32018	CA	
170-34	32018-32019	)	
170-35	32020-32026	domain	
170-36	32027-32030	and	
170-37	32031-32033	an	
170-38	32034-32037	EGF	
170-39	32038-32042	like	
170-40	32043-32044	(	
170-41	32044-32056	unclassified	
170-42	32057-32066	subfamily	
170-43	32066-32067	)	
170-44	32068-32074	domain	
170-45	32074-32075	.	

#Text=The protein encoded by this gene functions as a fibrillin 2, which is an extracellular matrix protein that may regulate the formation and maintenance of extracellular microfibrils.
171-1	32076-32079	The	
171-2	32080-32087	protein	
171-3	32088-32095	encoded	
171-4	32096-32098	by	
171-5	32099-32103	this	
171-6	32104-32108	gene	
171-7	32109-32118	functions	
171-8	32119-32121	as	
171-9	32122-32123	a	
171-10	32124-32133	fibrillin	
171-11	32134-32135	2	
171-12	32135-32136	,	
171-13	32137-32142	which	
171-14	32143-32145	is	
171-15	32146-32148	an	
171-16	32149-32162	extracellular	
171-17	32163-32169	matrix	
171-18	32170-32177	protein	
171-19	32178-32182	that	
171-20	32183-32186	may	
171-21	32187-32195	regulate	
171-22	32196-32199	the	
171-23	32200-32209	formation	
171-24	32210-32213	and	
171-25	32214-32225	maintenance	
171-26	32226-32228	of	
171-27	32229-32242	extracellular	
171-28	32243-32255	microfibrils	
171-29	32255-32256	.	

#Text=Mutations in FBN2 may cause congenital contractual arachnodactyly.
172-1	32257-32266	Mutations	
172-2	32267-32269	in	
172-3	32270-32274	FBN2	
172-4	32275-32278	may	
172-5	32279-32284	cause	
172-6	32285-32295	congenital	
172-7	32296-32307	contractual	
172-8	32308-32322	arachnodactyly	
172-9	32322-32323	.	

#Text=The lower expression of this gene in normal tissues, high expression in NSCLCs, and reduced growth, proliferation and/or survival of the transfected cells by the suppression of this gene suggest that this gene might be useful as a novel diagnostic marker and target for new drugs and immunotherapy. [0743] NSC 1420: CHDOL; this gene encodes a type I membrane protein with a carbohydrate recognition domain that is characteristic of C-type lectins in its extracellular portion.
173-1	32324-32327	The	
173-2	32328-32333	lower	
173-3	32334-32344	expression	
173-4	32345-32347	of	
173-5	32348-32352	this	
173-6	32353-32357	gene	
173-7	32358-32360	in	
173-8	32361-32367	normal	
173-9	32368-32375	tissues	
173-10	32375-32376	,	
173-11	32377-32381	high	
173-12	32382-32392	expression	
173-13	32393-32395	in	
173-14	32396-32402	NSCLCs	
173-15	32402-32403	,	
173-16	32404-32407	and	
173-17	32408-32415	reduced	
173-18	32416-32422	growth	
173-19	32422-32423	,	
173-20	32424-32437	proliferation	
173-21	32438-32441	and	
173-22	32441-32442	/	
173-23	32442-32444	or	
173-24	32445-32453	survival	
173-25	32454-32456	of	
173-26	32457-32460	the	
173-27	32461-32472	transfected	
173-28	32473-32478	cells	
173-29	32479-32481	by	
173-30	32482-32485	the	
173-31	32486-32497	suppression	
173-32	32498-32500	of	
173-33	32501-32505	this	
173-34	32506-32510	gene	
173-35	32511-32518	suggest	
173-36	32519-32523	that	
173-37	32524-32528	this	
173-38	32529-32533	gene	
173-39	32534-32539	might	
173-40	32540-32542	be	
173-41	32543-32549	useful	
173-42	32550-32552	as	
173-43	32553-32554	a	
173-44	32555-32560	novel	
173-45	32561-32571	diagnostic	
173-46	32572-32578	marker	
173-47	32579-32582	and	
173-48	32583-32589	target	
173-49	32590-32593	for	
173-50	32594-32597	new	
173-51	32598-32603	drugs	
173-52	32604-32607	and	
173-53	32608-32621	immunotherapy	
173-54	32621-32622	.	
173-55	32623-32624	[	
173-56	32624-32628	0743	
173-57	32628-32629	]	
173-58	32630-32633	NSC	
173-59	32634-32638	1420	
173-60	32638-32639	:	
173-61	32640-32645	CHDOL	
173-62	32645-32646	;	
173-63	32647-32651	this	
173-64	32652-32656	gene	
173-65	32657-32664	encodes	
173-66	32665-32666	a	
173-67	32667-32671	type	
173-68	32672-32673	I	
173-69	32674-32682	membrane	
173-70	32683-32690	protein	
173-71	32691-32695	with	
173-72	32696-32697	a	
173-73	32698-32710	carbohydrate	
173-74	32711-32722	recognition	
173-75	32723-32729	domain	
173-76	32730-32734	that	
173-77	32735-32737	is	
173-78	32738-32752	characteristic	
173-79	32753-32755	of	
173-80	32756-32762	C-type	
173-81	32763-32770	lectins	
173-82	32771-32773	in	
173-83	32774-32777	its	
173-84	32778-32791	extracellular	
173-85	32792-32799	portion	
173-86	32799-32800	.	

#Text=In other proteins, this domain is involved in endocytosis of glycoproteins and exogenous sugar-bearing pathogens.
174-1	32801-32803	In	
174-2	32804-32809	other	
174-3	32810-32818	proteins	
174-4	32818-32819	,	
174-5	32820-32824	this	
174-6	32825-32831	domain	
174-7	32832-32834	is	
174-8	32835-32843	involved	
174-9	32844-32846	in	
174-10	32847-32858	endocytosis	
174-11	32859-32861	of	
174-12	32862-32875	glycoproteins	
174-13	32876-32879	and	
174-14	32880-32889	exogenous	
174-15	32890-32903	sugar-bearing	
174-16	32904-32913	pathogens	
174-17	32913-32914	.	

#Text=The protein encoded by this gene predominantly localizes to the perinuclear region.
175-1	32915-32918	The	
175-2	32919-32926	protein	
175-3	32927-32934	encoded	
175-4	32935-32937	by	
175-5	32938-32942	this	
175-6	32943-32947	gene	
175-7	32948-32961	predominantly	
175-8	32962-32971	localizes	
175-9	32972-32974	to	
175-10	32975-32978	the	
175-11	32979-32990	perinuclear	
175-12	32991-32997	region	
175-13	32997-32998	.	

#Text=This protein was mainly detected in the cytoplasmic membrane and golgi by the immunocytochemical analysis.
176-1	32999-33003	This	
176-2	33004-33011	protein	
176-3	33012-33015	was	
176-4	33016-33022	mainly	
176-5	33023-33031	detected	
176-6	33032-33034	in	
176-7	33035-33038	the	
176-8	33039-33050	cytoplasmic	
176-9	33051-33059	membrane	
176-10	33060-33063	and	
176-11	33064-33069	golgi	
176-12	33070-33072	by	
176-13	33073-33076	the	
176-14	33077-33095	immunocytochemical	
176-15	33096-33104	analysis	
176-16	33104-33105	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
177-1	33106-33110	This	
177-2	33111-33124	transmembrane	
177-3	33125-33132	protein	
177-4	33133-33135	is	
177-5	33136-33144	supposed	
177-6	33145-33147	to	
177-7	33148-33150	be	
177-8	33151-33165	over-expressed	
177-9	33166-33168	on	
177-10	33169-33172	the	
177-11	33173-33180	surface	
177-12	33181-33183	of	
177-13	33184-33189	tumor	
177-14	33190-33195	cells	
177-15	33196-33199	but	
177-16	33200-33203	not	
177-17	33204-33206	on	
177-18	33207-33213	normal	
177-19	33214-33219	cells	
177-20	33219-33220	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis. [0744] NSC 1441: HSNOV1; this gene encodes an integral membrane protein DFU6 domain.
178-1	33221-33225	Thus	
178-2	33225-33226	,	
178-3	33227-33230	the	
178-4	33231-33238	protein	
178-5	33239-33242	may	
178-6	33243-33248	serve	
178-7	33249-33251	as	
178-8	33252-33253	a	
178-9	33254-33258	good	
178-10	33259-33265	target	
178-11	33266-33269	for	
178-12	33270-33287	receptor-targeted	
178-13	33288-33295	therapy	
178-14	33296-33298	or	
178-15	33299-33308	diagnosis	
178-16	33308-33309	.	
178-17	33310-33311	[	
178-18	33311-33315	0744	
178-19	33315-33316	]	
178-20	33317-33320	NSC	
178-21	33321-33325	1441	
178-22	33325-33326	:	
178-23	33327-33333	HSNOV1	
178-24	33333-33334	;	
178-25	33335-33339	this	
178-26	33340-33344	gene	
178-27	33345-33352	encodes	
178-28	33353-33355	an	
178-29	33356-33364	integral	
178-30	33365-33373	membrane	
178-31	33374-33381	protein	
178-32	33382-33386	DFU6	
178-33	33387-33393	domain	
178-34	33393-33394	.	

#Text=The protein encoded by this gene was mainly detected in the cytoplasmic membrane and golgi by the immunocytochemical analysis.
179-1	33395-33398	The	
179-2	33399-33406	protein	
179-3	33407-33414	encoded	
179-4	33415-33417	by	
179-5	33418-33422	this	
179-6	33423-33427	gene	
179-7	33428-33431	was	
179-8	33432-33438	mainly	
179-9	33439-33447	detected	
179-10	33448-33450	in	
179-11	33451-33454	the	
179-12	33455-33466	cytoplasmic	
179-13	33467-33475	membrane	
179-14	33476-33479	and	
179-15	33480-33485	golgi	
179-16	33486-33488	by	
179-17	33489-33492	the	
179-18	33493-33511	immunocytochemical	
179-19	33512-33520	analysis	
179-20	33520-33521	.	

#Text=This transmembrane protein is supposed to be over-expressed on the surface of tumor cells but not on normal cells.
180-1	33522-33526	This	
180-2	33527-33540	transmembrane	
180-3	33541-33548	protein	
180-4	33549-33551	is	
180-5	33552-33560	supposed	
180-6	33561-33563	to	
180-7	33564-33566	be	
180-8	33567-33581	over-expressed	
180-9	33582-33584	on	
180-10	33585-33588	the	
180-11	33589-33596	surface	
180-12	33597-33599	of	
180-13	33600-33605	tumor	
180-14	33606-33611	cells	
180-15	33612-33615	but	
180-16	33616-33619	not	
180-17	33620-33622	on	
180-18	33623-33629	normal	
180-19	33630-33635	cells	
180-20	33635-33636	.	

#Text=Thus, the protein may serve as a good target for receptor-targeted therapy or diagnosis.
181-1	33637-33641	Thus	
181-2	33641-33642	,	
181-3	33643-33646	the	
181-4	33647-33654	protein	
181-5	33655-33658	may	
181-6	33659-33664	serve	
181-7	33665-33667	as	
181-8	33668-33669	a	
181-9	33670-33674	good	
181-10	33675-33681	target	
181-11	33682-33685	for	
181-12	33686-33703	receptor-targeted	
181-13	33704-33711	therapy	
181-14	33712-33714	or	
181-15	33715-33724	diagnosis	
181-16	33724-33725	.	

#Text=Example 4
182-1	33726-33733	Example	
182-2	33734-33735	4	
